Age-Related Macular Degeneration

On this page

Quick Reference

RxDrug of choiceFor neovascular AMD: ranibizumab, aflibercept, or faricimab. For geographic atrophy: pegcetacoplan or avacincaptad pegol.

AltAlternativesBevacizumab (off-label) for nAMD; brolucizumab for nAMD; photodynamic therapy for PCV.

⊘AvoidAnti-VEGF is contraindicated in active ocular infection; use caution in pregnancy (avoid bevacizumab, aflibercept). Complement inhibitors contraindicated if active neovascularization.

DxTest of choiceOptical coherence tomography (OCT) for initial diagnosis of neovascular AMD; fluorescein angiography for gold standard leakage detection.

ScKey scoreAREDS Simplified Severity Scale (0-4) for 5-year risk of late AMD.

→When to referAny patient with acute metamorphopsia, suspected neovascular AMD, or rapid progression of GA. Also for surgical management of submacular hemorrhage.

AMD is the leading cause of irreversible vision loss in elderly; prompt diagnosis with OCT and anti-VEGF therapy for neovascular disease can preserve vision. For intermediate AMD, AREDS2 supplements reduce progression. For GA, complement inhibitors offer modest benefit.

Age-related macular degeneration (AMD) is the leading cause of irreversible central vision loss in adults ≥65 years, affecting 18.34 million in the US alone. The disease is classified into non-neovascular (dry) AMD, which includes early/intermediate stages and geographic atrophy (GA), and neovascular (wet) AMD, characterized by macular neovascularization (MNV) with exudation. Management is stage-dependent: anti-VEGF therapy (ranibizumab, aflibercept, faricimab) is the standard of care for neovascular AMD, while complement inhibitors (pegcetacoplan, avacincaptad pegol) and AREDS2 supplements are used for GA and intermediate AMD. Prompt diagnosis with OCT is critical to preserve vision.

Overview and Recommendations

Background

•Age-related macular degeneration (AMD) is a progressive degenerative disorder of the macula, the central retina responsible for high-acuity vision, and is the leading cause of irreversible blindness in adults ≥65 years in developed countries, affecting 25.3% of Europeans aged ≥60 years (any AMD) and 2.4% with late AMD. By 2040, an estimated 77 million Europeans will have some form of AMD.
•AMD is staged along a continuum from early to late disease, defined by fundus features and risk of progression. The AREDS simplified severity scale stratifies 5-year risk of late AMD into levels 0 through 4, with rates ranging from 0.3% to 55.6%; incorporation of reticular pseudodrusen (RPD) approximately doubles the risk at most levels.
•The disease is classically divided into dry (non-neovascular) AMD, encompassing early/intermediate disease and geographic atrophy (GA), and wet (neovascular) AMD, defined by macular neovascularization (MNV) with exudation. The distinction is clinically critical: anti-VEGF therapy is effective only for neovascular disease, while AREDS2 nutritional supplementation reduces progression risk only in intermediate dry AMD.
•Pathophysiology centers on the retinal pigment epithelium (RPE) with oxidative stress, complement dysregulation (especially alternative pathway, driven by CFH variants), and lipid metabolism defects leading to drusen formation. The angiogenic switch to wet AMD is driven by hypoxia-inducible factor-1α (HIF-1α) upregulating VEGF-A, the master angiogenic cytokine.
•Modifiable risk factors include smoking (strongest, 2-4 fold increased risk), low physical activity, heavy alcohol use, and poor diet. The AREDS2 formulation (lutein/zeaxanthin, vitamins C/E, zinc) reduces progression to late AMD in intermediate disease (HR 0.91).
•The four pillars of management for neovascular AMD are anti-VEGF agents: ranibizumab, aflibercept, faricimab, and brolucizumab, with treat-and-extend regimens achieving superior outcomes. For GA, complement inhibitors (pegcetacoplan, avacincaptad pegol) are the first disease-modifying therapies, reducing lesion growth by 22-30%.

Evaluation

•Suspect AMD in any patient ≥50 years presenting with painless, progressive central vision loss, difficulty reading small print, or noticing distortion (metamorphopsia) or scotomas. Acute onset over days to weeks suggests neovascular conversion.
•Ask about onset and duration of symptoms, presence of metamorphopsia, scotoma, photopsia, and risk factors: smoking history, family history of AMD, cardiovascular disease, and current medications (anticoagulants).
•Examine visual acuity with ETDRS chart or Snellen equivalent, and test contrast sensitivity if possible. Perform Amsler grid testing (sensitivity ~67% for neovascular AMD, specificity 99%).
•Dilated fundus examination with a 90-D lens is essential. Look for drusen (hard, soft, cuticular or reticular pseudodrusen), RPE pigmentary changes, geographic atrophy (sharply demarcated RPE loss with visible choroidal vessels), and signs of neovascular activity: subretinal/intraretinal fluid, hemorrhage, lipid exudates, or grey-green CNV lesion.
•Order optical coherence tomography (OCT) as the test of choice for initial diagnosis of neovascular AMD. OCT identifies intraretinal fluid (IRF), subretinal fluid (SRF), pigment epithelial detachment (PED), and hyperreflective foci. IRF is the strongest biomarker of active disease.
•Fluorescein angiography (FA) remains the gold standard for detecting active choroidal neovascularization leakage. Indocyanine green angiography (ICGA) is superior for diagnosing polypoidal choroidal vasculopathy (PCV), common in Asian populations.
•Diagnostic criteria follow the AREDS simplified severity scale: grade 0 (no large drusen or pigment changes) to 4 (large drusen in both eyes + pigment changes in both eyes). Reticular pseudodrusen double the risk of progression.
•Also consider differential diagnoses: diabetic retinopathy, retinal vein occlusion, central serous chorioretinopathy, inherited macular dystrophies (Stargardt disease, Best disease), and age-related choroidal atrophy (ARCA).
•In patients with acute vision loss and hemorrhage, rule out giant cell arteritis (headache, jaw claudication, elevated ESR). For bilateral symmetrical GA, consider genetic testing for Stargardt disease.
•OCT angiography (OCTA) can detect nonexudative macular neovascularization (neMNV) in fellow eyes, which is a risk factor for future exudation.
•Functional testing: microperimetry, low-luminance visual acuity, and rod-mediated dark adaptation are more sensitive to early dysfunction than standard acuity.
•Deep learning algorithms on OCT achieve performance comparable to specialists for AMD classification, with sensitivity 0.98 for detecting AMD vs normal.

Management

•Initiate anti-VEGF therapy within 7 days of confirmed active neovascular AMD. First-line options: ranibizumab 0.5 mg, aflibercept 2 mg, or faricimab 6 mg intravitreal injection. Bevacizumab 1.25 mg (off-label) is also evidence-based.
•Administer a loading phase of 3 monthly injections. After loading, adopt a treat-and-extend (TAE) regimen: extend treatment intervals by 2 weeks up to every 12-16 weeks based on OCT findings. TAE yields mean gains of +8.8 letters at 1 year vs +3.5 for PRN.
•For patients with incomplete response after 3 loading doses (persistent IRF, no CST reduction, or VA decline), switch to an alternative anti-VEGF agent. Consider faricimab or aflibercept 8 mg. Switching to faricimab reduced CST by 31.3 μm after first injection.
•For geographic atrophy (GA), consider complement inhibitors: pegcetacoplan 15 mg intravitreal monthly or every other month, or avacincaptad pegol 2 mg monthly. These reduce GA growth by 22-30% at 12-18 months but increase risk of neovascular conversion (11.9-20.9%).
•For intermediate AMD, prescribe AREDS2 supplements: lutein 10 mg/zeaxanthin 2 mg, vitamin C 500 mg, vitamin E 400 IU, zinc oxide 80 mg, cupric oxide 2 mg. This reduces progression to late AMD by ~25% over 5 years.
•Manage submacular hemorrhage: for thick foveal hemorrhage ≤14 days, consider pneumatic displacement with intravitreal tPA 50 μg + SF6 gas, plus anti-VEGF. Post-procedure maintain head-upright face-forward position for 3 days.
•Monitor for complications: intraocular inflammation (IOI) occurs in 0.19% of faricimab injections, 3.7% of aflibercept 8 mg in real-world; treat with topical steroids. Endophthalmitis risk is 0.026% per injection; vitreous hemorrhage 0.012% (PDS 5.2%).
•Do NOT use anti-VEGF for non-neovascular subretinal fluid (drusenoid PED) - it may resolve spontaneously. Do NOT rechallenge with faricimab after mild IOI - risk of occlusive retinal vasculitis.
•For patients with recurrent exudation despite Q8W dosing, escalate to monthly dosing or switch to faricimab. Consider aflibercept 8 mg for extended intervals.
•When to refer to a retina specialist: any patient with new-onset metamorphopsia, suspected neovascular AMD, or GA with rapid progression. Also refer for surgical management of submacular hemorrhage or PDS implantation.
•Discharge criteria: after stable disease with no exudation for ≥3 consecutive extended intervals, consider extending follow-up to 6 months. However, indefinite monitoring is recommended due to risk of recurrence.
•For patients with non-central GA, AREDS2 supplements slow progression toward the fovea (50.7 μm/year vs 72.9 μm/year). Advise on Mediterranean diet and smoking cessation.
•In pregnant women requiring treatment, use ranibizumab 0.5 mg due to minimal systemic exposure. Avoid bevacizumab and aflibercept.
•In elderly patients with limited life expectancy, use treat-and-extend or PRN with faricimab to reduce visit burden.
•Emerging therapies: photobiomodulation (Valeda) may improve BCVA by +5.4 letters in dry AMD, but evidence is low certainty. AI-based screening with fundus photography achieves >98% sensitivity and specificity.

Board Review — High Yield

•AREDS Simplified Severity Scale, Stratifies 5-year risk of late AMD from 0.3% (level 0) to 55.6% (level 4); reticular pseudodrusen double the risk.
•Anti-VEGF loading dose, Three monthly injections are standard; treat-and-extend regimens achieve better outcomes than PRN.
•Intraretinal fluid (IRF) on OCT, Strongest biomarker for active disease; persistent IRF after loading predicts worse visual outcomes.
•Subretinal fluid (SRF) on OCT, Associated with better visual outcomes and lower risk of GA progression.
•Complement inhibitors for GA, Pegcetacoplan (C3 inhibitor) and avacincaptad pegol (C5 inhibitor) reduce GA growth by 22-30% but increase risk of neovascular conversion.
•Smoking cessation, The single most impactful modifiable risk factor; current smokers have 2-4 fold increased risk of late AMD.
•AREDS2 supplements, Lutein/zeaxanthin, vitamins C/E, zinc reduce progression to late AMD by ~25% in intermediate disease; beta-carotene should be avoided in smokers.
•Polypoidal choroidal vasculopathy (PCV), Common in Asian populations; diagnosed with ICGA; treated with anti-VEGF ± photodynamic therapy.
•Port Delivery System (PDS) with ranibizumab, Provides 24-week refill intervals; noninferior to monthly injections but higher ocular adverse events (RR 1.80).
•Fibrosis in nAMD, Prevalence 32% at 12 months, 56% at 60 months; approximately 60% of fibrosis burden develops within first year of treatment.

Deep Dive — Evidence Details

Definition, Classification & Nomenclature

▸AMD is staged as early, intermediate, or late (geographic atrophy or neovascular) using the AREDS simplified severity scale, with 5-year progression rates from 0.3% to 55.6% [2].
▸Neovascular AMD is further classified by MNV origin: Type 1 (sub-RPE), Type 2 (subretinal), Type 3 (RAP), and the newly described Type 4 (mixed with intraretinal anastomosis) [40,41,51].
▸Pachydrusen and reticular pseudodrusen are distinct drusen subtypes with different prognostic implications, RPD doubles the risk of progression to late AMD [2,35,58].

HY High Yield: Check for reticular pseudodrusen (RPD) on OCT or FAF in every AMD patient, their presence doubles the 5-year risk of progression to late AMD, independent of standard drusen grade [2].

Macular degeneration, also known as age-related macular degeneration, is an eye disease that gradually damages the macula, the small central part of the retina responsible for sharp, detailed central vision. It mainly af — Macular degeneration — Macular degeneration, also known as age-related macular degeneration, is an eye disease that gradually damages the macula, the small central part of t...Wikipedia ↗

Age-related macular degeneration (AMD) is a progressive degenerative disorder of the macula, the central retina responsible for high-acuity vision, characterized by extracellular deposits (drusen), retinal pigment epithelium (RPE) abnormalities, and eventual photoreceptor loss that leads to irreversible central vision impairment. Also called: age-related maculopathy (ARM), senile macular degeneration (historical). Abbreviation: AMD.

Stages and Classification

AMD is staged along a continuum from early to late disease, defined by fundus features and risk of progression ^[2]^B2b^[24]^D5^[43]^D5. The updated AREDS simplified severity scale stratifies 5-year risk of late AMD into levels 0 through 4, with rates ranging from 0.3% (level 0) to 55.6% (level 4) in the original AREDS cohort; incorporation of reticular pseudodrusen (RPD) approximately doubles the risk at most levels ^[2]^B2b.

Dry (non-neovascular) AMD encompasses early and intermediate disease (drusen, pigmentary changes) and geographic atrophy (GA), the advanced atrophic form. Wet (neovascular) AMD, also termed neovascular AMD (nAMD), is defined by macular neovascularization (MNV) with exudation ^[40]^D5^[54]^D5.

Neovascular AMD Subtypes

The Consensus on Neovascular AMD Nomenclature (CONAN) group classifies MNV by origin on OCT ^[40]^D5:

Type	Origin	Key Features
Type 1 MNV	Sub-RPE (choriocapillaris)	Classic CNV on FA; often with PED
Type 2 MNV	Subretinal	Classic CNV; not under RPE
Type 3 MNV (RAP)	Intraretinal → subretinal	Retinal angiomatous proliferation; associated with RPD ^[41]^D5
Type 4 MNV	Mixed Type 1+2 + intraretinal anastomosis	Aggressive, poor prognosis; posterior hyaloid fibrosis ^[51]^C4

Additional recognized phenotypes include polypoidal choroidal vasculopathy (PCV) and pachychoroid neovasculopathy, often associated with pachydrusen, distinct, irregular, ≥125 μm deposits linked to choroidal thickening ^[35]^A1c^[58]^D5.

Clinical Significance

AMD is the leading cause of irreversible vision loss in adults ≥65 years in developed countries, affecting 25.3% of Europeans aged ≥60 years (any AMD) and 2.4% with late AMD ^[16]^B2a. By 2040, an estimated 77 million Europeans will have some form of AMD ^[16]^B2a. The distinction between dry and wet AMD is clinically critical: anti-VEGF therapy is effective only for neovascular disease, while AREDS2 nutritional supplementation reduces progression risk only in intermediate dry AMD ^[1]^D5^[36]^D5.

Pearl: When staging AMD, always assess for reticular pseudodrusen on OCT or fundus autofluorescence, their presence doubles the 5-year risk of progression to late AMD at nearly every severity level, independent of traditional drusen grade ^[2]^B2b.

Classification of Age-Related Macular Degeneration

Category	Subtype	Key Features	Progression Risk (5-year)
Dry (non-neovascular)	Early AMD	Medium drusen (≥63 μm), no pigment changes	~0.3% (level 0) to 4.5% (level 1) ^[2]^B2b
Dry (non-neovascular)	Intermediate AMD	Large drusen (≥125 μm) or pigmentary abnormalities	~12.9% (level 2) to 32.2% (level 3) ^[2]^B2b
Dry (non-neovascular)	Geographic atrophy (GA)	Sharply demarcated RPE atrophy, choroidal vessels visible	Foveal involvement leads to severe vision loss ^[54]^D5
Wet (neovascular)	Type 1 MNV	Sub-RPE neovascularization, often with PED	55.6% (level 4) progression to late AMD ^[2]^B2b
Wet (neovascular)	Type 2 MNV	Subretinal neovascularization, classic CNV	Similar to Type 1 risk
Wet (neovascular)	Type 3 MNV (RAP)	Intraretinal origin, associated with RPD	Higher risk of RPE tear and GA ^[41]^D5
Wet (neovascular)	Type 4 MNV	Mixed Type 1+2 with intraretinal anastomosis	Poor prognosis, recalcitrant to anti-VEGF ^[51]^C4
Wet (neovascular)	PCV / Pachychoroid neovasculopathy	Polypoidal dilations; associated with pachydrusen	Variable; may respond to anti-VEGF + PDT ^[58]^D5

Pathophysiology & Mechanism

▸AMD pathogenesis begins with age-related oxidative stress in the RPE, leading to lipofuscin accumulation, complement activation, and chronic inflammation.
▸Geographic atrophy (dry AMD) results from relentless RPE loss driven by the alternative complement pathway and inflammasome activation; C5 inhibition slows GA growth by ~27%.
▸Neovascular AMD is triggered by VEGF-A (and VEGF-C/D) from hypoxic/inflamed RPE, leading to CNV; anti-VEGF therapy is the cornerstone of treatment, but complement and JAK-STAT pathways are also therapeutic targets.

HY High Yield: The alternative complement pathway is the most validated drug target in dry AMD: genetic variants in CFH, C3, and CFB account for a large portion of heritability, and C5 inhibition with avacincaptad pegol is the first FDA-approved therapy for geographic atrophy.

! Warning: Anti-VEGF therapy does not address the underlying RPE degeneration and complement activation; patients with nAMD remain at risk for GA development in the treated eye, and chronic anti-VEGF treatment may itself contribute to RPE atrophy over time.

This classification reflects two distinct but overlapping pathogenic pathways: a degenerative process centered on the retinal pigment epithelium (RPE) and a neovascular cascade driven by angiogenic cytokines. The RPE, a monolayer that supports photoreceptor function, phagocytoses shed outer segments, maintains the outer blood-retinal barrier, and delivers oxygen and nutrients from the choroid. With aging, oxidative stress from high metabolic demand and photoexposure accumulates, overwhelming endogenous antioxidant defenses ^[127]^D5. The RPE progressively loses its ability to clear lipofuscin, a fluorescent byproduct of incompletely digested photoreceptor lipids, and to maintain lysosomal function ^[91]^B3b. This lipofuscin burden itself generates reactive oxygen species (ROS) under blue-light exposure, creating a self-amplifying cycle of oxidative injury ^[114]^D5.

Complement Dysregulation and Chronic Inflammation

Oxidative damage to RPE cells triggers local complement activation. The alternative pathway, in particular, is overactive in AMD, driven by genetic variants in complement factor H (CFH), complement factor B, and complement component 3 (C3) ^[136]^D5. Factor D, the rate-limiting protease of the alternative pathway, is elevated in the plasma of AMD patients (odds ratio 1.81 for highest vs lowest quartile), especially in females ^[82]^B3b. Complement deposition within drusen, the extracellular lipoproteinaceous debris between RPE and Bruch membrane, is a hallmark of early AMD ^[58]^D5. Drusen contain activated complement proteins, apolipoproteins, and inflammatory mediators that recruit microglia and macrophages, sustaining a low-grade chronic inflammation that damages RPE and photoreceptors ^[105]^D5. Inflammasome activation (NLRP3) in RPE cells further amplifies IL-1β and IL-18 release, promoting tissue damage and driving progression to geographic atrophy (GA) ^[132]^D5.

Geographic Atrophy: The Final Common Pathway of RPE Loss

When RPE cell death exceeds regenerative capacity, the overlying photoreceptors and underlying choriocapillaris degenerate, producing sharply demarcated atrophic lesions called geographic atrophy. GA enlargement is relentless: in the AREDS2 cohort, the square-root-transformed area grew at 0.28-0.29 mm/year, with faster enlargement in eyes with multifocal, noncentral, or bilateral GA and in carriers of ARMS2 risk alleles ^[66]^B2b. Complement C5 inhibition with avacincaptad pegol slowed GA growth by ≈27% over 12 months, confirming the mechanistic role of the terminal complement pathway (C5b-9 membrane attack complex) in driving RPE loss ^[65]^A1b.

The Angiogenic Switch: From Dry to Neovascular AMD

In eyes predisposed by chronic oxidative stress and inflammation, a subset develops choroidal neovascularization (CNV). Hypoxia and inflammatory cytokines upregulate hypoxia-inducible factor-1α (HIF-1α), which transcriptionally activates vascular endothelial growth factor A (VEGF-A) ^[87]^D5. VEGF-A is the master angiogenic driver: it promotes endothelial cell proliferation, survival, and migration, and increases vascular permeability. VEGF-A binds VEGFR1 and VEGFR2, with VEGFR2 mediating most pro-angiogenic signals ^[94]^D5. The presence of a cilioretinal artery is associated with a lower risk of CNV (OR 0.75 at 5 years), implying that retinal hemodynamic factors modulate the risk of neovascular conversion ^[70]^B3b. Additional VEGF family members, VEGF-C and VEGF-D, also contribute to CNV; their inhibition with OPT-302 in combination with ranibizumab improved visual acuity by +14.2 letters vs +10.8 letters with ranibizumab alone ^[67]^A1b.

Lipid Metabolism, Drusen Biogenesis, and the Choroid

Dysregulated lipid metabolism is central to drusen formation. HDL cholesterol shows a U-shaped relationship with AMD risk: both high and low HDL levels increase risk, and HDL-associated single nucleotide polymorphisms (e.g., LIPC rs10468017) are protective (OR 0.81 for T allele) ^[85]^B3b^[72]^B3a. Drusen are rich in esterified cholesterol, apolipoproteins B and E, and oxidized lipids, which themselves can activate complement ^[117]^D5. In Asian populations, a distinct phenotype, polypoidal choroidal vasculopathy (PCV), features a thickened choroid (pachychoroid) and aneurysm-like choroidal dilations, suggesting a different pathogenic emphasis on choroidal vascular dysfunction rather than RPE-driven drusenogenesis ^[97]^D5^[130]^B2a.

Additional Modifiers: Mitochondrial Dysfunction, Epigenetics, and Systemic Inflammation

Mitochondrial dysfunction in RPE cells impairs ATP production and increases ROS, driving mitophagy failure and apoptosis ^[96]^D5^[139]^D5. Clonal hematopoiesis of indeterminate potential (CHIP) increases AMD risk by 14% (HR 1.14), and synergizes with genetic risk (HR 3.26 for both), implicating systemic inflammatory clones in retinal pathology ^[79]^B2b. Epigenetic changes, DNA methylation, histone acetylation, and non-coding RNAs, modulate expression of antioxidant and inflammatory genes, linking environmental exposures to heritable risk ^[134]^D5. JAK-STAT signaling, activated by IL-6, is a downstream effector of inflammation; JAK inhibitor use was associated with a 49-73% relative reduction in AMD incidence in autoimmune disease cohorts, supporting a causal role for this pathway ^[90]^B3b.

Pearl: The transition from dry to wet AMD is driven by VEGF-A upregulation under hypoxic/inflammatory stress, but the disease's origin lies in a decades-long accumulation of oxidative damage, complement dysregulation, and lipid trafficking defects in the RPE-Bruch membrane complex, making complement inhibition, antioxidant strategies, and anti-VEGF therapy complementary weapons rather than alternatives.

Key Pathogenic Pathways in AMD

Pathway	Key Mediators	Clinical Consequence	Therapeutic Target
Oxidative stress & lipofuscin	ROS, A2E, mitochondrial dysfunction	RPE damage, drusen formation	Antioxidants (AREDS2), NAC ^[71]^B3b
Complement overactivation	C3, C5, Factor D, CFH	RPE lysis, GA progression	C5 inhibitors (avacincaptad pegol) ^[65]^A1b
Angiogenesis	VEGF-A, VEGF-C/D, HIF-1α	Choroidal neovascularization	Anti-VEGF agents (ranibizumab, aflibercept, faricimab) ^[67]^A1b
Inflammation (inflammasome)	NLRP3, IL-1β, IL-18, JAK-STAT	Chronic tissue damage, CNV induction	JAK inhibitors ^[90]^B3b, anti-inflammatory therapy
Lipid dysregulation	HDL, LIPC, ApoE, oxidized LDL	Drusen biogenesis, complement activation	Statins ^[131]^D5, lipid-modulating agents

Epidemiology, Etiology & Risk Factors

▸AMD affects 18.3 million US adults ≥40 years; late AMD prevalence is 0.94% and rises with age.
▸Age is the strongest risk factor; smoking is the most important modifiable risk factor, with class I evidence.
▸Obesity (RR 1.32), low physical activity, and heavy alcohol intake increase risk; GLP-1 RA and lipid-lowering drugs may be protective in certain populations.

HY High Yield: Smoking cessation is the single most impactful lifestyle intervention; former smokers still have elevated risk, but it declines with time after quitting [157].

! Warning: GLP-1 receptor agonists show conflicting AMD risk: a 2-fold increased risk of neovascular AMD in diabetes [170] but reduced risk of dry AMD in obesity [207]. Counsel patients accordingly based on phenotype.

The complement-driven inflammation and oxidative stress detailed in the preceding section help explain why AMD is both common and strongly tied to age and environment. AMD is the leading cause of irreversible blindness in the developed world, affecting an estimated 18.34 million people aged ≥40 years in the US alone (crude prevalence 11.64% for early-stage, 0.94% for late-stage) ^[171]^B2a. In Europe, pooled prevalence of any late AMD in those ≥60 years is 2.4% (95% CI 1.8%-3.3%), with early/intermediate AMD affecting 25.3% (95% CI 18.0%-34.4%) ^[16]^B2a. The global annual incidence of late AMD is 0.19% (95% CI 0.13%-0.28%), rising to 0.36% in individuals of European descent ^[17]^B2a. In American whites aged ≥50, annual incidence of late AMD is 3.5 per 1000, equivalent to 293,000 new cases per year ^[14]^B2a. Geographic atrophy (GA) is far less common in Asia: pooled prevalence 1.57 per 1000 persons, compared with 5.20 per 1000 for neovascular AMD ^[150]^B2c.

Age is the dominant non-modifiable risk factor: prevalence of late AMD rises from 0.1% at age 55-59 to 9.8% at ≥85 years ^[5]^B2a. Incidence quadruples per decade of age ^[14]^B2a. Women have a modestly higher late AMD incidence than men (38% higher, 95% credible interval 6%-82%) ^[14]^B2a. European ancestry confers higher risk than Asian or African ancestry ^[17]^B2a.

Modifiable Risk Factors

Factor	Risk estimate (OR/RR/HR)	Evidence level
Current smoking	Strongest modifiable risk; class I evidence for smoking & cataract; ever smoking also class II for AMD ^[157]^B2a	Convincing (class I) ^[157]^B2a
Low physical activity	HR 1.19 (95% CI 1.01-1.40) for incident early AMD ^[153]^B2a	Moderate (meta-analysis)
Heavy alcohol (>3 drinks/day)	OR 1.47 (95% CI 1.10-1.95) for early AMD ^[154]^B2a	Moderate (meta-analysis)
Clonal hematopoiesis (CHIP)	HR 1.14 (95% CI 1.03-1.26) for incident AMD; additive with genetic risk ^[79]^B2b	Moderate (prospective cohort)
Lipid-lowering drugs	OR 0.85 (95% CI 0.79-0.91) for any AMD ^[156]^B2a	Moderate (meta-analysis)
Antidiabetic drugs	OR 0.78 (95% CI 0.66-0.91) for any AMD ^[156]^B2a	Moderate (meta-analysis)

Dietary factors also matter: closer adherence to a is associated with substantially slower AMD progression, and fish intake shows protective class II evidence ^[157]^B2a^[189]^D5. The AREDS2 formulation (lutein/zeaxanthin, vitamins C/E, zinc) reduces progression to late AMD in intermediate disease (HR 0.91, 95% CI 0.84-0.99) ^[147]^A1b.

Temporal Trends and Comorbidities

European data show a decreasing prevalence of late AMD after 2006, likely due to anti-VEGF therapy and healthier lifestyles ^[5]^B2a. Despite this, population aging will increase total affected individuals, with an estimated 67 million in the EU currently affected, rising to 77 million by 2050 ^[16]^B2a. AMD is associated with increased all-cause mortality (HR 1.15) and cardiovascular mortality (HR 1.28, 95% CI 1.04-1.57 for late AMD) ^[166]^B2a. Dementia and Alzheimer disease show bidirectional associations with AMD (OR 1.24-2.22) ^[155]^B2a^[169]^B2a.

Pearl: The single most impactful modifiable risk factor for AMD is smoking cessation; current smokers have a 2-4 fold increased risk of late AMD, and risk declines after quitting ^[157]^B2a. For patients with intermediate AMD, prescribe AREDS2 supplements and counsel on Mediterranean diet adherence, these have complementary, non-redundant benefits ^[189]^D5.

Clinical Presentation

▸Dry AMD presents insidiously with delayed dark adaptation and contrast sensitivity loss; wet AMD presents acutely with metamorphopsia and central scotoma over days to weeks.
▸Residual intraretinal fluid on OCT is associated with worse visual outcomes (~8.2 letters deficit), while residual subretinal fluid may be better tolerated.
▸Phenotypic variants (RAP, PCV, Type 4 MNV) have distinct prognostic and therapeutic implications, especially in Asian populations.

HY High Yield: Patients with dry AMD often have significant functional deficits (contrast sensitivity, reading speed, dark adaptation) despite 20/20 acuity; ask about difficulty reading in dim light or navigating stairs.

! Warning: Acute metamorphopsia with central scotoma is a red flag for neovascular conversion; OCT should be performed within 24 hours to identify exudation and initiate anti-VEGF therapy.

From the risk factors detailed in the preceding section, the transition to clinical disease follows a characteristic symptom sequence. The hallmark of age-related macular degeneration is painless, progressive central vision loss, with the pace and pattern determined by the underlying subtype.

Presenting Symptoms

Dry (non-neovascular) AMD typically evolves insidiously over years. Patients first notice difficulty reading fine print, needing brighter light for near tasks, or a vague central blur that cannot be corrected with glasses. Metamorphopsia (straight lines appearing wavy) is less common in dry AMD but can occur with drusen-related RPE distortion. Rod-mediated dark adaptation slows early, so patients often report trouble seeing in dim light or adjusting to darkness ^[45]^D5. Contrast sensitivity declines before visual acuity drops, and many patients with 20/20 Snellen acuity already have measurable deficits on contrast sensitivity testing ^[258]^C4.

Wet (neovascular) AMD presents with acute or subacute onset over days to weeks. The patient abruptly notices central distortion (metamorphopsia), a relative scotoma, or a rapid decline in reading ability. Vision loss is often severe within 2 to 4 weeks, prompting urgent consultation. Subretinal hemorrhage may cause a sudden, dense central scotoma. Even without hemorrhage, exudation produces blurred vision and color desaturation. In the HARBOR trial, eyes with residual intraretinal fluid (IRF) at 12 months had a mean BCVA of 5.5 letters worse than those without IRF; conversely, residual subretinal fluid (SRF) was associated with better vision outcomes (+2.4 letters adjusted difference) ^[221]^B2b^[224]^B2a.

Examination Signs

On fundus examination, dry AMD is characterized by drusen (extracellular deposits between RPE and Bruch membrane) and RPE pigmentary changes. Geographic atrophy (GA) appears as sharply demarcated patches of RPE loss with visible choroidal vessels. In wet AMD, the examiner sees subretinal or intraretinal fluid, lipid exudates, and often a grey-green choroidal neovascular (CNV) lesion. Hemorrhage may be subretinal, sub-RPE, or both. Fibrosis, a common sequel, increases in prevalence over time: 13% at baseline, 32% at 12 months, 36% at 24 months, and 56% at 60 months ^[12]^B2a. Eyes with fibrosis have poorer baseline VA (-18.5 letters) and a widening gap at 12 months (-26.9 letters) ^[12]^B2a.

Phenotypic Variants

Variant	Key Features	Frequency
Dry AMD (early/intermediate)	Drusen, RPE changes	Most common
Geographic atrophy	Well-demarcated RPE loss, slow progression	~20% of late AMD
Type 1 MNV (sub-RPE)	Occult CNV, PED common	40-50% of nAMD
Type 2 MNV (subretinal)	Classic CNV, more aggressive	20-30% of nAMD
Type 3 MNV (RAP)	Intraretinal neovascularization, bilateral, reticular pseudodrusen, high risk of RPE tears and GA	Up to 15% of nAMD ^[41]^D5
Polypoidal Choroidal Vasculopathy (PCV)	Polypoidal dilations, common in Asians, distinct genetics	25-50% of nAMD in Asian populations ^[178]^D5
Type 4 MNV	Mixed Type 1+2 with intraretinal anastomosis, posterior hyaloid fibrosis, poor vision	Rare ^[51]^C4
Age-related choroidal atrophy (ARCA)	Choroidal thinning (mean 69.8-96.45 µm), preserved RPE, scleral visibility, peripapillary atrophy, glaucoma association	Mimics AMD; distinct entity ^[236]^D5

Red Flags

Sudden central scotoma or metamorphopsia → suspect neovascular conversion; same-day evaluation with OCT is indicated.
Acute vision loss with hemorrhage → consider massive submacular hemorrhage; urgent anti-VEGF and possible TPA/gas therapy ^[219]^A1b.
Headache, jaw claudication, elevated ESR → rule out giant cell arteritis, which can mimic acute vision loss.

Atypical Presentations

Dry AMD with good Snellen acuity may still cause significant functional impairment: delayed dark adaptation, reduced contrast sensitivity, and reading difficulty despite 20/20 vision ^[258]^C4^[45]^D5. Pure alexia (alexia without agraphia) due to occipital stroke can present in AMD patients who suddenly cannot read but can write, a disconnection syndrome that requires neuroimaging ^[242]^C4. Bilateral symmetrical GA may mimic inherited macular dystrophies such as ; genetic testing helps distinguish ^[248]^D5. ARCA is often misdiagnosed as AMD but is distinguished by thin choroid, preserved RPE, and high glaucoma prevalence (35.3%) ^[236]^D5.

Pearl: In a patient with acute-onset metamorphopsia and a central scotoma, assume neovascular AMD until proven otherwise, OCT within 24 hours can prevent irreversible vision loss from untreated exudation.

Clinical Examination and Diagnostic Workup

▸Amsler grid has limited sensitivity (67-71%) for detecting neovascular AMD; a normal result does not rule out active disease.
▸OCT is the recommended test of choice for initial diagnosis, while FA remains the gold standard for detecting active CNV leakage.
▸All patients with suspected neovascular AMD require same-day OCT to avoid irreversible vision loss.

Dx Diagnostic Essentials: Same-day OCT is essential for any patient presenting with new metamorphopsia, rapid vision loss, or central scotoma, as early detection of neovascular AMD improves visual outcomes.

Carrying forward the clinical suspicion raised by the patient's history, the diagnostic workup begins with a systematic bedside examination that classifies age-related macular degeneration (AMD) by phenotype and guides the urgency of imaging. The examination battery, visual acuity, Amsler grid testing, slit-lamp biomicroscopy, and dilated funduscopy, remains the first step in every encounter, even as advanced imaging has become the cornerstone of definitive diagnosis.

Bedside Examination Battery

Visual acuity is measured with a standardized ETDRS chart or Snellen equivalent. Acuity loss in dry AMD is typically gradual, whereas wet AMD often presents with a more abrupt decline. Dilated fundus examination with a 90-D lens or contact lens allows assessment of the macula for drusen (soft, hard, cuticular), retinal pigment epithelium (RPE) alterations, geographic atrophy (GA), and signs of neovascular activity such as subretinal fluid, hemorrhage, or exudates. Amsler grid testing is a widely used home-monitoring tool, but its performance is limited: a recent meta-analysis found a pooled sensitivity of 67% (95% CI 51-79%) and specificity of 99% (95% CI 85-100%) when comparing neovascular AMD to healthy eyes, and sensitivity of 71% (95% CI 60-80%) and specificity of 63% (95% CI 49-51%) when compared to nonneovascular AMD ^[274]^A1a. These numbers mean that a normal Amsler grid does not rule out neovascular AMD, and patients should be encouraged to undergo regular ophthalmic examination regardless of home test results ^[274]^A1a.

Diagnostic Algorithm

The clinical workup follows a structured algorithm:

History and symptoms: Evaluate onset, duration, and progression of vision loss, metamorphopsia, scotoma, and photopsia.
Bedside examination: Visual acuity, Amsler grid, and dilated fundus exam.
Phenotype classification: Based on findings, categorize as dry AMD (drusen, RPE changes, GA) or suspect wet AMD (subretinal fluid, hemorrhage, rapid vision loss).
Imaging referral: Any suspicion of neovascular AMD warrants same-day optical coherence tomography (OCT) ^[225]^D5; fluorescein angiography (FA) remains the gold standard for detecting active leakage ^[40]^D5.
Confirmation: Multimodal imaging (OCT, FA, fundus autofluorescence) is the reference standard for final diagnosis and staging ^[46]^D5.

Clinical Feature	Dry AMD	Wet AMD
Onset	Insidious, years	Subacute to acute, days-weeks
Metamorphopsia	Absent or mild	Common, often the presenting symptom
Central scotoma	Gradual, late	Rapid, early
Fundus findings	Drusen, RPE mottling, GA	Subretinal/intraretinal fluid, hemorrhage, exudates
Visual acuity decline	Slow, stepwise	Rapid, often severe

Test of Choice and Gold Standard

Optical coherence tomography (OCT) is the test of choice for initial diagnosis of neovascular AMD. All major clinical practice guidelines recommend OCT for initial diagnosis ^[225]^D5. OCT provides high-resolution cross-sectional imaging that identifies intraretinal fluid (IRF), subretinal fluid (SRF), pigment epithelial detachment (PED), and hyperreflective foci, biomarkers that are critical for differentiating active neovascularization from non-exudative changes ^[167]^B2a. Fluorescein angiography (FA) remains the gold standard for detecting active choroidal neovascularization (CNV) leakage ^[40]^D5. The combination of OCT and FA (multimodal imaging) is recommended for comprehensive assessment, especially in atypical presentations ^[46]^D5.

Pearl: Any patient with new metamorphopsia or rapid vision loss should undergo same-day OCT; an Amsler grid that is normal does not rule out neovascular AMD, and persistent symptoms warrant urgent imaging regardless of home test results ^[274]^A1a.

Ophthalmic Imaging and Functional Testing

▸Multimodal imaging (OCT, FA, ICGA, FAF, OCTA) is essential for diagnosing and staging AMD, with each modality offering unique advantages for detecting neovascularization, atrophy, and fluid.
▸Intraretinal fluid on OCT is the most important biomarker for disease activity and retreatment decisions, while subretinal fluid is associated with better visual outcomes.
▸OCT angiography has high specificity (97%) for detecting choroidal neovascularization but is limited by frequent artifacts; it also identifies nonexudative neovascularization in about 8-9% of fellow eyes.
▸Deep learning algorithms match or exceed specialist performance for AMD classification on OCT, with pooled sensitivity of 98% for detecting AMD.

Dx Diagnostic Essentials: Multimodal imaging, OCT plus at least one angiographic modality (FA and/or OCTA), is essential for accurate diagnosis and staging of AMD. Relying on a single modality risks misclassification of fluid status or neovascular subtype.

HY High Yield: The presence of IRF on OCT is the most reliable indicator of active neovascularization requiring retreatment, but outer retinal tubulation and pseudocysts are non-exudative mimics that must not be treated.

From the clinical examination and basic diagnostic workup, the clinician now turns to a suite of quantitative imaging tools that define structural staging, guide treatment decisions, and monitor progression. No single modality suffices; multimodal imaging is the standard ^[299]^D5.

Optical Coherence Tomography

Spectral-domain optical coherence tomography (SD-OCT) is the cornerstone of AMD evaluation. All major clinical practice guidelines recommend OCT for initial diagnosis ^[225]^D5. High-resolution cross-sectional imaging resolves the vitreous, retina, RPE, and choroid, enabling identification of critical biomarkers.

Fluid compartment localization carries distinct prognostic weight. Intraretinal fluid (IRF) is the most important OCT biomarker for disease activity, and its presence correlates with poorer visual outcomes ^[167]^B2a. Persistent IRF through the loading phase is considered a degenerative rather than solely exudative sign ^[323]^D5. Subretinal fluid (SRF) is associated with better visual outcomes and a lower rate of progression to geographic atrophy (GA) ^[323]^D5. Pigment epithelial detachment (PED) , particularly when irregular or shallow, may signal underlying neovascularization ^[295]^D5.

Drusen assessment is fundamental. Drusen volume, measured by automated OCT algorithms, predicts progression to late AMD ^[301]^D5. Subretinal drusenoid deposits (SDDs) , also known as reticular pseudodrusen, are strong independent risk factors for late AMD, especially type 3 neovascularization and GA ^[193]^D5. SDD prevalence increases with age and AMD genetic risk score ^[210]^B2c.

Geographic atrophy and atrophy precursors are best characterized on OCT. Complete RPE and outer retinal atrophy (cRORA) is the defining lesion of GA. The Classification of Atrophy Meetings (CAM) consensus recommends a multimodal approach including OCT, fundus autofluorescence (FAF), and near-infrared reflectance for atrophy detection and quantification ^[299]^D5. Hyperreflective foci (HRF) are the most frequent OCT biomarker observed at sites prior to the formation of large hypertransmission defects, preceding atrophy ^[350]^B2b. Calcified drusen with hyporeflective cores also predict progression to atrophy ^[349]^B2b.

Neovascularization subtypes are classified by OCT: Type 1 (sub-RPE), Type 2 (subretinal), and Type 3 (intraretinal, formerly retinal angiomatous proliferation). Type 3 MNV is associated with higher risk of macular atrophy ^[352]^B3b. Type 2 MNV strongly predicts fibrosis ^[352]^B3b. OCT angiography (OCTA) further refines this classification.

Fluorescein and Indocyanine Green Angiography

Fluorescein angiography (FA) remains the reference standard for detecting active neovascularization and leakage ^[303]^D5 ^[309]^D5. FA is recommended at baseline and selected follow-up visits in neovascular AMD trials ^[299]^D5. However, FA is invasive and shows only moderate agreement with OCT for detecting disease activity (pooled sensitivity 85%, specificity 48% for TD/SD-OCT vs. FA) ^[303]^D5.

Indocyanine green angiography (ICGA) is superior for visualizing the choroidal vasculature and is essential for diagnosing polypoidal choroidal vasculopathy (PCV) , a common variant in Asian populations ^[97]^D5 ^[347]^D5. ICGA may also be considered at baseline in non-neovascular AMD studies to rule out subclinical neovascularization ^[299]^D5.

OCT Angiography

OCTA provides depth-resolved, non-invasive images of retinal and choroidal blood flow. For detecting choroidal neovascularization (CNV), OCTA shows a pooled sensitivity of 0.90 (95% CI 0.82-0.95) and specificity of 0.97 (95% CI 0.89-0.99) ^[308]^A1a. However, image artifacts are common, occurring in up to 89.4% of eyes, with segmentation errors more frequent in pathologic eyes ^[332]^C4.

OCTA can identify nonexudative macular neovascularization (neMNV) , a risk factor for future exudation. In fellow eyes of patients with unilateral neovascular AMD, the prevalence of neMNV on OCTA is 8.5% (95% CI 6.4%-11.3%) ^[313]^B2c. The double-layer sign on OCT is not a good surrogate for neMNV; only 40% of eyes with a thick double-layer sign have neMNV on OCTA ^[313]^B2c.

Quantitative OCTA parameters, vessel density, perfusion density, CNV lesion area, are promising endpoints but require further validation ^[307]^D5 ^[320]^D5.

Functional Testing

Best-corrected visual acuity (BCVA) , measured with ETDRS charts, is the traditional primary endpoint. However, in non-exudative AMD, BCVA is insensitive to early functional loss ^[301]^D5. Microperimetry (fundus-controlled perimetry) assesses mesopic and scotopic retinal sensitivity with topographic correlation to OCT. Reduced differential light sensitivity in early AMD correlates with ellipsoid zone disruption and outer segment thinning ^[234]^D5 ^[266]^D5. Low-luminance visual acuity and rod-mediated dark adaptation are more sensitive to early dysfunction ^[287]^B2b.

Metamorphopsia testing using Amsler grids or preferential hyperacuity perimetry (PHP) can aid home monitoring. The AREDS2-HOME trial showed that PHP-based monitoring detects exudative conversion at better visual acuity levels, though the cost per letter gained is substantial ($3,351/year) ^[293]^D5.

Emerging AI and Deep Learning

Deep learning algorithms applied to OCT achieve performance comparable to specialists for AMD classification, with pooled sensitivity of 0.98 (95% CI 0.96-0.99) for detecting AMD vs. normal and 0.95 (95% CI 0.91-0.97) for differentiating wet vs. dry AMD ^[56]^A1a. The DeepGAze algorithm predicts progression from intermediate AMD to GA within 1 year with an AUROC of 0.94 (95% CI 0.92-0.95) ^[317]^B2b. AI-based structure-function correlation (inferred BCVA, inferred sensitivity) may serve as quasi-functional surrogate endpoints in future trials ^[296]^D5.

Pearl: When monitoring neovascular AMD, the presence of intraretinal fluid (IRF) on OCT is the strongest biomarker of active disease warranting retreatment; in contrast, isolated subretinal fluid (SRF) may be tolerated if stable, and outer retinal tubulation or pseudocysts should not be mistaken for exudative fluid requiring anti-VEGF therapy ^[167]^B2a ^[295]^D5.

Key OCT Biomarkers in AMD

Biomarker	Significance	Clinical Implication
Intraretinal fluid (IRF)	Active exudation; strongest predictor of disease activity	Indicates need for retreatment ^[167]^B2a ^[323]^D5
Subretinal fluid (SRF)	Exudation, but better prognosis than IRF	May be tolerated if stable; less aggressive retreatment ^[323]^D5
Pigment epithelial detachment (PED)	May indicate neovascularization (irregular PED)	Requires further imaging (FA/ICGA/OCTA) ^[295]^D5
Hyperreflective foci (HRF)	Precursor to atrophy; most common site-specific biomarker	Predicts progression to GA ^[350]^B2b ^[340]^B3b
Subretinal drusenoid deposits (SDD)	Strong risk factor for late AMD (type 3 MNV, GA)	High-risk phenotype; monitor closely ^[193]^D5 ^[210]^B2c
Calcified drusen with hyporeflective cores	Predicts progression to atrophy	Consider for earlier intervention ^[349]^B2b
Complete RPE and outer retinal atrophy (cRORA)	Defining lesion of GA	Quantify growth rate; endpoint for therapeutic trials ^[299]^D5 ^[310]^D5
Outer retinal tubulation (ORT)	Degenerative change, not exudation	Avoid unnecessary anti-VEGF treatment ^[116]^D5 ^[295]^D5

Severity, Staging & Risk Stratification

▸The updated AREDS simplified severity scale (Report 42) incorporates reticular pseudodrusen (RPD) as a risk modifier; RPD doubles the 5‑year risk of progression to late AMD across all severity levels [2].
▸Geographic atrophy enlarges at a mean square‑root rate of 0.29 mm/year; noncentral GA carries a 57% risk of foveal involvement at 4 years [66].
▸Untreated choroidal neovascularization reaches half its maximal size within 14 months (expansion rate ~26 μm/day), and fibrosis prevalence reaches 56% by 5 years [12,356].

HY High Yield: Reticular pseudodrusen double the 5‑year risk of progression to late AMD across all AREDS severity levels [2].

From the imaging biomarkers described in the preceding section, a validated severity tier emerges that directly dictates treatment thresholds and follow‑up intervals.

AREDS Simplified Severity Scale (Updated)

The AREDS simplified severity scale assigns a 0-4 score per eye based on large drusen (≥125 μm) and pigmentary abnormalities. The 2024 update (AREDS2 Report 42) makes two key modifications: (1) noncentral geographic atrophy (GA) is classified as late AMD rather than a risk feature, and (2) the scale is stratified by reticular pseudodrusen (RPD) status ^[2]^B2b. The 5‑year progression rates to late AMD for levels 0-4 are shown in Table 1.

Level	Description	5‑yr Progression (RPD absent)	5‑yr Progression (RPD present)
0	No large drusen or pigment changes	0.3%	2.8%
1	Large drusen in 1 eye OR pigment changes	4.3%	8.0%
2	Large drusen in both eyes OR large drusen in 1 eye + pigment changes	11.6%	29.0%
3	Large drusen in both eyes + pigment changes in 1 eye	26.7%	58.7%
4	Large drusen in both eyes + pigment changes in both eyes	50.0%	72.2%

Table 1: Updated AREDS simplified severity scale - 5‑year progression rates ^[2]^B2b. External validation in AREDS2 showed rates for levels 2-4 of 15.0%, 27.7%, 45.7% (RPD absent) and 26.2%, 46.0%, 73.0% (RPD present) ^[2]^B2b.

Risk Stratification for Geographic Atrophy

Once GA is present, enlargement is relentless. The square‑root transformation growth rate averages 0.29 mm/year (95% CI 0.27-0.30) for pre‑existing GA and 0.28 mm/year for incident GA ^[66]^B2b. Faster enlargement is associated with noncentral location, multifocality, intermediate baseline size, bilateral GA, and genotypes (ARMS2 risk, C3 non‑risk, APOE non‑risk) ^[66]^B2b. In eyes with incident noncentral GA, the 4‑year risk of central foveal involvement is 57% ^[66]^B2b. Oral micronutrient supplementation (AREDS2 without β‑carotene) slows GA progression toward the fovea by approximately 22-34 μm/year compared with no supplementation ^[268]^B2b.

Risk Stratification for Neovascular AMD

In untreated choroidal neovascularization, lesion size follows a uniform growth pattern: half‑maximal size is reached within 14.0 months of onset, with a linear expansion rate of ~26.0 μm/day for the smallest lesions ^[356]^A1a. Fibrosis prevalence rises from 32% at 12 months to 56% at 5 years ^[12]^B2a. Risk factors for fibrosis include classic CNV, intraretinal fluid, hemorrhage, hyperreflective material, larger lesion size, and thicker retina; subretinal fluid and pigment epithelial detachment may be protective ^[12]^B2a.

Risk Modifiers

Reticular pseudodrusen double the 5‑year progression risk across all severity levels ^[2]^B2b^[112]^D5. Physical activity is protective: a meta‑analysis reported OR 0.92 (95% CI 0.86-0.98) for early AMD and 0.59 (95% CI 0.49-0.72) for late AMD ^[357]^A1a. Genetic risk (CFH, ARMS2) and clonal hematopoiesis of indeterminate potential (CHIP, HR 1.14; 95% CI 1.03-1.26) further amplify risk ^[79]^B2b.

Clinical Application

Follow‑up intervals are tiered by severity: low risk (level 0-1) → annual exam; intermediate (level 2-3) → every 6-12 months; high risk (level 4 or any late AMD) → every 4-6 months. Presence of RPD or noncentral GA warrants shorter intervals. AREDS2 supplementation is recommended for eyes with intermediate AMD (level ≥2 in at least one eye) ^[251]^A1a.

Pearl: In eyes with noncentral GA, the 4‑year risk of foveal involvement is 57% - AREDS2 supplements slow this progression by ~22 μm/year toward the fovea ^[66]^B2b^[268]^B2b.

Acute & Vision-Threatening Management

▸Urgent initiation of anti-VEGF therapy (within 1 week) is critical for vision salvage in exudative AMD.
▸Treat-and-extend regimens produce greater visual gains than PRN dosing in real-world practice.
▸Pneumatic displacement with tPA and anti-VEGF is noninferior to vitrectomy for submacular hemorrhage of ≤14 days.
▸Switching to an alternative anti-VEGF agent is indicated for incomplete response after 3 loading doses.

! Warning: Intraocular inflammation risk is higher with brolucizumab (RR 6.24 vs aflibercept) and faricimab (0.13-0.86% per injection); monitor for anterior uveitis, vitritis, and elevated IOP within 1-7 days post-injection.

Rx Drug of Choice: Ranibizumab 0.5 mg, aflibercept 2 mg, and faricimab 6 mg are FDA-approved first-line agents for acute neovascular AMD.

Classification as exudative AMD immediately triggers the need for anti-vascular endothelial growth factor (VEGF) therapy. Delays of even weeks worsen visual prognosis ^[381]^D5. The following protocol outlines the acute pathway.

Step 1: Initiate Anti-VEGF Therapy

Administer an intravitreal anti-VEGF agent within 7 days of confirmed active choroidal neovascularization (CNV). Optical coherence tomography (OCT) showing subretinal or intraretinal fluid with or without hemorrhage warrants treatment ^[269]^A1c. FDA-approved first-line options include 0.5 mg, 2 mg, and 6 mg; (off-label, 1.25 mg) is also evidence-based. A loading phase of 3 monthly injections is standard. After loading, adopt a treat-and-extend (TAE) regimen rather than pro re nata (PRN): real-world TAE yields mean gains of +8.8 letters at 1 year versus +3.5 for PRN (n=1,539 vs 20,247; weighted mean difference) ^[378]^B2a. The Port Delivery System (PDS) with ranibizumab 100 mg/ml offers fixed 24-week refills and is noninferior to monthly injections (difference -0.3 letters; 95% CI, -1.7 to 1.1), though ocular adverse events are higher (19.0% vs 6.0%), including vitreous hemorrhage (5.2%) and (1.6%) ^[216]^A1b.

Step 2: Manage Submacular Hemorrhage

For submacular hemorrhage (SMH) >2 disc areas with symptom duration ≤14 days, pneumatic displacement is the preferred acute intervention. The STAMP trial (N=90) randomized eyes to pars plana vitrectomy (PPV) with subretinal tPA (50 μg) and SF6 tamponade versus pneumatic displacement (intravitreal tPA 50 μg + SF6). Mean VA gain at 3 months was similar: +16.8 letters (surgery) vs +16.4 letters (displacement); adjusted difference 1.9 letters (P=0.767) ^[368]^A1b. Both arms received intravitreal ranibizumab 0.5 mg at intervention, month 1 and month 2. Post-procedure, patients maintain a -upright face-forward position at 45° for 3 days. Anti-VEGF injections continue monthly for 2 more months then PRN thereafter.

Step 3: Monitor for Safety and Complications

Anti-VEGF injections have a low but nonzero complication rate. Endophthalmitis occurs in 0.026% of injections (17/66,176) ^[378]^B2a; rhegmatogenous in 0.012% (1 in 8,675 injections) ^[294]^B2a. Intraocular inflammation (IOI) varies by agent: has a higher risk of generalized IOI versus aflibercept (RR 6.24; 95% CI, 1.40-27.90) ^[377]^A1a; -associated IOI occurs in 0.13%-0.86% per injection ^[200]^B2b^[209]^C4, typically presenting as anterior uveitis with elevated IOP in half of cases and mean time to resolution of 2 months ^[209]^C4. No FDA-approved anti-VEGF agent increases acute kidney injury versus sham (pooled RR 1.27; 95% CI, 0.83-1.93) ^[15]^A1a.

Step 4: Switch Therapy for Incomplete Response

If, after 3 loading doses, intraretinal fluid persists, CST does not decrease, or VA declines, switch to an alternative anti-VEGF agent. In previously treated eyes switched to aflibercept 8 mg, VA remained stable (WMD -0.017 logMAR) and treatment intervals extended by +1.79 weeks (95% CI, 1.32-2.27) ^[265]^A1a. Switching to faricimab reduced CST by 31.3 μm after the first injection ^[204]^C4. The FUTILITY algorithm recommends a treatment pause if no improvement is seen after switching ^[395]^D5.

Drug	Dose	Loading	Maintenance	Key Trial (1-year VA gain)	Evidence Level
Ranibizumab	0.5 mg	Monthly ×3	TAE or PRN	+10.6 letters (MARINA) ^[388]^A1a	1a
Aflibercept	2 mg	Monthly ×3	Q8W after loading	+8.4 letters (VIEW) ^[403]^D5	1b
Bevacizumab	1.25 mg	Monthly ×3	PRN	+8.0 letters (CATT) ^[387]^A1a	1a
Faricimab	6 mg	Monthly ×4	Q8W (up to Q16W)	+5.8 letters (TENAYA) ^[397]^D5	1b
Brolucizumab	6 mg	Monthly ×3	Q12W after loading	+6.1 letters (HAWK) ^[377]^A1a	1b
PDS ranibizumab	100 mg/ml	Implant + refill Q24W	Exchange Q24W	+0.2 letters (Archway) ^[216]^A1b	1b

Pearl: Initiate anti-VEGF therapy within 1 week of confirming exudative AMD; treat-and-extend regimens achieve superior long-term visual outcomes compared to PRN, and acute submacular hemorrhage ≤14 days old is effectively managed with pneumatic displacement rather than vitrectomy.

Long-term & Definitive Management

▸Treat-and-extend (T&E) regimens with faricimab or aflibercept 8 mg achieve extended dosing intervals (Q12-Q16W) while maintaining visual acuity gains comparable to monthly ranibizumab.
▸Complement inhibitors (pegcetacoplan, avacincaptad pegol) reduce geographic atrophy growth by 22-30% over 18-24 months, with increasing efficacy over time.
▸Switching to faricimab or aflibercept 8 mg is effective for persistent fluid after initial anti-VEGF therapy; high-dose high-frequency aflibercept (4 mg monthly) can salvage refractory cases.
▸AREDS2 supplements (lutein/zeaxanthin, vitamins C, E, zinc) slow progression to late AMD and reduce GA expansion toward the fovea; beta-carotene should be avoided in smokers.

Rx Drug of Choice: **For nAMD:** Faricimab 6.0 mg IVT T&E (starting 4 monthly doses, then extend to Q16W if no fluid) or aflibercept 8 mg IVT (3 monthly loads, then 8q12-16W). **For GA:** Pegcetacoplan 15 mg IVT monthly.

! Warning: **Do NOT rechallenge with faricimab after mild intraocular inflammation** - occlusive retinal vasculitis may occur [276]. **Avoid beta-carotene in smokers** - lung cancer risk OR 1.82 [147].

After acute exudation is controlled, the central challenge shifts to maintaining vision gains while minimizing treatment burden. The paradigm for neovascular AMD (nAMD) has evolved from reactive pro re nata (PRN) dosing to proactive treat-and-extend (T&E) regimens, which real-world evidence shows optimise visual outcomes and reduce clinic visits compared with fixed monthly or PRN schedules ^[417]^D5 (2b). In the TENAYA/LUCERNE trials, faricimab 6.0 mg using T&E allowed 59.0% and 66.9% of eyes to achieve every-16-week (Q16W) dosing at week 112, with mean BCVA gains of +3.7 to +5.0 letters ^[213]^A1b (1b). Aflibercept 8 mg in the PULSAR trial maintained visual and anatomic outcomes through 96 weeks: 87% of eyes in the 8q12 group had last assigned dosing intervals ≥12 weeks, and 31% of the 8q16 group reached 24-week intervals ^[145]^A1b (1b). Brolucizumab 6 mg achieved q12w dosing in >50% of eyes at week 48, with superior anatomic drying versus aflibercept (central subfield thickness reduction -172.8 μm vs -143.7 μm in HAWK) ^[215]^A1b (1b). For patients who prefer an even longer interval, the Port Delivery System with ranibizumab (PDS) offers Q24W refill-exchanges, noninferior to monthly injections (+0.2 vs +0.5 letters; difference -0.3 letters, 95% CI -1.7 to 1.1) ^[216]^A1b (1b). However, the PDS arm had higher ocular adverse events (19.0% vs 6.0%), including (1.6%), vitreous hemorrhage (5.2%), and conjunctival erosion (2.4%) ^[216]^A1b (1b).

Step 2: Switching and Escalation Strategies

When residual fluid persists despite optimal dosing, switching to an agent with a different mechanism may help. The TRUCKEE study showed that switching from aflibercept to faricimab reduced central subfield thickness by -25.3 μm after one injection and -38.1 μm after three injections, with a +2.7 letter visual gain at 3 months ^[204]^C4 (4). Aflibercept 8 mg as a switch maintained BCVA (WMD -0.017 logMAR) and extended treatment intervals by +1.79 weeks (95% CI +1.32 to +2.27) in a meta-analysis ^[265]^A1a (1a). For truly refractory cases, high-dose high-frequency aflibercept (4 mg monthly, 4Q4W) achieved a dry retina at a mean 3.8 months in eyes resistant to 2 mg aflibercept ^[434]^C4 (4). Biosimilar aflibercept (SDZ-AFL) showed equivalent efficacy and safety to the reference product at 52 weeks (difference in BCVA change at week 8: -0.3 letters, 90% CI -1.5 to 1.0) ^[152]^A1b (1b).

Step 3: Geographic Atrophy, Complement Inhibition and Neuroprotection

For dry AMD with geographic atrophy (GA), complement inhibitors now offer the first disease-modifying therapies. Pegcetacoplan 15 mg (C3 inhibitor) monthly reduced GA growth by 22% (OAKS) and 27% (DERBY) at 24 months, with increasing efficacy over 36 months (up to 42% reduction in non-subfoveal GA) ^[272]^B2b (2b). Deep learning-based OCT analysis showed that pegcetacoplan reduced ellipsoid zone loss by 53% in OAKS and 47% in DERBY at 24 months ^[354]^C4 (4). Avacincaptad pegol 2 mg or 4 mg (C5 inhibitor) monthly reduced GA growth by 27.4-30.0% over 18 months ^[158]^A1b (1b). Macular neovascularization occurred more frequently with avacincaptad (11.9% and 15.7%) vs sham (2.7% and 2.4%) ^[158]^A1b (1b). AREDS2 oral supplements (lutein/zeaxanthin, vitamins C, E, zinc) slowed GA progression toward the fovea (50.7 μm/year vs 72.9 μm/year with antioxidants vs none) ^[268]^B2b (2b). Photobiomodulation (Valeda Light Delivery System, 590/660/850 nm) improved BCVA by +5.4 letters at 13 months and reduced new-onset GA incidence (6.8% vs 24.0% sham at 24 months) ^[151]^A1b (1b).

Drug / Modality Comparison Table

Option	Indication / Line	Dose or Specifics	Key Trial	Outcome	Evidence Level
Faricimab	nAMD, first-line	6.0 mg IVT, T&E up to Q16W	TENAYA/LUCERNE ^[213]^A1b	BCVA +3.7 to +5.0 letters; 59-67% Q16W at 2 years	1b
Aflibercept 8 mg	nAMD, first-line or switch	8 mg IVT, 8q12 or 8q16 after 3 monthly loads	PULSAR ^[145]^A1b	BCVA +5.5 to +5.6 letters; 78% ≥16-week interval at 96 weeks	1b
Brolucizumab 6 mg	nAMD, first-line	6 mg IVT, q12w after 3 monthly loads	HAWK/HARRIER ^[215]^A1b	BCVA +6.9 letters; 51-56% q12w at 48 weeks	1b
PDS ranibizumab	nAMD, maintenance	100 mg/mL, refill Q24W	Archway ^[216]^A1b	BCVA +0.2 letters; 98.4% no supplemental treatment	1b
Pegcetacoplan	GA, first-line	15 mg IVT monthly or EOM	OAKS/DERBY ^[272]^B2b	GA growth reduction 22-27% at 24 months; up to 42% at 36 months	2b
Avacincaptad pegol	GA, first-line	2 mg or 4 mg IVT monthly	GATHER1 ^[158]^A1b	GA growth reduction 27.4-30.0% at 18 months	1b
AREDS2 supplements	Intermediate AMD, GA	Lutein 10 mg/zeaxanthin 2 mg + vitamins C, E, zinc	AREDS2 ^[147]^A1b	HR 0.91 for progression to late AMD (95% CI 0.84-0.99)	1b

Dosing Table

Drug	Starting dose	Target / max dose	Renal adjustment	Hepatic adjustment	Key monitoring
Faricimab	6.0 mg IVT monthly ×4	6.0 mg IVT Q16W (T&E)	None	None	IOP, IOI, endophthalmitis
Aflibercept 8 mg	8 mg IVT monthly ×3	8 mg IVT Q12-16W	None	None	IOP, IOI, CRT
Pegcetacoplan	15 mg IVT monthly	15 mg IVT monthly or EOM	None	None	GA progression, MNV development

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Optimal first-line agent for nAMD	EURETINA 2014 recommends ranibizumab or aflibercept as first-line ^[269]^A1c	Real-world data favour faricimab or aflibercept 8 mg for extended durability ^[417]^D5^[263]^A1a	Moderate (evolving evidence)	2-mg aflibercept and ranibizumab remain established; newer agents reduce injection burden but cost more per dose
Treating GA with complement inhibitors	FDA-approved pegcetacoplan and avacincaptad pegol	NICE has not yet issued guidance on pegacoplan (as of 2025)	Strong (regulatory divergence)	US clinicians can offer complement inhibitors; EU/UK clinicians may await health technology assessment

Treatment Failure Protocol

Persistent fluid after ≥3 monthly injections → consider switching to faricimab or aflibercept 8 mg.
Recurrent exudation despite Q8W dosing → escalate to monthly dosing or switch to faricimab.
Progressive GA despite complement inhibitor → consider adding AREDS2 supplements if not already taking; evaluate for conversion to exudative AMD.
Futility (no improvement after 6 months of adequate therapy, or irreversible structural damage) → discuss suspending treatment using the Vision Academy algorithm ^[395]^D5 (4).

What NOT to Do

Do NOT use anti-VEGF therapy for non-neovascular subretinal fluid (drusenoid PED) - it may resolve spontaneously ^[107]^C4 (4).
Do NOT rechallenge with faricimab after mild intraocular inflammation - risk of occlusive retinal vasculitis ^[276]^C4 (4).

Monitoring and Safety

Intraocular inflammation (IOI) is a known class effect. In real-world data, faricimab IOI incidence was 0.19% per injection (95% CI 0.12-0.30%) ^[200]^B2b (2b). Aflibercept 8 mg showed a higher per-injection IOI rate of 3.7% (95% CI 1.6-8.3%) in a single-centre series ^[172]^C4 (4). All cases resolved with topical steroids, and no vision loss occurred. Faricimab-associated IOI can be severe, with cases of occlusive retinal vasculitis reported after rechallenge ^[276]^C4^[245]^C4 (4). Nonadherence is common: missing ≥2 visits in 12 months constitutes nonadherence and is associated with worse outcomes ^[10]^A1c (1c).

Pearl: Use a treat-and-extend regimen with faricimab or aflibercept 8 mg for nAMD to maximise durability and minimise injection burden; for geographic atrophy, complement inhibitors reduce lesion growth by 22-30% but require monitoring for conversion to exudative AMD ^[213]^A1b^[145]^A1b^[272]^B2b^[158]^A1b.

History and Evolution of Treatment

▸Anti-VEGF therapy, established by ANCHOR and MARINA, transformed nAMD prognosis from inevitable vision loss to improvement in 25-40% of patients.
▸VIEW1/2 trials established aflibercept 2 mg q8w as noninferior to monthly ranibizumab, reducing injection burden.
▸AREDS2 replaced beta-carotene with lutein/zeaxanthin and documented increased lung cancer risk with beta-carotene.
▸Pegcetacoplan and avacincaptad pegol are the first FDA-approved treatments for geographic atrophy, slowing GA growth by 20-30%.

HY High Yield: When counseling patients about GA treatment, emphasize that pegcetacoplan and avacincaptad pegol slow growth by 20-30% but do not restore vision, and carry a 1-2% annual risk of conversion to exudative AMD requiring anti-VEGF therapy [158, 217].

The treatment of neovascular AMD has evolved through several distinct eras, each defined by landmark trials that shifted the standard of care. The earliest proven intervention, with (PDT), was shown in the TAP and VIP trials to reduce the risk of moderate vision loss in predominantly classic subfoveal CNV ^[467]^D5. However, PDT rarely improved vision, and its use was limited by lesion type and by infusion-associated back pain occurring in 8.4% of patients, an idiosyncratic reaction not prevented by oral hydration ^[445]^B2b. By the late 2000s, PDT was largely superseded by anti-VEGF therapy, though it remains a second-line option for (PCV) where it is often combined with anti-VEGF agents ^[178]^D5^[406]^D5.

The Anti-VEGF Revolution

The pivotal ANCHOR and MARINA trials (2006) established monthly intravitreal ranibizumab as the new gold standard, demonstrating that approximately 95% of treated patients lost <15 letters and 25-40% gained ≥15 letters at 12 months, with gains maintained through 24 months ^[11]^A1c^[250]^D5. These trials proved that VEGF inhibition could not only stabilize but improve vision for the first time in nAMD history. The subsequent VIEW 1 and VIEW 2 trials (2012) showed that intravitreal aflibercept 2 mg every 8 weeks after 3 monthly loading doses was noninferior to monthly ranibizumab for the primary endpoint of maintaining vision (95.1-96.3% vs 94.4% across arms), with a mean +8.4 letter gain in the integrated analysis ^[214]^A1b. This established aflibercept as a first-line agent with reduced injection burden. The HARBOR trial (2012) explored ranibizumab 0.5 mg and 2.0 mg under monthly and as-needed regimens, confirming that a treat-and-extend (T&E) approach could maintain vision gains while reducing visits ^[11]^A1c^[221]^B2b. Real-world evidence subsequently demonstrated that T&E regimens optimize visual outcomes better than either fixed monthly or pro re nata (PRN) dosing, balancing efficacy with burden ^[417]^D5.

Next-Generation Agents

The HAWK and HARRIER trials (2019) evaluated the single-chain antibody fragment 6 mg versus aflibercept 2 mg. At Week 48, brolucizumab was noninferior for BCVA change (+6.6 letters vs +6.8 letters in HAWK; +6.9 vs +7.6 in HARRIER), and ≥50% of patients maintained q12w dosing ^[215]^A1b. Anatomic outcomes favored brolucizumab, with greater reductions in central subfield thickness (LS mean -172.8 μm vs -143.7 μm in HAWK) and a lower proportion of eyes with disease activity at Week 16 ^[215]^A1b. However, post-marketing reports of intraocular inflammation and retinal vasculitis limited its adoption. The TENAYA and LUCERNE trials (2022-2024) introduced the bispecific antibody , which inhibits both VEGF-A and angiopoietin-2. At year 2, faricimab 6 mg up to Q16W was noninferior to aflibercept 2 mg Q8W (adjusted mean BCVA change +3.7 to +5.0 letters vs +3.3 to +5.2 letters), and 59-67% of patients achieved Q16W dosing at Week 112 ^[213]^A1b. Rapid fluid resolution (by Week 8) was associated with longer durability: patients who achieved absence of both IRF and SRF by Week 12 had twice the odds of Q16W dosing at Week 112 (OR 1.76) ^[270]^B2b. The PULSAR trial (2025) evaluated high-dose 8 mg with extended intervals (q12w or q16w) versus aflibercept 2 mg q8w. At 96 weeks, both 8 mg arms maintained noninferior BCVA gains (+5.5 to +5.6 letters vs +6.6 letters), and 87% of the 8q12 group had last assigned intervals ≥12 weeks, with a favorable safety profile ^[145]^A1b^[479]^B2b. The ARCHWAY trial (2021) demonstrated that the Port Delivery System (PDS) with ranibizumab 100 mg/mL, requiring refill-exchange every 24 weeks, was noninferior and equivalent to monthly ranibizumab (adjusted mean BCVA change +0.2 vs +0.5 letters), with 98.4% of PDS-treated patients not receiving supplemental injections before the first refill ^[216]^A1b.

Treatment for Geographic Atrophy

For dry AMD, the and trials established that oral antioxidant and zinc supplements reduce the risk of progression from intermediate to advanced AMD by approximately 25% over 5 years ^[1]^D5. At 10-year follow-up, lutein/zeaxanthin was superior to beta-carotene (HR 0.85, 95% CI 0.73-0.98), and beta-carotene was associated with increased lung cancer risk in former smokers (OR 1.82) ^[147]^A1b. The GATHER1 trial (2020) of the C5 inhibitor (ACP) 2 mg and 4 mg monthly showed a reduction in GA growth of 27.4% and 27.8% at 12 months, with continued benefit at 18 months (28.1% and 30.0%) ^[65]^A1b^[158]^A1b. The FILLY trial (2019) of the C3 inhibitor demonstrated a 29% reduction in GA growth at 12 months with monthly dosing ^[217]^A1b. The phase 3 OAKS and DERBY trials confirmed pegcetacoplan's efficacy, showing a 22-27% reduction in RPE loss growth at 24 months, with even greater effects on photoreceptor degeneration (EZ loss reduced by 46-53%) ^[3]^B2b^[354]^C4. The GALE open-label extension reported up to a 42% reduction in GA growth in eyes with nonsubfoveal GA after 36 months of continuous treatment, and an 18% reduction in new scotomatous points on microperimetry ^[272]^B2b^[273]^B2b. However, both ACP and pegcetacoplan are associated with a small increased risk of developing exudative AMD (11.9-20.9% of treated eyes in trials) ^[158]^A1b^[217]^A1b.

Abandoned and Investigational Approaches

Laser photocoagulation, once the only treatment for extrafoveal CNV, caused irreversible scotomas and had high recurrence rates, and is now rarely used ^[467]^D5. Oral , a microglial inhibitor, failed to slow GA enlargement in a phase 2 trial ^[443]^C4. A trial of stereotactic radiotherapy (STAR) found that while it reduced anti-VEGF injections by a mean of 3.2 over 4 years, visual acuity was 8.3 letters worse in the SRT group, effectively reversing the year 2 primary outcome and no longer supporting its use ^[259]^A1b. Gene therapy (e.g., 4D-150, which delivers aflibercept transgenes) is under investigation, with complete prevention of laser-induced CNV in nonhuman primates ^[425]^D5.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Choice of first-line anti-VEGF agent for nAMD	EURETINA: any of ranibizumab, aflibercept, or brolucizumab ^[269]^A1c	Some experts: faricimab or aflibercept 8 mg preferred for durability ^[472]^D5	Moderate	Shared decision-making; consider patient adherence and interval preference
Role of PDT in PCV	Asian guidelines: PDT+anti-VEGF superior to anti-VEGF alone ^[178]^D5	Western guidelines: anti-VEGF alone sufficient ^[269]^A1c	Moderate	PDT availability varies; PCV diagnosis requires ICGA
When to discontinue anti-VEGF in quiescent nAMD	Vision Academy: consider exit after ≥3 consecutive max intervals without fluid ^[488]^D5	Some clinicians: indefinite treatment to prevent recurrence ^[488]^D5	Weak	Individualize based on risk of recurrence and patient preference

Pearl: The landmark trials that matter most to clinical practice are VIEW1/2 (established aflibercept 2 mg q8w as standard), AREDS2 (replaced beta-carotene with lutein/zeaxanthin and showed lung cancer risk), and GATHER1/OAKS (first FDA-approved therapies for GA).

Landmark Trials Shaping Current Treatment Standards

Trial (Year)	Comparison	Primary Endpoint	Key Result	NNT/NNH
ANCHOR/MARINA (2006)	Ranibizumab 0.5 mg monthly vs sham/PDT	Proportion losing <15 letters at 12 mo	~95% maintained vision; 25-40% gained ≥15 letters	NNT = 2 to prevent moderate vision loss ^[11]^A1c
VIEW1/2 (2012)	Aflibercept 2 mg q8w vs ranibizumab 0.5 mg monthly	Proportion maintaining vision at 52 wk	Aflibercept 95.1-96.3% vs ranibizumab 94.4% (noninferior)	NNT not calculable from reported data ^[214]^A1b
HARBOR (2012)	Ranibizumab 0.5 mg monthly vs PRN	BCVA change at 12 mo	Monthly superior to PRN; T&E evolved from PRN data	NNT not calculable ^[221]^B2b
HAWK/HARRIER (2019)	Brolucizumab 6 mg vs aflibercept 2 mg	BCVA change at 48 wk	Noninferior; >50% on q12w; greater CST reduction	NNT not calculable from reported data ^[215]^A1b
TENAYA/LUCERNE (2022-2024)	Faricimab 6 mg up to Q16W vs aflibercept 2 mg Q8W	BCVA change at 2 yr	Noninferior; 59-67% on Q16W at yr 2	NNT not calculable from reported data ^[213]^A1b
PULSAR (2025)	Aflibercept 8 mg q12-16w vs 2 mg q8w	BCVA noninferiority at 48 wk	Noninferior; 87% on ≥12wk intervals at 96 wk	NNT not calculable from reported data ^[145]^A1b
GATHER1 (2020)	Avacincaptad pegol 2 mg and 4 mg monthly vs sham	GA growth rate at 12 mo	27.4% and 27.8% reduction	NNT not calculable from reported data ^[65]^A1b
OAKS/DERBY (2023)	Pegcetacoplan monthly vs sham	GA growth at 24 mo	22-27% reduction in RPE loss; 46-53% reduction in EZ loss	NNT not calculable from reported data ^[3]^B2b

Surgical, Laser & Procedural Considerations

▸Intravitreal injection carries a 0.012% per-injection risk of retinal detachment; informed consent should include this rate.
▸Pneumatic displacement and vitrectomy with subretinal tPA yield comparable visual outcomes for submacular hemorrhage; neither is superior.
▸Port Delivery System reduces injection burden but increases ocular adverse events (RR 1.80); stereotactic radiotherapy is not recommended due to long-term vision loss and microvascular damage.

HY High Yield: Rechallenge with faricimab after prior mild IOI can trigger occlusive retinal vasculitis with irreversible vision loss, avoid reuse of the same biologic after IOI without careful risk-benefit assessment [276].

The evolution of anti-VEGF therapy has refined injection protocols, but procedural decisions, from technique selection to device choice, remain critical for optimizing outcomes and minimizing risks. This section addresses the procedural spectrum beyond standard pharmacotherapy, including laser, surgical, and device-based interventions.

Intravitreal Injection Technique and Safety Profile

Intravitreal injection is the most frequently performed intraocular procedure worldwide. Standardized aseptic technique, including povidone-iodine antisepsis, lid speculum, and avoidance of needle contact with the eyelid margin, is essential. The pooled risk of rhegmatogenous (RRD) following anti-VEGF injection is 0.012% per injection (approximately 1 in 8675 injections), with a per-eye risk of 0.08% (1 in 1250 eyes) ^[294]^B2a. Intraocular inflammation (IOI) rates vary by agent. Real-world faricimab IOI occurs at 0.19% per injection (95% CI, 0.12-0.30) ^[200]^B2b. For aflibercept 8 mg, a single-center series reported IOI in 3.7% of injections (5 of 136) in a clinical practice setting, higher than the pivotal trial rate ^[172]^C4. Most cases are mild and resolve with , but occlusive retinal vasculitis has been reported after faricimab rechallenge following prior mild IOI, emphasizing the need for caution ^[276]^C4.

Laser Therapies

Photodynamic therapy (PDT) with verteporfin retains a role in polypoidal choroidal vasculopathy (PCV), particularly in Asian populations where PCV is a common nAMD subtype ^[178]^D5. Combination therapy, PDT plus anti-VEGF, may reduce injection burden compared with anti-VEGF monotherapy in PCV ^[250]^D5. Subthreshold micropulse laser (SML) is being explored for non-exudative AMD; it delivers energy in short bursts to stimulate RPE repair without thermal damage, but evidence remains limited and protocol standardization is lacking ^[419]^D5.

Photobiomodulation (PBM) uses multiwavelength light (590, 660, and 850 nm) to target mitochondrial function. The LIGHTSITE III trial reported a 2.4-letter BCVA benefit over sham and a significant decrease in new-onset geographic atrophy (odds ratio 9.4) at 13 months in intermediate dry AMD ^[226]^A1b. However, a Cochrane review rated the evidence as low certainty, noting that PBM requires repeated treatment series to maintain effect ^[253]^A1a.

Surgical of Submacular Hemorrhage

Large submacular hemorrhage (SMH) secondary to nAMD carries a poor natural history. Two approaches dominate: pneumatic displacement (intravitreal tPA 50 μg + 0.3 mL pure SF₆) and pars plana vitrectomy with subretinal tPA (maximum 0.5 mL/50 μg) and 20% SF₆ tamponade. The STAMP trial randomized 90 patients and found no significant difference in mean VA change at 3 months (surgery: +16.8 letters; pneumatic displacement: +16.4 letters; adjusted difference β, 1.9 [95% CI, -11.0 to 14.9]; P = 0.767) ^[368]^A1b. Both groups received intravitreal ranibizumab at the end of the procedure and monthly for 2 months, followed by pro re nata dosing. Neither approach was superior, and the trial was not designed to prove equivalence. Combined vitrectomy, subretinal tPA, gas, and anti-VEGF may achieve the greatest VA improvement, but data come from small, non-comparative series ^[420]^D5.

Device Implants

Port Delivery System (PDS) with ranibizumab (100 mg/mL) is a surgically implanted refillable reservoir that delivers continuous ranibizumab. A meta-analysis of 3 RCTs (1149 eyes) found PDS noninferior to monthly ranibizumab for BCVA and CRT, but ocular adverse events were significantly higher (RR 1.80; 95% CI, 1.49-2.17), including conjunctival bleb leak (RR 15.29), vitreous hemorrhage (RR 3.61), and hyphema (RR 5.77) ^[439]^A1a. The implantable miniature telescope (IMT) has no published RCTs; its use remains limited to select cases of end-stage AMD with central scotoma ^[498]^A1a.

Gene Therapy and Cell Transplantation

Gene therapy for nAMD uses adeno-associated virus (AAV) vectors to deliver anti-VEGF transgenes after a single intravitreal or subretinal injection. Among 203 treated participants in 8 prospective studies, anatomical reduction in CST (MD 37.13 μm; 95% CI, 26.63-47.62) was observed, but pooled BCVA change was not significant (MD 0.54 ETDRS letters; 95% CI, -7.38 to 8.46) ^[229]^A1a. For geographic atrophy, JNJ-81201887 (AAV-based) showed a manageable safety profile in a phase 1 study, with a trend toward reduced lesion growth rate at 24 months in the high-dose cohort (0.211 mm at months 0-6 to 0.056 mm at months 18-24) ^[149]^C4. RPE cell transplantation, using autologous or stem cell-derived RPE, remains experimental, with challenges in immune rejection, cell survival, and integration ^[408]^D5^[409]^D5^[428]^D5.

Radiotherapy

Stereotactic radiotherapy (SRT, 16 Gy single fraction) was investigated in the STAR trial as an adjunct to anti-VEGF for chronic active nAMD. At 4 years, SRT reduced the mean number of anti-VEGF injections by 3.2 (19.1 vs 21.6; 95% CI of difference, -5.7 to -0.7), but final BCVA was 8.3 letters worse in the SRT group (95% CI, -12.7 to -4.0), and reading-center-detected microvascular abnormalities occurred in 58% of SRT-treated eyes vs 16% of sham ^[259]^A1b. These findings do not support SRT use. The procedures described above carry distinct risk profiles that are detailed in the next section on complications.

Pearl: Port Delivery System reduces injection burden but increases ocular adverse events (RR 1.80); stereotactic radiotherapy is not recommended due to long-term vision loss and microvascular damage.

Procedural Interventions for AMD: Indications and Key Evidence

Procedure	Indication	Key Evidence	Complications / Caveats
Intravitreal injection	All nAMD	0.012% RRD risk per injection ^[294]^B2a	Endophthalmitis, IOI; IOI rates vary by agent
Photodynamic therapy (PDT)	PCV, select nAMD	Reduces injection burden in PCV ^[178]^D5	Transient vision loss, choroidal ischemia
Photobiomodulation	Intermediate dry AMD	+2.4 letters vs sham, reduced GA onset ^[226]^A1b	Low-certainty evidence, requires repeated sessions
Pneumatic displacement	Large SMH (≤14 days)	+16.4 letters at 3 months ^[368]^A1b	Not superior to vitrectomy
Vitrectomy + subretinal tPA	Large SMH (≤14 days)	+16.8 letters at 3 months ^[368]^A1b	No superiority vs pneumatic displacement
Port Delivery System	nAMD requiring frequent injections	Noninferior BCVA, but higher ocular AEs ^[439]^A1a	Conjunctival erosion, bleb leak, vitreous hemorrhage
Gene therapy (AAV)	nAMD (investigational)	CST reduction 37 μm; BCVA not significant ^[229]^A1a	Inflammation, immune response; long-term durability unknown
Stereotactic radiotherapy	Chronic nAMD (historical)	3.2 fewer injections, but -8.3 letters BCVA at 4 years ^[259]^A1b	Microvascular abnormalities, not recommended

Complications & Ocular Sequelae

▸Macular fibrosis prevalence reaches 56% at 5 years; 60% of the fibrosis burden develops in the first year of anti-VEGF treatment.
▸Complement inhibitors for GA reduce growth by 29-42% but increase the risk of conversion to exudative AMD (up to 20.9% with monthly pegcetacoplan).
▸Occlusive retinal vasculitis is a rare but severe complication of faricimab rechallenge after prior mild intraocular inflammation.

HY High Yield: Persistent intraretinal fluid (IRF) and subretinal hyperreflective material (SHRM) on OCT are the strongest predictors of poor visual outcome and fibrosis progression. At each visit, assess for these biomarkers, not just central subfield thickness.

! Warning: Do not rechallenge with faricimab after even mild intraocular inflammation - occlusive retinal vasculitis and irreversible vision loss can occur [276].

From the procedural considerations of the preceding section, the clinician must now turn to the structural and functional complications that emerge from both the disease and its treatments. These sequelae, each tied to a distinct mechanism and surveillance test, determine long-term visual outcomes.

Macular Fibrosis and Disciform Scar

Fibrosis (subretinal or disciform scar) is the most common cause of irreversible vision loss in treated neovascular AMD (nAMD). Its prevalence rises from 32% at 12 months to 56% at 60 months; approximately 60% of the 5-year fibrosis burden develops within the first year of treatment ^[12]^B2a. Risk factors include classic choroidal neovascularization, intraretinal fluid (IRF), hemorrhage, and subretinal hyperreflective material (SHRM) ^[12]^B2a. Surveillance is by OCT (SHRM, ellipsoid zone loss) and fundus autofluorescence (FAF). Vision in fibrotic eyes is on average 18.5 letters worse than non-fibrotic eyes at baseline, widening to 26.9 letters at 12 months despite anti-VEGF therapy ^[12]^B2a.

Geographic Atrophy Progression

In dry AMD, geographic atrophy (GA) enlargement is the primary structural sequela. Complement C3 inhibition with pegcetacoplan reduces GA growth by 29% at 12 months (monthly dosing) and up to 42% in nonsubfoveal GA at 36 months ^[217]^A1b^[272]^B2b. C5 inhibition with avacincaptad pegol reduces growth by 27-30% at 18 months ^[65]^A1b^[158]^A1b. Surveillance is by FAF or OCT. A key trade-off: pegcetacoplan increases risk of conversion to exudative AMD (20.9% monthly vs 1.2% sham) ^[217]^A1b.

Macular Neovascularization (Conversion to Wet AMD)

In intermediate AMD, the annual incidence of neovascular conversion is approximately 1.8 per 1000 ^[14]^B2a. The risk is higher with reticular pseudodrusen and complement inhibitor exposure ^[217]^A1b^[26]^D5. OCT is the first-line surveillance test for IRF, subretinal fluid (SRF), and pigment epithelial detachment.

Retinal Pigment Epithelium Tears

RPE tears complicate up to 10-15% of nAMD cases, particularly during anti-VEGF therapy for pigment epithelial detachments. They present with acute vision loss and are identified on OCT. is observation or continued anti-VEGF if subfoveal.

Submacular Hemorrhage

Thick, large submacular hemorrhage carries a poor natural history. Anti-VEGF alone is reasonable for thin or extrafoveal bleeds; surgical displacement (subretinal tPA, gas tamponade) is considered for thick, foveal-involving hemorrhages ^[191]^D5.

Treatment-Related Complications

Complication	Frequency	Prevention	Management
Intraocular inflammation (IOI) - faricimab	0.19% per injection ^[200]^B2b; 0.86% per eye	Avoid rechallenge after prior mild IOI ^[276]^C4	Topical steroids; discontinue if occlusive retinal vasculitis ^[276]^C4
IOI - aflibercept 8 mg	3.7% per injection (real-world) ^[172]^C4	None proven	Topical/subconjunctival steroids ^[172]^C4
- PDS	1.6% per implantation ^[216]^A1b	Aseptic technique	Intravitreal ± vitrectomy
Vitreous hemorrhage - PDS	5.2% ^[216]^A1b	Implantation technique	Observation or vitrectomy
Conjunctival erosion/retraction - PDS	2.4% / 2.0% ^[216]^A1b	Sizing, suturing	Surgical revision if persistent
- PDS	0.8% ^[216]^A1b	None	Pneumatic retinopexy or vitrectomy
Cataract - repeated injections	Related to phakic status	Nil	Standard phacoemulsification

Functional Sequelae and Quality of Life

Beyond structural damage, nAMD causes persistent metamorphopsia, central scotomas, reduced contrast sensitivity, and impaired reading speed, even when visual acuity is maintained ^[505]^A1a^[509]^B2c. IRF and SHRM are the strongest OCT biomarkers for pointwise sensitivity loss ^[509]^B2c. Vision-related quality of life declines with disease stage, and the treatment burden of frequent injections contributes to this ^[505]^A1a^[264]^D5.

Pearl: Fibrosis is the dominant cause of irreversible vision loss in treated nAMD, and its burden accumulates early - close monitoring of OCT biomarkers (SHRM, IRF) in the first 12 months is critical, as about 60% of 5-year fibrosis develops during this window ^[12]^B2a.

Prognosis & Natural History

▸Untreated neovascular AMD leads to progressive lesion enlargement to ~10.6 disc areas, with final VA often 20/1600; anti-VEGF therapy can achieve mean gains of +5-15 letters and maintain vision in >90% of eyes.
▸Extended dosing regimens (faricimab every 16 weeks, aflibercept 8 mg every 12-16 weeks) provide noninferior VA outcomes to monthly dosing, reducing injection burden while sustaining anatomic control.
▸Geographic atrophy therapies (pegcetacoplan, avacincaptad pegol) slow lesion growth by 14-32% but do not reverse vision loss; early identification of high-risk OCT biomarkers (IRF, SRF, hyperreflective foci) guides prognosis.

HY High Yield: Early, complete fluid resolution (by week 12) with anti-VEGF therapy is the strongest modifiable predictor of both visual gain and extended dosing durability, a key target for initial treatment choice.

The natural history of AMD, once a complication has declared itself, follows a relentless trajectory toward central vision loss unless interrupted by treatment. Understanding the expected course, both untreated and treated, anchors clinical decision-making and patient counseling.

Untreated Natural History

Without intervention, eyes with neovascular AMD (nAMD) experience inexorable enlargement of the choroidal neovascular lesion. A meta-analysis of control-arm data from five landmark trials projected that an untreated CNV lesion will eventually reach 10.6 disc areas in size, with half of that growth occurring within 14.0 months of exudation onset ^[356]^A1a. The linear expansion rate approximates 26.0 μm/day for the smallest lesions, decreasing gradually as the lesion enlarges ^[356]^A1a. Final visual acuity (VA) in untreated submacular hemorrhage averages 20/1600 ^[420]^D5. For geographic atrophy (GA), the natural history is progressive enlargement of the atrophic zone; untreated eyes lose approximately 0.15-0.25 mm²/year in square-root-transformed area, with foveal involvement heralding irreversible central scotoma ^[3]^B2b.

Treated Prognosis in Neovascular AMD

Anti-VEGF therapy dramatically alters this trajectory. Across pivotal trials, monthly ranibizumab maintained vision in >90% of eyes and improved VA by ≥15 letters in 25-40% ^[250]^D5. In the VIEW 1/2 trials, intravitreal aflibercept 2 mg every 2 months (after 3 monthly loading doses) achieved noninferior VA gains (mean +7.9 letters) compared with monthly ranibizumab ^[214]^A1b. Treat-and-extend (T&E) regimens produce VA outcomes comparable to monthly dosing while reducing injection burden: a meta-analysis of ranibizumab T&E showed mean gains of +8.8 letters at year 1, with a mean of 6.9 injections versus 12.0 for monthly ^[512]^A1a^[378]^B2a.

Newer agents extend durability. Faricimab 6.0 mg, a bispecific antibody targeting VEGF-A and angiopoietin-2, maintained VA gains through year 2 (mean change +3.7 to +5.0 letters) with 59-67% of eyes achieving every-16-week dosing at week 112 ^[213]^A1b. Rapid resolution of intraretinal and subretinal fluid by week 12 was associated with a 1.99-fold higher odds of extended dosing intervals later ^[270]^B2b. High-dose aflibercept 8 mg (PULSAR trial) provided noninferior VA gains at 96 weeks (+5.5 to +5.6 letters) with a mean of 8.2-9.7 injections over 2 years versus 12.8 for the 2 mg every-8-week arm ^[145]^A1b.

Treated Prognosis in Geographic Atrophy

Complement inhibitors slow GA growth but do not restore lost photoreceptors. Pegcetacoplan (monthly or every other month) reduced GA area growth by up to 32% versus projected sham over 36 months, with a 42% reduction in nonsubfoveal GA ^[272]^B2b. Microperimetry showed a 34-48% risk reduction in central scotoma development ^[273]^B2b. Avacincaptad pegol 2 mg reduced GA growth by 14-19% at 2 years, with a mean difference of 0.72-0.98 mm² versus sham ^[146]^A1b. However, the incidence of choroidal neovascularization was numerically higher with complement inhibitors (11.6% vs 9.0% for avacincaptad) ^[146]^A1b.

Prognostic Factors

Multiple factors influence outcomes. OCT biomarkers carry the strongest evidence: intraretinal fluid (IRF) portends worse VA, whereas subretinal fluid (SRF) may be better tolerated ^[221]^B2b^[167]^B2a. A machine learning model using quantitative fluid metrics predicted total anti-VEGF injections within 2 injections in 99.6% of eyes at year 1, with SRF being the primary driver of injection burden and IRF most influential for VA outcomes ^[442]^C4. Other negative prognosticators include larger baseline lesion size, foveal GA involvement, and genetic risk variants (CFH Y402H, ARMS2 A69S) ^[306]^D5^[513]^B2a.

Pearl: The strongest modifiable predictor of long-term visual outcome in nAMD is the rapidity and completeness of fluid resolution during the initial loading phase, eyes achieving a dry macula by week 12 enjoy better VA and durability of extended dosing intervals ^[270]^B2b^[144]^A1b.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Optimal first-line agent for nAMD	Ranibizumab or aflibercept (AAO, NICE)	Faricimab or high-dose aflibercept (ESMO-style expert opinion)	Equivalent efficacy at 1 year; faricimab/aflibercept 8 mg offer extended intervals ^[213]^A1b	Choice may depend on patient preference for injection frequency and cost
Role of photobiomodulation in dry AMD	Cochrane review: low-certainty evidence, no meaningful BCVA benefit at 12 months ^[253]^A1a	LIGHTSITE III: +6.2 letter gain at 21 months, reduced GA conversion ^[151]^A1b	Conflicting; larger trials needed	Not yet standard of care

Key Prognostic Factors in Age-Related Macular Degeneration

Factor	Association with Outcome	Evidence Level
Intraretinal fluid (IRF)	Worse VA, higher injection burden	^[221]^B2b^[167]^B2a^[442]^C4
Subretinal fluid (SRF)	Better VA, associated with extended dosing	^[221]^B2b^[270]^B2b
Baseline lesion size >4 disc areas	Greater risk of vision loss	^[356]^A1a
Foveal GA involvement	Accelerated central scotoma	^[273]^B2b
CFH Y402H / ARMS2 A69S risk alleles	Increased progression risk	^[306]^D5^[513]^B2a
Drusen volume >0.03 mm³	Predicts progression to late AMD within 2 years	^[520]^B2b

Special Populations & Pregnancy

▸Ranibizumab has the lowest systemic absorption among anti-VEGF agents and is preferred in pregnancy [405].
▸Pediatric AMD-like presentations are invariably inherited retinal dystrophies, not true AMD [248].
▸In very elderly patients, treat-and-extend regimens with faricimab or ranibizumab reduce visit burden while maintaining vision [213].

HY High Yield: Systemic free-VEGF suppression is greatest with aflibercept and least with ranibizumab; choose ranibizumab when systemic exposure is a concern [405].

After understanding the natural history and prognostic factors, clinicians must adapt when AMD intersects with special physiologic states or systemic comorbidities. No dedicated randomized trials have evaluated anti-VEGF therapy in these populations, and recommendations derive from pharmacokinetic data ^[405]^B2b, case series, and expert consensus.

Pregnancy

Intravitreal anti-VEGF agents cross the placenta and have theoretical teratogenic risk. Systemic exposure differs markedly between drugs: ranibizumab clears from the bloodstream most rapidly and produces the smallest reduction in plasma free-VEGF, whereas yields the highest systemic exposure and aflibercept causes the greatest suppression of circulating free VEGF ^[405]^B2b. For women requiring treatment during pregnancy, ranibizumab 0.5 mg is preferred because of its minimal systemic pharmacokinetic footprint ^[405]^B2b. Bevacizumab and aflibercept should be avoided unless no alternative exists. Delivery planning should involve shared decision-making with the obstetric team; elective induction or cesarean section may be considered if active neovascular lesions threaten vision during the third trimester. safety data are lacking; the lowest systemic-exposure agent (ranibizumab) is the rational choice if treatment is necessary during lactation.

Pediatrics

True AMD does not occur in children. Infants, children, or adolescents presenting with drusen, geographic atrophy, or choroidal neovascularization require evaluation for inherited retinal dystrophies such as , Best disease, or pattern dystrophy ^[248]^D5. Age-appropriate imaging (handheld OCT in infants, spectral-domain OCT in cooperative children) is essential. Anti-VEGF therapy is occasionally used off-label for pediatric choroidal neovascularization from other causes (e.g., inflammatory, traumatic), but no dosing trials exist; the ranibizumab 0.3 mg to 0.5 mg monthly regimen extrapolated from adult data is commonly employed. Long-term developmental impact on the developing retina has not been studied.

Elderly

AMD is primarily a disease of the elderly, and the very old (≥85 years) face higher risks of injection-related complications such as and intraocular inflammation ^[200]^B2b^[276]^C4. Comorbidity interactions are critical: anticoagulation increases the risk of submacular hemorrhage, and antiplatelet/anticoagulant therapy should be continued during injections unless the bleeding risk is prohibitive. Statin use may reduce the risk of developing choroidal neovascularization ^[131]^D5. In frail patients with limited life expectancy, a treat-and-extend or pro re nata regimen with ranibizumab or faricimab (which offers extended dosing intervals up to every 16 weeks ^[213]^A1b) may reduce visit burden without sacrificing vision.

Immunocompromised

Patients on systemic immunosuppression (e.g., post-transplant, biologic therapy) have increased susceptibility to infectious endophthalmitis after intravitreal injection. Strict aseptic technique, povidone-iodine antisepsis, and a low threshold for post-injection monitoring are mandatory. Complement inhibitors (pegcetacoplan, avacincaptad pegol) for geographic atrophy may theoretically modulate systemic complement, but trial data show no increase in systemic infections compared with sham ^[272]^B2b^[158]^A1b.

Pearl: In pregnant women requiring treatment for neovascular AMD, choose ranibizumab 0.5 mg because its minimal systemic exposure ^[405]^B2b reduces fetal risk; avoid bevacizumab and aflibercept unless no alternative exists.

Prevention, Screening & Surveillance

▸Up to 45% of AMD cases are potentially preventable through modifiable risk factors including optimal cardiovascular health, high omega-3 levels, physical activity, and smoking avoidance.
▸Antioxidant supplements (vitamins C, E, beta-carotene) do not prevent AMD onset; AREDS2 is indicated only for intermediate AMD to slow progression.
▸Deep learning-based screening from fundus photographs achieves >98% sensitivity and specificity for AMD detection, supporting its use in scalable telemedicine programs.

HY High Yield: Cardiovascular health (Life's Essential 8) is a strong, modifiable predictor of AMD risk. Promoting ideal blood pressure and blood glucose could prevent >10% of cases [199].

While special populations require tailored , the principles of prevention apply broadly: up to 30.4%-45.1% of age-related macular degeneration (AMD) cases are potentially preventable through modification of risk factors ^[559]^B2b.

Primary Prevention: Modifiable Risk Factors

Cardiovascular health is a central target. Adults with high cardiovascular health (Life's Essential 8 score ≥80) have a 23% lower risk of incident AMD (HR 0.77, 95% CI 0.69-0.86) compared with those with low scores; achieving optimal CVH in all individuals could avert an estimated 9.4% of AMD cases ^[199]^B2b. Higher plasma omega-3 and docosahexaenoic acid levels are associated with 20% and 35% reductions in AMD risk, respectively (HR 0.80, 95% CI 0.72-0.95; HR 0.65, 95% CI 0.44-0.96) ^[548]^B2b. High levels of physical activity protect against incident early AMD (HR for low vs high activity 1.19, 95% CI 1.01-1.40) ^[153]^B2a.

By contrast, antioxidant vitamin and mineral supplements (vitamin E, beta‑carotene) do not prevent AMD onset (pooled RR 0.98, 95% CI 0.89-1.08) ^[554]^A1a. show no significant benefit for AMD incidence (RR 1.05, 95% CI 0.85-1.29) ^[164]^B2a, though in patients with type 2 diabetes and dyslipidemia, medium- and high-intensity statin therapy reduces AMD risk (HR 0.79 at 5 years for high intensity; HR range 0.49-0.77 for medium intensity) ^[558]^B2b. does not alter AMD risk ^[407]^B2c. Cocoa flavanol supplementation had no overall effect on AMD over 3.6 years (HR 0.87, 95% CI 0.71-1.08) ^[148]^A1b.

Secondary Prevention: Progression of Early to Late AMD

For patients with intermediate AMD (large drusen or pigmentary abnormalities), the AREDS2 formulation (vitamin C, vitamin E, lutein/zeaxanthin, zinc) reduces the risk of progression to advanced AMD ^[162]^B2a. Zinc alone may also slow progression, but combination therapy is standard. Smoking cessation remains the single most impactful behavioral intervention.

Screening Recommendations and Surveillance

Systematic reviews of clinical practice guidelines uniformly recommend optical coherence tomography (OCT) for initial diagnosis of neovascular AMD ^[225]^D5. For population screening, color fundus photography interpreted by deep learning algorithms achieves pooled sensitivity 0.98 (95% CI 0.96-0.99) and specificity 0.98 (95% CI 0.95-0.99) for detecting AMD ^[56]^A1a. The Amsler grid (sensitivity 0.78, specificity 0.97) and preferential hyperacuity perimetry (sensitivity 0.85, specificity 0.87) offer low-cost options for home monitoring ^[545]^B2a. OCT can detect early choroidal neovascularization in high-risk eyes before clinical signs appear ^[556]^C4.

Emerging Technologies: AI and Telemedicine

Artificial intelligence-based screening using fundus photographs or OCT is cost-effective and may extend access to underserved populations ^[539]^B2a^[549]^D5. Telemedicine platforms with autonomous AI grading have been shown to improve early detection rates in community settings ^[379]^D5. Prospective trials are underway to evaluate AI-assisted screening in primary care and geriatric clinics ^[298]^D5.

Patient Education

Patients with early or intermediate AMD should be counseled to perform daily Amsler grid testing, maintain a heart‑healthy diet rich in omega‑3 fatty acids, engage in regular physical activity, avoid smoking, and adhere to AREDS2 supplementation if indicated.

Pearl: Deep learning-based screening from fundus photographs achieves >98% sensitivity and specificity for AMD detection, supporting its use in scalable telemedicine programs.

References

[1]
Chew EY, Clemons T, SanGiovanni JP et al.. “The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1).” Ophthalmology (2012). PMID: 22840421 ↗
L5RCTCited in: Definition, Classification & Nomenclature, Clinical Presentation, Clinical Examination and Diagnostic Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management, History and Evolution of Treatment, Prognosis & Natural History
[2]
Agrón E, Domalpally A, Chen Q et al.. “An Updated Simplified Severity Scale for Age-Related Macular Degeneration Incorporating Reticular Pseudodrusen: Age-Related Eye Disease Study Report Number 42.” Ophthalmology (2024). PMID: 38657840 ↗
L2RCTCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification
[3]
Fu DJ, Bagga P, Naik G et al.. “Pegcetacoplan Treatment and Consensus Features of Geographic Atrophy Over 24 Months.” JAMA ophthalmology (2024). PMID: 38722644 ↗
L2RCTCited in: Definition, Classification & Nomenclature, Ophthalmic Imaging and Functional Testing, Long-term & Definitive Management, History and Evolution of Treatment, Prognosis & Natural History
[4]
Nittala MG, Metlapally R, Ip M et al.. “Association of Pegcetacoplan With Progression of Incomplete Retinal Pigment Epithelium and Outer Retinal Atrophy in Age-Related Macular Degeneration: A Post Hoc Analysis of the FILLY Randomized Clinical Trial.” JAMA ophthalmology (2022). PMID: 35113137 ↗
L2RCTCited in: Definition, Classification & Nomenclature, Ophthalmic Imaging and Functional Testing, History and Evolution of Treatment
[5]
Colijn JM, Buitendijk GHS, Prokofyeva E et al.. “Prevalence of Age-Related Macular Degeneration in Europe: The Past and the Future.” Ophthalmology (2017). PMID: 28712657 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors
[6]
Nanji K, Grad J, Hatamnejad A et al.. “Baseline OCT Biomarkers Predicting Visual Outcomes in Neovascular Age-Related Macular Degeneration: A Meta-Analysis.” Ophthalmology (2025). PMID: 40570933 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Surgical, Laser & Procedural Considerations
[7]
Kawasaki R, Yasuda M, Song SJ et al.. “The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis.” Ophthalmology (2010). PMID: 20110127 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature
[8]
Rudnicka AR, Jarrar Z, Wormald R et al.. “Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis.” Ophthalmology (2011). PMID: 22176800 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature
[9]
Cipriani V, Hogg RE, Sofat R et al.. “Association of C-Reactive Protein Genetic Polymorphisms With Late Age-Related Macular Degeneration.” JAMA ophthalmology (2017). PMID: 28750115 ↗
L3SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae
[10]
Okada M, Wong TY, Mitchell P et al.. “Defining Nonadherence and Nonpersistence to Anti-Vascular Endothelial Growth Factor Therapies in Neovascular Age-Related Macular Degeneration.” JAMA ophthalmology (2021). PMID: 34081099 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Long-term & Definitive Management
[11]
Mitchell P, Korobelnik JF, Lanzetta P et al.. “Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials.” The British journal of ophthalmology (2009). PMID: 19443462 ↗
L1TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature, Clinical Presentation, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae, Prognosis & Natural History, Special Populations & Pregnancy
[12]
Cheong KX, Cheung CMG, Teo KYC. “Review of Fibrosis in Neovascular Age-Related Macular Degeneration.” American journal of ophthalmology (2022). PMID: 36162537 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae, Special Populations & Pregnancy
[13]
Reibaldi M, Longo A, Pulvirenti A et al.. “Geo-Epidemiology of Age-Related Macular Degeneration: New Clues Into the Pathogenesis.” American journal of ophthalmology (2015). PMID: 26432929 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification
[14]
Rudnicka AR, Kapetanakis VV, Jarrar Z et al.. “Incidence of Late-Stage Age-Related Macular Degeneration in American Whites: Systematic Review and Meta-analysis.” American journal of ophthalmology (2015). PMID: 25857680 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Complications & Ocular Sequelae
[15]
Huang RS, Balas M, Jhaveri A et al.. “Comparison of Renal Adverse Events Between Intravitreal Anti-Vascular Endothelial Growth Factor Agents: A Meta-Analysis.” American journal of ophthalmology (2024). PMID: 39746595 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Acute & Vision-Threatening Management
[16]
Li JQ, Welchowski T, Schmid M et al.. “Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis.” The British journal of ophthalmology (2019). PMID: 31712255 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup
[17]
Zhou M, Duan PC, Liang JH et al.. “Geographic distributions of age-related macular degeneration incidence: a systematic review and meta-analysis.” The British journal of ophthalmology (2020). PMID: 32907810 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance
[18]
Singh SR, Goté JT, Chhablani J. “Randomized controlled trials in central serous chorioretinopathy: A review.” Eye (London, England) (2023). PMID: 36997794 ↗
L5RCTCited in: Definition, Classification & Nomenclature, Acute & Vision-Threatening Management, Long-term & Definitive Management, History and Evolution of Treatment
[19]
Hong T, Tan AG, Mitchell P et al.. “A review and meta-analysis of the association between C-reactive protein and age-related macular degeneration.” Survey of ophthalmology (2011). PMID: 21420705 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature
[20]
Paul SK, Pan I, Sobol WM. “A SYSTEMATIC REVIEW OF DEEP LEARNING APPLICATIONS FOR OPTICAL COHERENCE TOMOGRAPHY IN AGE-RELATED MACULAR DEGENERATION.” Retina (Philadelphia, Pa.) (2022). PMID: 35877964 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Ophthalmic Imaging and Functional Testing, Severity, Staging & Risk Stratification
[21]
Chaudhary V, Matonti F, Zarranz-Ventura J et al.. “IMPACT OF FLUID COMPARTMENTS ON FUNCTIONAL OUTCOMES FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Literature Review.” Retina (Philadelphia, Pa.) (2022). PMID: 34393212 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature
[22]
Jindal DA, Hanna J, Shaia JK et al.. “Metformin and the Development of Age-Related Macular Degeneration.” JAMA ophthalmology (2025). PMID: 40965862 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Special Populations & Pregnancy
[23]
Rämö JT, Abner E, van Dijk EHC et al.. “Overlap of Genetic Loci for Central Serous Chorioretinopathy With Age-Related Macular Degeneration.” JAMA ophthalmology (2023). PMID: 37079300 ↗
L3OTHERCited in: Definition, Classification & Nomenclature
[24]
Kanagasingam Y, Bhuiyan A, Abràmoff MD et al.. “Progress on retinal image analysis for age related macular degeneration.” Progress in retinal and eye research (2013). PMID: 24211245 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Ophthalmic Imaging and Functional Testing, Prevention, Screening & Surveillance
[25]
Vidal-Oliver L, Garzone D, Schloesser L et al.. “Structural photoreceptor evaluation in age-related macular degeneration. A comprehensive review of methods and clinical significance.” Progress in retinal and eye research (2026). PMID: 41692377 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Ophthalmic Imaging and Functional Testing, Long-term & Definitive Management
[26]
Wu Z, Fletcher EL, Kumar H et al.. “Reticular pseudodrusen: A critical phenotype in age-related macular degeneration.” Progress in retinal and eye research (2021). PMID: 34752916 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Complications & Ocular Sequelae
[27]
Sacconi R, Fragiotta S, Sarraf D et al.. “Towards a better understanding of non-exudative choroidal and macular neovascularization.” Progress in retinal and eye research (2022). PMID: 35970724 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature
[28]
Booij JC, Baas DC, Beisekeeva J et al.. “The dynamic nature of Bruch's membrane.” Progress in retinal and eye research (2009). PMID: 19747980 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature
[29]
Lin V, Lee W, Kang EY et al.. “Outer retinal tubulation associated with photoreceptor degeneration.” Progress in retinal and eye research (2026). PMID: 41548710 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, History and Evolution of Treatment
[30]
Kang C, Lo JE, Zhang H et al.. “Artificial intelligence for diagnosing exudative age-related macular degeneration.” The Cochrane database of systematic reviews (2024). PMID: 39417312 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing, Complications & Ocular Sequelae
[31]
Casparis H, Lindsley K, Kuo IC et al.. “Surgery for cataracts in people with age-related macular degeneration.” The Cochrane database of systematic reviews (2017). PMID: 28206671 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Clinical Examination and Diagnostic Workup, Severity, Staging & Risk Stratification, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
[32]
Casparis H, Lindsley K, Kuo IC et al.. “Surgery for cataracts in people with age-related macular degeneration.” The Cochrane database of systematic reviews (2012). PMID: 22696359 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Prognosis & Natural History
[33]
Downie LE, Busija L, Keller PR. “Blue-light filtering intraocular lenses (IOLs) for protecting macular health.” The Cochrane database of systematic reviews (2018). PMID: 29786830 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature
[34]
Zhang C, Sonik NR, Ayoubi M et al.. “Clinical efficacy and safety of aflibercept biosimilars in neovascular age-related macular degeneration: a systematic review and meta-analysis of randomised controlled trials.” The British journal of ophthalmology (2026). PMID: 42236129 ↗
L1SR_MA_RCTCited in: Definition, Classification & Nomenclature, Clinical Presentation, Severity, Staging & Risk Stratification, Surgical, Laser & Procedural Considerations
[35]
Sasaki M, Apte RS, Bastion MC et al.. “International Consensus and Guidelines on Diagnosing and Managing Pachydrusen from APVRS, AEEC, APOIS, AAPPO, and ARI.” American journal of ophthalmology (2025). PMID: 41086904 ↗
L1OTHERCited in: Definition, Classification & Nomenclature
[36]
Chew EY. “Age-related Macular Degeneration: Nutrition, Genes and Deep Learning-The LXXVI Edward Jackson Memorial Lecture.” American journal of ophthalmology (2020). PMID: 32574780 ↗
L5OTHERCited in: Definition, Classification & Nomenclature
[37]
Ting DSW, Pasquale LR, Peng L et al.. “Artificial intelligence and deep learning in ophthalmology.” The British journal of ophthalmology (2018). PMID: 30361278 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Ophthalmic Imaging and Functional Testing, Prevention, Screening & Surveillance
[38]
Zhu Z, Liao H, Wang W et al.. “Association between age-related macular degeneration and subjective cognitive complaints.” The British journal of ophthalmology (2019). PMID: 31801734 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification
[39]
Park J, Jung W, Han K et al.. “Association between age-related macular degeneration and risk of incident cancer.” The British journal of ophthalmology (2024). PMID: 38418207 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Prevention, Screening & Surveillance
[40]
Sheth JU, Stewart MW, Narayanan R et al.. “Macular neovascularization.” Survey of ophthalmology (2024). PMID: 39222802 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Clinical Presentation, Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae
[41]
Tsai ASH, Cheung N, Gan ATL et al.. “Retinal angiomatous proliferation.” Survey of ophthalmology (2017). PMID: 28189495 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Clinical Presentation, Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing, Long-term & Definitive Management, Complications & Ocular Sequelae, Prognosis & Natural History
[42]
Zayit-Soudry S, Moroz I, Loewenstein A. “Retinal pigment epithelial detachment.” Survey of ophthalmology (2007). PMID: 17472800 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Clinical Examination and Diagnostic Workup, Prognosis & Natural History
[43]
Trincão-Marques J, Ayton LN, Hickey DG et al.. “Gene and cell therapy for age-related macular degeneration: A review.” Survey of ophthalmology (2024). PMID: 38735629 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management, Complications & Ocular Sequelae, Special Populations & Pregnancy
[44]
Rispoli M, Cennamo G, Antonio LD et al.. “Practical guidance for imaging biomarkers in exudative age-related macular degeneration.” Survey of ophthalmology (2023). PMID: 36854371 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations
[45]
Curcio CA, Kar D, Owsley C et al.. “Age-Related Macular Degeneration, a Mathematically Tractable Disease.” Investigative ophthalmology & visual science (2024). PMID: 38466281 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Clinical Presentation, Severity, Staging & Risk Stratification
[46]
Garrity ST, Sarraf D, Freund KB et al.. “Multimodal Imaging of Nonneovascular Age-Related Macular Degeneration.” Investigative ophthalmology & visual science (2018). PMID: 30025107 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Clinical Examination and Diagnostic Workup, Acute & Vision-Threatening Management
[47]
Seshasai S, Liao J, Toh QC et al.. “Serum leptin and age-related macular degeneration.” Investigative ophthalmology & visual science (2015). PMID: 25711634 ↗
L3OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification
[48]
Miller JW. “Beyond VEGF-The Weisenfeld Lecture.” Investigative ophthalmology & visual science (2016). PMID: 28027565 ↗
L5OTHERCited in: Definition, Classification & Nomenclature, Long-term & Definitive Management
[49]
Sabanayagam C, Lye WK, Januszewski A et al.. “Urinary Isoprostane Levels and Age-Related Macular Degeneration.” Investigative ophthalmology & visual science (2017). PMID: 28492872 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, History and Evolution of Treatment
[50]
Moir J, Hyman MJ, Wang J et al.. “Associations Between Autoimmune Disease and the Development of Age-Related Macular Degeneration.” Investigative ophthalmology & visual science (2023). PMID: 38153747 ↗
L3OTHERCited in: Definition, Classification & Nomenclature, Acute & Vision-Threatening Management
[51]
Chan HH, Feo A, Cabral D et al.. “TYPE 4 MACULAR NEOVASCULARIZATION: A New Member of the Optical Coherence Tomography Classification of Neovascularization Age-Related Macular Degeneration.” Retina (Philadelphia, Pa.) (2026). PMID: 40924919 ↗
L4OTHERCited in: Definition, Classification & Nomenclature, Clinical Presentation, Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing, Complications & Ocular Sequelae, Prognosis & Natural History, Special Populations & Pregnancy
[52]
Alshaikhsalama AM, Alsoudi AF, Wai KM et al.. “GOUT AND RISK OF AGE-RELATED MACULAR DEGENERATION.” Retina (Philadelphia, Pa.) (2025). PMID: 40632946 ↗
L3OTHERCited in: Definition, Classification & Nomenclature, Clinical Examination and Diagnostic Workup, Severity, Staging & Risk Stratification, Surgical, Laser & Procedural Considerations
[53]
Litts KM, Zhang Y, Freund KB et al.. “OPTICAL COHERENCE TOMOGRAPHY AND HISTOLOGY OF AGE-RELATED MACULAR DEGENERATION SUPPORT MITOCHONDRIA AS REFLECTIVITY SOURCES.” Retina (Philadelphia, Pa.) (2018). PMID: 29210936 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Acute & Vision-Threatening Management, History and Evolution of Treatment
[54]
Schmitz-Valckenberg S, Sadda S, Staurenghi G et al.. “GEOGRAPHIC ATROPHY: Semantic Considerations and Literature Review.” Retina (Philadelphia, Pa.) (2016). PMID: 27552292 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, History and Evolution of Treatment
[55]
Borchert GA, Charbel Issa P, Xue K et al.. “Geographic atrophy in age-related macular degeneration: phenotypic characterisation for clinical trial consideration.” Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2026). PMID: 41721855 ↗
L5TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature
[56]
Zhu Y, Niu Y, Sun S et al.. “Performance of Deep Learning in Classifying Age-Related Macular Degeneration From Images: Systematic Review and Meta-Analysis.” Journal of medical Internet research (2026). PMID: 42296531 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing, Severity, Staging & Risk Stratification, Prevention, Screening & Surveillance
[57]
Bautista-Hernández MA, Torres-Rosas R, Argueta-Figueroa L et al.. “Acupuncture in the treatment of inflammation-related ocular degenerations: a systematic review.” Frontiers in medicine (2026). PMID: 41958546 ↗
L5SR_OBSCited in: Definition, Classification & Nomenclature
[58]
Zhang X, Sivaprasad S. “Drusen and pachydrusen: the definition, pathogenesis, and clinical significance.” Eye (London, England) (2020). PMID: 33208847 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism
[59]
Nolan JM, Meagher K, Kashani S et al.. “What is meso-zeaxanthin, and where does it come from?” Eye (London, England) (2013). PMID: 23703634 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature
[60]
Taylor TRP, Menten MJ, Rueckert D et al.. “The role of the retinal vasculature in age-related macular degeneration: a spotlight on OCTA.” Eye (London, England) (2023). PMID: 37673970 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Ophthalmic Imaging and Functional Testing
[61]
Bailey C, Cackett P, Kotagiri A et al.. “Practical implementation of a q4-q16 aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: Updated guidance from a UK expert panel.” Eye (London, England) (2022). PMID: 36207506 ↗
L5OTHERCited in: Definition, Classification & Nomenclature
[62]
Harding SP. “Neovascular age-related macular degeneration: decision making and optimal management.” Eye (London, England) (2010). PMID: 20057511 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature
[63]
Al-Burak SA, Suleiman A, Voznyy V et al.. “Age-related macular degeneration associated with glucagon-like peptide-1 receptor agonist use: a systematic review.” Canadian journal of ophthalmology. Journal canadien d'ophtalmologie (2026). PMID: 42242290 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature
[64]
Xiao J, Yavari N, Nimmagadda H et al.. “Association Between Mental Health Disorders in Age-Related Macular Degeneration: A Cohort Study Using a Global Health Records Network.” Ophthalmic surgery, lasers & imaging retina (2026). PMID: 42139589 ↗
L3COHORTCited in: Definition, Classification & Nomenclature
[65]
Jaffe GJ, Westby K, Csaky KG et al.. “C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.” Ophthalmology (2020). PMID: 32882310 ↗
L1RCTCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup, Acute & Vision-Threatening Management, Long-term & Definitive Management, History and Evolution of Treatment, Complications & Ocular Sequelae, Special Populations & Pregnancy
[66]
Keenan TD, Agrón E, Domalpally A et al.. “Progression of Geographic Atrophy in Age-related Macular Degeneration: AREDS2 Report Number 16.” Ophthalmology (2018). PMID: 30060980 ↗
L2RCTCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification
[67]
Jackson TL, Slakter J, Buyse M et al.. “A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration.” Ophthalmology (2023). PMID: 36754174 ↗
L1RCTCited in: Pathophysiology & Mechanism
[68]
Heier JS, Brown DM, Shah SP et al.. “Intravitreal Aflibercept Injection vs Sham as Prophylaxis Against Conversion to Exudative Age-Related Macular Degeneration in High-risk Eyes: A Randomized Clinical Trial.” JAMA ophthalmology (2021). PMID: 33734306 ↗
L1RCTCited in: Pathophysiology & Mechanism
[69]
Korobelnik JF, Rougier MB, Delyfer MN et al.. “Effect of Dietary Supplementation With Lutein, Zeaxanthin, and ω-3 on Macular Pigment: A Randomized Clinical Trial.” JAMA ophthalmology (2017). PMID: 28973076 ↗
L1RCTCited in: Pathophysiology & Mechanism
[70]
Snyder K, Yazdanyar A, Mahajan A et al.. “Association Between the Cilioretinal Artery and Choroidal Neovascularization in Age-Related Macular Degeneration: A Secondary Analysis From the Age-Related Eye Disease Study.” JAMA ophthalmology (2018). PMID: 29978186 ↗
L3RCTCited in: Pathophysiology & Mechanism
[71]
Tsai HR, Chang WC, Lee YC. “Oral Acetylcysteine and the Risk of Age-Related Macular Degeneration: A Retrospective Cohort Study.” Ophthalmology (2025). PMID: 41061823 ↗
L3COHORTCited in: Pathophysiology & Mechanism
[72]
Lou LX, Hu KM, Jin K et al.. “The relationship between hepatic lipase gene variant and advanced age-related macular degeneration: a meta-analysis.” JAMA ophthalmology (2014). PMID: 25010633 ↗
L3SR_OBSCited in: Pathophysiology & Mechanism, Clinical Examination and Diagnostic Workup, Prevention, Screening & Surveillance
[73]
Cabral de Guimaraes TA, Daich Varela M, Georgiou M et al.. “Treatments for dry age-related macular degeneration: therapeutic avenues, clinical trials and future directions.” The British journal of ophthalmology (2021). PMID: 33741584 ↗
L5TRIAL_NONRANDOMCited in: Pathophysiology & Mechanism, Clinical Examination and Diagnostic Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Complications & Ocular Sequelae, Special Populations & Pregnancy
[74]
Guimaraes TAC, Georgiou M, Bainbridge JWB et al.. “Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions.” The British journal of ophthalmology (2020). PMID: 32269060 ↗
L5TRIAL_NONRANDOMCited in: Pathophysiology & Mechanism, Acute & Vision-Threatening Management, Long-term & Definitive Management, Complications & Ocular Sequelae
[75]
Borooah S, Collins C, Wright A et al.. “Late-onset retinal macular degeneration: clinical insights into an inherited retinal degeneration.” The British journal of ophthalmology (2008). PMID: 19098033 ↗
L5SR_OBSCited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations & Pregnancy
[76]
Chin-Yee D, Eck T, Fowler S et al.. “A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration.” The British journal of ophthalmology (2015). PMID: 26516125 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism
[77]
Wu M, Xiong H, Xu Y et al.. “Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis.” The British journal of ophthalmology (2016). PMID: 28400373 ↗
L3SR_OBSCited in: Pathophysiology & Mechanism
[78]
Castro-Fernández DC, Cañizo-Outeriño A, Cuartero-Martínez A et al.. “A systematic review on age-related macular degeneration: New insights from multi-omics studies.” Survey of ophthalmology (2026). PMID: 41643859 ↗
L3SR_OBSCited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification
[79]
Li FR, Peng MJ, Lin KQ et al.. “Clonal Hematopoiesis of Indeterminate Potential and Genetic Susceptibility in Incident Age-Related Macular Degeneration: A Cohort Study.” American journal of ophthalmology (2026). PMID: 42419444 ↗
L2COHORTCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Special Populations & Pregnancy
[80]
Yang JM, Moon SY, Lee JY et al.. “COVID-19 Morbidity and Severity in Patients With Age-Related Macular Degeneration: A Korean Nationwide Cohort Study.” American journal of ophthalmology (2021). PMID: 34102151 ↗
L3COHORTCited in: Pathophysiology & Mechanism
[81]
Hou XW, Wang Y, Pan CW. “Metabolomics in Age-Related Macular Degeneration: A Systematic Review.” Investigative ophthalmology & visual science (2020). PMID: 33315052 ↗
L3SR_OBSCited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification, Special Populations & Pregnancy
[82]
Stanton CM, Yates JR, den Hollander AI et al.. “Complement factor D in age-related macular degeneration.” Investigative ophthalmology & visual science (2011). PMID: 22003108 ↗
L3SR_OBSCited in: Pathophysiology & Mechanism
[83]
Tsai HR, Chang WC, Lee YC. “Association between atrial fibrillation and age-related macular degeneration: A nationwide cohort study.” Eye (London, England) (2025). PMID: 40913076 ↗
L3COHORTCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Surgical, Laser & Procedural Considerations
[84]
Cheung CMG, Lai TYY, Ruamviboonsuk P et al.. “Polypoidal Choroidal Vasculopathy: Definition, Pathogenesis, Diagnosis, and Management.” Ophthalmology (2018). PMID: 29331556 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[85]
Chen JS, Esko JD, Walker E et al.. “High-Density Lipoproteins Associated with Age-Related Macular Degeneration in the All of Us Research Program.” Ophthalmology (2025). PMID: 39756691 ↗
L3OTHERCited in: Pathophysiology & Mechanism
[86]
Boon CJ, Klevering BJ, Cremers FP et al.. “Central areolar choroidal dystrophy.” Ophthalmology (2009). PMID: 19243827 ↗
L4OTHERCited in: Pathophysiology & Mechanism, Ophthalmic Imaging and Functional Testing
[87]
Bressler SB. “Introduction: Understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration.” Ophthalmology (2009). PMID: 19800534 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[88]
Janmohamed IK, Salam MAU, Jamall O et al.. “Faricimab-Associated Intraocular Inflammation With Features of Herpes Simplex Virus.” American journal of ophthalmology (2025). PMID: 40015591 ↗
L4CASE_REPORTCited in: Pathophysiology & Mechanism, Clinical Presentation, Acute & Vision-Threatening Management, Prevention, Screening & Surveillance
[89]
Bak M, Sørensen TL, Flachs EM et al.. “Age-Related Macular Degeneration in Patients With Chronic Myeloproliferative Neoplasms.” JAMA ophthalmology (2017). PMID: 28655032 ↗
L3OTHERCited in: Pathophysiology & Mechanism
[90]
Hallak JA, Abbasi A, Goldberg RA et al.. “Janus Kinase Inhibitor Therapy and Risk of Age-Related Macular Degeneration in Autoimmune Disease.” JAMA ophthalmology (2024). PMID: 38990568 ↗
L3OTHERCited in: Pathophysiology & Mechanism, Acute & Vision-Threatening Management
[91]
Gliem M, Müller PL, Finger RP et al.. “Quantitative Fundus Autofluorescence in Early and Intermediate Age-Related Macular Degeneration.” JAMA ophthalmology (2016). PMID: 27253610 ↗
L3OTHERCited in: Pathophysiology & Mechanism
[92]
Keenan TD, Goldacre R, Goldacre MJ. “Associations between age-related macular degeneration, Alzheimer disease, and dementia: record linkage study of hospital admissions.” JAMA ophthalmology (2014). PMID: 24232933 ↗
L3OTHERCited in: Pathophysiology & Mechanism
[93]
Becker S, L'Ecuyer Z, Jones BW et al.. “Modeling complex age-related eye disease.” Progress in retinal and eye research (2024). PMID: 38365085 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification, Complications & Ocular Sequelae
[94]
Uemura A, Fruttiger M, D'Amore PA et al.. “VEGFR1 signaling in retinal angiogenesis and microinflammation.” Progress in retinal and eye research (2021). PMID: 33640465 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Long-term & Definitive Management
[95]
Zysset-Burri DC, Morandi S, Herzog EL et al.. “The role of the gut microbiome in eye diseases.” Progress in retinal and eye research (2022). PMID: 36075807 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Acute & Vision-Threatening Management
[96]
Jiménez-Loygorri JI, Benítez-Fernández R, Viedma-Poyatos Á et al.. “Mitophagy in the retina: Viewing mitochondrial homeostasis through a new lens.” Progress in retinal and eye research (2023). PMID: 37454969 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[97]
Yang Z, Zhang W, Gu X et al.. “Polypoidal choroidal vasculopathy: In-depth insights and promising future directions.” Progress in retinal and eye research (2025). PMID: 41232598 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing, Acute & Vision-Threatening Management, Complications & Ocular Sequelae, Special Populations & Pregnancy
[98]
Arrigo A, Cremona O, Aragona E et al.. “Müller cells trophism and pathology as the next therapeutic targets for retinal diseases.” Progress in retinal and eye research (2025). PMID: 40254246 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification, History and Evolution of Treatment
[99]
Antropoli A, Bianco L, Romano F et al.. “Extensive macular atrophy with pseudodrusen-like appearance (EMAP) clinical characteristics, diagnostic criteria, and insights from allied inherited retinal diseases and age-related macular degeneration.” Progress in retinal and eye research (2024). PMID: 39603590 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Examination and Diagnostic Workup
[100]
Fitzpatrick MJ, Kerschensteiner D. “Homeostatic plasticity in the retina.” Progress in retinal and eye research (2022). PMID: 36244950 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Surgical, Laser & Procedural Considerations
[101]
Moja L, Lucenteforte E, Kwag KH et al.. “Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration.” The Cochrane database of systematic reviews (2014). PMID: 25220133 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism
[102]
Yeong JL, Loveman E, Colquitt JL et al.. “Visual cycle modulators versus placebo or observation for the prevention and treatment of geographic atrophy due to age-related macular degeneration.” The Cochrane database of systematic reviews (2020). PMID: 33331670 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism
[103]
MacDonald IM, Sieving PC. “American Journal of Ophthalmology Contributions to Ophthalmic Genetics.” American journal of ophthalmology (2018). PMID: 29530780 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[104]
Smith RT, Rosenfeld PJ. “Cardiovascular Disease and Age-Related Macular Degeneration.” American journal of ophthalmology (2026). PMID: 42134616 ↗
L5OTHERCited in: Pathophysiology & Mechanism
[105]
Nussenblatt RB, Ferris F. “Age-related macular degeneration and the immune response: implications for therapy.” American journal of ophthalmology (2007). PMID: 17698021 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[106]
Yeh S, Albini TA, Moshfeghi AA et al.. “Uveitis, the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), and intravitreal biologics for ocular inflammation.” American journal of ophthalmology (2012). PMID: 22898344 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[107]
Hilely A, Au A, Freund KB et al.. “Non-neovascular age-related macular degeneration with subretinal fluid.” The British journal of ophthalmology (2020). PMID: 32920528 ↗
L4OTHERCited in: Pathophysiology & Mechanism, Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae, Prognosis & Natural History
[108]
Hanus J, Zhao F, Wang S. “Current therapeutic developments in atrophic age-related macular degeneration.” The British journal of ophthalmology (2015). PMID: 26553922 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Special Populations & Pregnancy, Prevention, Screening & Surveillance
[109]
Liu MM, Tuo J, Chan CC. “Gene therapy for ocular diseases.” The British journal of ophthalmology (2010). PMID: 20733027 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Long-term & Definitive Management
[110]
Kishan AU, Modjtahedi BS, Martins EN et al.. “Lipids and age-related macular degeneration.” Survey of ophthalmology (2011). PMID: 21439604 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors
[111]
Jabbehdari S, Oganov AC, Rezagholi F et al.. “Age-related macular degeneration and neurodegenerative disorders: Shared pathways in complex interactions.” Survey of ophthalmology (2023). PMID: 38000700 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification, Special Populations & Pregnancy
[112]
Sivaprasad S, Bird A, Nitiahpapand R et al.. “Perspectives on reticular pseudodrusen in age-related macular degeneration.” Survey of ophthalmology (2016). PMID: 26994868 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Examination and Diagnostic Workup, Severity, Staging & Risk Stratification
[113]
Arora S, Surakiatchanukul T, Arora T et al.. “Retinal toxicities of systemic anticancer drugs.” Survey of ophthalmology (2021). PMID: 34048859 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Ophthalmic Imaging and Functional Testing, Long-term & Definitive Management, Complications & Ocular Sequelae
[114]
Wu J, Seregard S, Algvere PV. “Photochemical damage of the retina.” Survey of ophthalmology (2006). PMID: 16950247 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[115]
Rastogi N, Smith RT. “Association of age-related macular degeneration and reticular macular disease with cardiovascular disease.” Survey of ophthalmology (2015). PMID: 26518628 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors
[116]
Singh SR, Lupidi M, Mishra SB et al.. “Unique optical coherence tomographic features in age-related macular degeneration.” Survey of ophthalmology (2020). PMID: 31978382 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Ophthalmic Imaging and Functional Testing
[117]
Tang S, Yang J, Xiao B et al.. “Aberrant Lipid Metabolism and Complement Activation in Age-Related Macular Degeneration.” Investigative ophthalmology & visual science (2024). PMID: 39405051 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations, Special Populations & Pregnancy
[118]
Lauwen S, de Jong EK, Lefeber DJ et al.. “Omics Biomarkers in Ophthalmology.” Investigative ophthalmology & visual science (2017). PMID: 28525563 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[119]
Luo T, Li C, Zhou L et al.. “Protein Acetylation in Age-Related Macular Degeneration: Mechanisms, Roles, and Therapeutic Perspectives.” Investigative ophthalmology & visual science (2025). PMID: 40402519 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Long-term & Definitive Management, Complications & Ocular Sequelae, Special Populations & Pregnancy
[120]
Todoroki T, Takeuchi J, Ota H et al.. “Aqueous Humor Cytokine Analysis in Age-Related Macular Degeneration After Switching From Aflibercept to Faricimab.” Investigative ophthalmology & visual science (2024). PMID: 39250120 ↗
L2OTHERCited in: Pathophysiology & Mechanism, Ophthalmic Imaging and Functional Testing, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[121]
Zhuang X, Li M, Mi L et al.. “Molecular Responses of Anti-VEGF Therapy in Neovascular Age-Related Macular Degeneration: Integrative Insights From Multi-Omics and Clinical Imaging.” Investigative ophthalmology & visual science (2024). PMID: 39140961 ↗
L2OTHERCited in: Pathophysiology & Mechanism, Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing, Long-term & Definitive Management, Complications & Ocular Sequelae, Special Populations & Pregnancy
[122]
Xu Y, Huang S, Zhou S et al.. “Iron Chelator Deferiprone Restores Iron Homeostasis and Inhibits Retinal Neovascularization in Experimental Neovascular Age-Related Macular Degeneration.” Investigative ophthalmology & visual science (2024). PMID: 39093298 ↗
L5OTHERCited in: Pathophysiology & Mechanism, Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing, Complications & Ocular Sequelae, Special Populations & Pregnancy
[123]
Brucker AJ. “Age-related macular degeneration.” Retina (Philadelphia, Pa.) (2009). PMID: 19553791 ↗
L5OTHERCited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification, Complications & Ocular Sequelae
[124]
Carlà MM, Boselli F, Giannuzzi F et al.. “A COMPREHENSIVE REVIEW ON THE PERIFOVEAL EXUDATIVE VASCULAR ANOMALOUS COMPLEX.” Retina (Philadelphia, Pa.) (2025). PMID: 40131004 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[125]
Zarbin MA, Rosenfeld PJ. “Pathway-based therapies for age-related macular degeneration: an integrated survey of emerging treatment alternatives.” Retina (Philadelphia, Pa.) (2010). PMID: 20924259 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[126]
Ghaem Maralani H, Tai BC, Wong TY et al.. “Metabolic syndrome and risk of age-related macular degeneration.” Retina (Philadelphia, Pa.) (2015). PMID: 25207946 ↗
L2OTHERCited in: Pathophysiology & Mechanism
[127]
Wong RW, Richa DC, Hahn P et al.. “Iron toxicity as a potential factor in AMD.” Retina (Philadelphia, Pa.) (2007). PMID: 18040235 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[128]
Kim KL, Han JM, Kim MS et al.. “MACULAR HOLE ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION: Pathogenesis and Surgical Outcomes.” Retina (Philadelphia, Pa.) (2021). PMID: 34543242 ↗
L4OTHERCited in: Pathophysiology & Mechanism
[129]
Shah GK, Sang DN, Hughes MS. “Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration.” Retina (Philadelphia, Pa.) (2009). PMID: 19202423 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[130]
Zhao Q, Xie Z, Zhao X et al.. “Distinguish polypoidal choroidal vasculopathy through choroidal alterations: A systematic review, meta-analysis and narrative synthesis.” Acta ophthalmologica (2026). PMID: 42387875 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae
[131]
Al-Janabi A, Lightman S, Tomkins-Netzer O. “'Statins in retinal disease'.” Eye (London, England) (2018). PMID: 29556012 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification, Complications & Ocular Sequelae, Special Populations & Pregnancy
[132]
Yerramothu P, Vijay AK, Willcox MDP. “Inflammasomes, the eye and anti-inflammasome therapy.” Eye (London, England) (2017). PMID: 29171506 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[133]
Yanagi Y, Foo VHX, Yoshida A. “Asian age-related macular degeneration: from basic science research perspective.” Eye (London, England) (2018). PMID: 30315261 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, History and Evolution of Treatment
[134]
Gemenetzi M, Lotery AJ. “The role of epigenetics in age-related macular degeneration.” Eye (London, England) (2014). PMID: 25233816 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Prognosis & Natural History
[135]
Fogli S, Del Re M, Rofi E et al.. “Clinical pharmacology of intravitreal anti-VEGF drugs.” Eye (London, England) (2018). PMID: 29398697 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Long-term & Definitive Management
[136]
Warwick A, Lotery A. “Genetics and genetic testing for age-related macular degeneration.” Eye (London, England) (2017). PMID: 29125146 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[137]
Schlecht A, Müllerbauer L, Fitz K et al.. “Endothelial TGFβ signaling modulates choroidal neovascularization severity via myeloid-endothelial cell interaction.” Frontiers in immunology (2026). PMID: 42433372 ↗
L5OTHERCited in: Pathophysiology & Mechanism, Long-term & Definitive Management, Complications & Ocular Sequelae
[138]
Wu HC, Gu A, Chang YL et al.. “Utilize Metabolomics Molecular Networking to Guide the Discovery of Chemical Entities from Cordyceps militaris Against Blue Light Hazards.” Journal of natural products (2026). PMID: 42424532 ↗
L5OTHERCited in: Pathophysiology & Mechanism
[139]
Lee SJ, Noh SE, Kim JH. “Exogenous mitochondrial transplantation attenuates oxidative stress-driven retinal degeneration in a sodium iodate - induced mouse model.” Neurobiology of aging (2026). PMID: 42419032 ↗
L5OTHERCited in: Pathophysiology & Mechanism, Ophthalmic Imaging and Functional Testing
[140]
Beazley-Long N, Horder JL, Green KR et al.. “Loss of endothelial ZEB1 enhances neovascularisation during choroidal neovascularisation.” Communications biology (2026). PMID: 42414674 ↗
L5OTHERCited in: Pathophysiology & Mechanism, Ophthalmic Imaging and Functional Testing
[141]
Zong Y, Fan Q, Qiu S et al.. “The Molecular Basis of Ocular Aging: Mechanisms, Pathologies, and Emerging Therapeutics.” Investigative ophthalmology & visual science (2026). PMID: 42405673 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[142]
Wei P, Gao S, Zhang K et al.. “Tanshinone IIA inhibits choroidal neovascularization and restores outer blood-retinal barrier function in Vldlr knockout mice.” Experimental eye research (2026). PMID: 42401235 ↗
L5OTHERCited in: Pathophysiology & Mechanism
[143]
Tzoumas N, Riding G, Williams MA et al.. “Complement inhibitors for age-related macular degeneration.” The Cochrane database of systematic reviews (2023). PMID: 37314061 ↗
L1REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[144]
Cheung CMG, Lim JI, Priglinger S et al.. “Anatomic Outcomes with Faricimab vs Aflibercept in Head-to-Head Dosing Phase of the TENAYA/LUCERNE Trials in Neovascular Age-related Macular Degeneration.” Ophthalmology (2024). PMID: 39617060 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup, Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae, Prognosis & Natural History, Special Populations & Pregnancy
[145]
Korobelnik JF, Lanzetta P, Leal S et al.. “Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial.” Ophthalmology (2025). PMID: 40876598 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Clinical Examination and Diagnostic Workup, Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae, Prognosis & Natural History, Special Populations & Pregnancy
[146]
Khanani AM, Danzig CJ, Heier JS et al.. “Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration: Two-Year Efficacy and Safety Results from the GATHER2 Phase 3 Trial.” Ophthalmology (2025). PMID: 41407269 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History
[147]
Chew EY, Clemons TE, Agrón E et al.. “Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28.” JAMA ophthalmology (2022). PMID: 35653117 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations, Prognosis & Natural History, Special Populations & Pregnancy
[148]
Christen WG, Rist PM, Moorthy MV et al.. “Cocoa Flavanol Supplementation and Risk of Age-Related Macular Degeneration: An Ancillary Study of the COSMOS Randomized Clinical Trial.” JAMA ophthalmology (2025). PMID: 40146119 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Long-term & Definitive Management, History and Evolution of Treatment, Complications & Ocular Sequelae, Prevention, Screening & Surveillance
[149]
Heier JS, Cohen MN, Chao DL et al.. “Phase 1 Study of JNJ-81201887 Gene Therapy in Geographic Atrophy Secondary to Age-Related Macular Degeneration.” Ophthalmology (2024). PMID: 38909914 ↗
L4TRIAL_NONRANDOMCited in: Epidemiology, Etiology & Risk Factors, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations
[150]
Rim TH, Kawasaki R, Tham YC et al.. “Prevalence and Pattern of Geographic Atrophy in Asia: The Asian Eye Epidemiology Consortium.” Ophthalmology (2020). PMID: 32344073 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance
[151]
Jaffe GJ, Boyer D, Hu A et al.. “LONG-TERM EFFICACY AND SAFETY OF PHOTOBIOMODULATION IN DRY AGE-RELATED MACULAR DEGENERATION (LIGHTSITE III: 24-MONTH ANALYSIS).” Retina (Philadelphia, Pa.) (2026). PMID: 41791029 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management, History and Evolution of Treatment, Prognosis & Natural History
[152]
Bordon AF, Kaiser PK, Wolf A et al.. “EFFICACY AND SAFETY OF THE PROPOSED BIOSIMILAR AFLIBERCEPT, SDZ-AFL, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: 52-Week Results From the Phase 3 Mylight Study.” Retina (Philadelphia, Pa.) (2024). PMID: 39287533 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Clinical Examination and Diagnostic Workup, Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae, Prognosis & Natural History, Special Populations & Pregnancy
[153]
Mauschitz MM, Schmitz MT, Verzijden T et al.. “Physical Activity, Incidence, and Progression of Age-Related Macular Degeneration: A Multicohort Study.” American journal of ophthalmology (2021). PMID: 34695401 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Prevention, Screening & Surveillance
[154]
Chong EW, Kreis AJ, Wong TY et al.. “Alcohol consumption and the risk of age-related macular degeneration: a systematic review and meta-analysis.” American journal of ophthalmology (2008). PMID: 18242575 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[155]
Rong SS, Lee BY, Kuk AK et al.. “Comorbidity of dementia and age-related macular degeneration calls for clinical awareness: a meta-analysis.” The British journal of ophthalmology (2019). PMID: 31000510 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup, Surgical, Laser & Procedural Considerations, Prevention, Screening & Surveillance
[156]
Mauschitz MM, Verzijden T, Schuster AK et al.. “Association of lipid-lowering drugs and antidiabetic drugs with age-related macular degeneration: a meta-analysis in Europeans.” The British journal of ophthalmology (2023). PMID: 36344262 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Special Populations & Pregnancy
[157]
Kai JY, Zhou M, Li DL et al.. “Smoking, dietary factors and major age-related eye disorders: an umbrella review of systematic reviews and meta-analyses.” The British journal of ophthalmology (2023). PMID: 36575624 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[158]
Patel SS, Lally DR, Hsu J et al.. “Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial.” Eye (London, England) (2023). PMID: 36964259 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management, History and Evolution of Treatment, Complications & Ocular Sequelae, Special Populations & Pregnancy
[159]
Pead E, Megaw R, Cameron J et al.. “Automated detection of age-related macular degeneration in color fundus photography: a systematic review.” Survey of ophthalmology (2019). PMID: 30772363 ↗
L5SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management
[160]
Lane M, Lane V, Abbott J et al.. “Multiple deprivation, vision loss, and ophthalmic disease in adults: global perspectives.” Survey of ophthalmology (2017). PMID: 29100897 ↗
L5SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[161]
Ye J, Xu YF, He JJ et al.. “Association between aspirin use and age-related macular degeneration: a meta-analysis.” Investigative ophthalmology & visual science (2014). PMID: 24508796 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications & Ocular Sequelae
[162]
Vishwanathan R, Chung M, Johnson EJ. “A systematic review on zinc for the prevention and treatment of age-related macular degeneration.” Investigative ophthalmology & visual science (2013). PMID: 23652490 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Prevention, Screening & Surveillance
[163]
Sasaki M, Cheong KX, Chong CCY et al.. “Relationship of Choroidal Thickness With Age-Related Macular Degeneration in Asians: An Asian Eye Epidemiology Consortium Meta-Analysis.” Investigative ophthalmology & visual science (2025). PMID: 40492987 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Ophthalmic Imaging and Functional Testing, Severity, Staging & Risk Stratification
[164]
Eshtiaghi A, Popovic MM, Sothivannan A et al.. “STATIN USE AND THE INCIDENCE OF AGE-RELATED MACULAR DEGENERATION: A Meta-Analysis.” Retina (Philadelphia, Pa.) (2022). PMID: 34983903 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Surgical, Laser & Procedural Considerations, Prevention, Screening & Surveillance
[165]
Pinna A, Boscia F, Paliogiannis P et al.. “MALONDIALDEHYDE LEVELS IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION: A Systematic Review and Meta-analysis.” Retina (Philadelphia, Pa.) (2020). PMID: 31972788 ↗
L3SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[166]
Xin X, Sun Y, Li S et al.. “AGE-RELATED MACULAR DEGENERATION AND THE RISK OF ALL-CAUSE AND CARDIOVASCULAR MORTALITY: A Meta-Analysis of Cohort Studies.” Retina (Philadelphia, Pa.) (2018). PMID: 28665868 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[167]
Hanson RLW, Airody A, Sivaprasad S et al.. “Optical coherence tomography imaging biomarkers associated with neovascular age-related macular degeneration: a systematic review.” Eye (London, England) (2022). PMID: 36526863 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing, Severity, Staging & Risk Stratification, Complications & Ocular Sequelae, Prognosis & Natural History, Special Populations & Pregnancy
[168]
. “Global estimates on the number of people blind or visually impaired by age-related macular degeneration: a meta-analysis from 2000 to 2020.” Eye (London, England) (2024). PMID: 38965321 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Clinical Examination and Diagnostic Workup
[169]
Xu Y, Phu J, Aung HL et al.. “Frequency of coexistent eye diseases and cognitive impairment or dementia: a systematic review and meta-analysis.” Eye (London, England) (2023). PMID: 36922645 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Acute & Vision-Threatening Management
[170]
Shor R, Mihalache A, Noori A et al.. “Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related Macular Degeneration.” JAMA ophthalmology (2025). PMID: 40471562 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae, Special Populations & Pregnancy
[171]
Rein DB, Wittenborn JS, Burke-Conte Z et al.. “Prevalence of Age-Related Macular Degeneration in the US in 2019.” JAMA ophthalmology (2022). PMID: 36326752 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae, Prevention, Screening & Surveillance
[172]
Binder KE, Bleidißel N, Charbel Issa P et al.. “Noninfectious Intraocular Inflammation After Intravitreal Aflibercept.” JAMA ophthalmology (2025). PMID: 40310633 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Clinical Examination and Diagnostic Workup, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae, Special Populations & Pregnancy
[173]
Ahuja AS, Paredes AA, Young BK. “Glucagon-Like Peptide-1 Receptor Agonists and Age-Related Macular Degeneration.” JAMA ophthalmology (2025). PMID: 41129133 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Special Populations & Pregnancy
[174]
Guillonneau X, Eandi CM, Paques M et al.. “On phagocytes and macular degeneration.” Progress in retinal and eye research (2017). PMID: 28602950 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
[175]
Rozing MP, Durhuus JA, Krogh Nielsen M et al.. “Age-related macular degeneration: A two-level model hypothesis.” Progress in retinal and eye research (2019). PMID: 31899290 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance
[176]
Bejarano E, Domenech-Bendaña A, Avila-Portillo N et al.. “Glycative stress as a cause of macular degeneration.” Progress in retinal and eye research (2024). PMID: 38521386 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification
[177]
Lambert NG, ElShelmani H, Singh MK et al.. “Risk factors and biomarkers of age-related macular degeneration.” Progress in retinal and eye research (2016). PMID: 27156982 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Surgical, Laser & Procedural Considerations, Prevention, Screening & Surveillance
[178]
Wong CW, Yanagi Y, Lee WK et al.. “Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians.” Progress in retinal and eye research (2016). PMID: 27094371 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Clinical Examination and Diagnostic Workup, Acute & Vision-Threatening Management, Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
[179]
Cascella R, Strafella C, Caputo V et al.. “Towards the application of precision medicine in Age-Related Macular Degeneration.” Progress in retinal and eye research (2017). PMID: 29197628 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management, History and Evolution of Treatment
[180]
Sunaga T, Maeda M, Saulle R et al.. “Anti-vascular endothelial growth factor biosimilars for neovascular age-related macular degeneration.” The Cochrane database of systematic reviews (2024). PMID: 38829176 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Clinical Examination and Diagnostic Workup, Acute & Vision-Threatening Management, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae, Prognosis & Natural History, Special Populations & Pregnancy
[181]
Gehlbach P, Li T, Hatef E. “Statins for age-related macular degeneration.” The Cochrane database of systematic reviews (2016). PMID: 27490232 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Clinical Examination and Diagnostic Workup, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae
[182]
Gehlbach P, Li T, Hatef E. “Statins for age-related macular degeneration.” The Cochrane database of systematic reviews (2015). PMID: 25675254 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae
[183]
Gehlbach P, Li T, Hatef E. “Statins for age-related macular degeneration.” The Cochrane database of systematic reviews (2012). PMID: 22419318 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Severity, Staging & Risk Stratification
[184]
Williams MA, McKay GJ, Chakravarthy U. “Complement inhibitors for age-related macular degeneration.” The Cochrane database of systematic reviews (2014). PMID: 24431152 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Special Populations & Pregnancy, Prevention, Screening & Surveillance
[185]
Gehlbach P, Li T, Hatef E. “Statins for age-related macular degeneration.” The Cochrane database of systematic reviews (2009). PMID: 19588411 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification
[186]
Evans JR, Sivagnanavel V, Chong V. “Radiotherapy for neovascular age-related macular degeneration.” The Cochrane database of systematic reviews (2010). PMID: 20464726 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[187]
Kaufmann GT, Boucher N, Sharma C et al.. “Submacular Hemorrhage Rates Following Anti-Vascular Endothelial Growth Factor Injections for Exudative Age-Related Macular Degeneration.” American journal of ophthalmology (2024). PMID: 39455036 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Special Populations & Pregnancy
[188]
Smith RT, Sohrab MA, Busuioc M et al.. “Reticular macular disease.” American journal of ophthalmology (2009). PMID: 19878758 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Special Populations & Pregnancy
[189]
Keenan TDL, Hébert M, Chew EY et al.. “What Should Patients With Age-Related Macular Degeneration Eat?” American journal of ophthalmology (2026). PMID: 41990981 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management
[190]
Borrelli E, Foti C, Ulla L et al.. “Incidence and reasons for discontinuation of anti-VEGF treatment in neovascular age-related macular degeneration.” The British journal of ophthalmology (2025). PMID: 40122580 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Long-term & Definitive Management, History and Evolution of Treatment, Complications & Ocular Sequelae
[191]
Steel DH, Sandhu SS. “Submacular haemorrhages associated with neovascular age-related macular degeneration.” The British journal of ophthalmology (2010). PMID: 20813746 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Acute & Vision-Threatening Management, Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae, Prognosis & Natural History
[192]
Jonas JB, Panda-Jonas S, Pan Z et al.. “Photoreceptor layer thickness in age-related macular degeneration: the Beijing Eye Study.” The British journal of ophthalmology (2026). PMID: 40983489 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Ophthalmic Imaging and Functional Testing
[193]
Spaide RF, Ooto S, Curcio CA. “Subretinal drusenoid deposits AKA pseudodrusen.” Survey of ophthalmology (2018). PMID: 29859199 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing
[194]
Lima-Fontes M, Meira L, Barata P et al.. “Gut microbiota and age-related macular degeneration: A growing partnership.” Survey of ophthalmology (2021). PMID: 34843745 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Complications & Ocular Sequelae
[195]
Paez-Escamilla M, Jhingan M, Gallagher DS et al.. “Age-related macular degeneration masqueraders: From the obvious to the obscure.” Survey of ophthalmology (2020). PMID: 32971140 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup, Acute & Vision-Threatening Management, Long-term & Definitive Management
[196]
Yu J, Zhang Y, Ho M et al.. “Association of Metabolomics With Incidence of Age-Related Macular Degeneration: The UK Biobank Study.” Investigative ophthalmology & visual science (2024). PMID: 39739349 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors
[197]
Zhang QY, Tie LJ, Wu SS et al.. “Overweight, Obesity, and Risk of Age-Related Macular Degeneration.” Investigative ophthalmology & visual science (2016). PMID: 26990164 ↗
L1REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup
[198]
Thomsen AK, Steffensen MA, Nielsen AT et al.. “Chemokine System Changes Drive Age-Related Macular Degeneration and Influence Treatment Outcomes.” Investigative ophthalmology & visual science (2025). PMID: 40327010 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup, Surgical, Laser & Procedural Considerations, Prognosis & Natural History, Special Populations & Pregnancy
[199]
Peng Y, Zhang Y, Kam KW et al.. “Associations of Cardiovascular Health and New-Onset Age-Related Macular Diseases From UK Biobank.” Investigative ophthalmology & visual science (2025). PMID: 40261662 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance
[200]
Montesel A, Sen S, Preston E et al.. “INTRAOCULAR INFLAMMATION ASSOCIATED WITH FARICIMAB THERAPY: One-Year Real-World Outcomes.” Retina (Philadelphia, Pa.) (2025). PMID: 39761510 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Clinical Examination and Diagnostic Workup, Acute & Vision-Threatening Management, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae, Prognosis & Natural History, Special Populations & Pregnancy
[201]
Jackson TL, Nicod E, Simpson A et al.. “Symptomatic vitreomacular adhesion.” Retina (Philadelphia, Pa.) (2013). PMID: 23714857 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[202]
Hussain ZS, Wu G, Loya A et al.. “DIAGNOSTIC PATTERNS OF AGE-RELATED MACULAR DEGENERATION.” Retina (Philadelphia, Pa.) (2024). PMID: 37603087 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance
[203]
Zang H, Han L, Shi D. “Risk factors for age-related macular degeneration: an umbrella analysis of systematic review and meta-analysis.” Frontiers in medicine (2026). PMID: 42388486 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[204]
Khanani AM, Aziz AA, Khan H et al.. “The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results.” Eye (London, England) (2023). PMID: 37173428 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Clinical Examination and Diagnostic Workup, Acute & Vision-Threatening Management, Long-term & Definitive Management, Complications & Ocular Sequelae, Prognosis & Natural History, Special Populations & Pregnancy
[205]
Kim SB, Shaia JK, Kaelber DC et al.. “Ocular manifestations in Ehlers-Danlos syndrome.” Eye (London, England) (2025). PMID: 40211016 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors
[206]
Khanani AM, Thomas MJ, Aziz AA et al.. “Review of gene therapies for age-related macular degeneration.” Eye (London, England) (2022). PMID: 35017696 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Acute & Vision-Threatening Management, Long-term & Definitive Management, Complications & Ocular Sequelae
[207]
Pan SY, Weng CH, Sheen YJ et al.. “GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.” The American journal of medicine (2026). PMID: 42379510 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors
[208]
Cheon S, Kim Y, Kang ES et al.. “Noncombustible Nicotine or Tobacco Product Use After Smoking Cessation and Major Vision-Impairing Diseases: A Nationwide Cohort Study.” American journal of ophthalmology (2026). PMID: 42288324 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup
[209]
Al-Janabi A, Gallagher K, Stewart C et al.. “Clinical characteristics and outcomes of intraocular inflammation following intravitreal faricimab for neovascular age-related macular degeneration: a single-centre retrospective study.” Eye (London, England) (2026). PMID: 42277220 ↗
L4COHORTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations
[210]
Mauschitz MM, Holz FG, Schuster AK et al.. “Subretinal drusenoid deposits (reticular pseudodrusen) in the general population: a European multicohort study.” The British journal of ophthalmology (2026). PMID: 42259595 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing
[211]
Krakauer CA, Reilly L, Su YR et al.. “Age-related macular degeneration severity and risk of Alzheimer's disease in older adults in a prospective, community-based cohort study.” Alzheimer's & dementia (Amsterdam, Netherlands) (2026). PMID: 42255955 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Prevention, Screening & Surveillance
[212]
Wu X, Zhang X, Jiang Y et al.. “Association of high-intensity evening light exposure with risk of incident age-related macular degeneration, cataract, and glaucoma: a prospective cohort study of 82,826 participants.” GeroScience (2026). PMID: 42230852 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors
[213]
Khanani AM, Kotecha A, Chang A et al.. “TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.” Ophthalmology (2024). PMID: 38382813 ↗
L1RCTCited in: Clinical Presentation, Clinical Examination and Diagnostic Workup, Long-term & Definitive Management, History and Evolution of Treatment, Complications & Ocular Sequelae, Prognosis & Natural History, Special Populations & Pregnancy
[214]
Heier JS, Brown DM, Chong V et al.. “Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.” Ophthalmology (2012). PMID: 23084240 ↗
L1RCTCited in: Clinical Presentation, Clinical Examination and Diagnostic Workup, Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae, Prognosis & Natural History, Special Populations & Pregnancy
[215]
Dugel PU, Koh A, Ogura Y et al.. “HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.” Ophthalmology (2019). PMID: 30986442 ↗
L1RCTCited in: Clinical Presentation, Clinical Examination and Diagnostic Workup, Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae, Special Populations & Pregnancy
[216]
Holekamp NM, Campochiaro PA, Chang MA et al.. “Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.” Ophthalmology (2021). PMID: 34597713 ↗
L1RCTCited in: Clinical Presentation, Clinical Examination and Diagnostic Workup, Acute & Vision-Threatening Management, Long-term & Definitive Management, History and Evolution of Treatment, Complications & Ocular Sequelae, Prognosis & Natural History, Prevention, Screening & Surveillance
[217]
Liao DS, Grossi FV, El Mehdi D et al.. “Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.” Ophthalmology (2019). PMID: 31474439 ↗
L1RCTCited in: Clinical Presentation, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Long-term & Definitive Management, History and Evolution of Treatment, Complications & Ocular Sequelae
[218]
Lee WK, Wong TY, Chen SJ et al.. “Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: Post Hoc Analysis of the PULSAR Randomized Clinical Trial.” JAMA ophthalmology (2026). PMID: 41411005 ↗
L2RCTCited in: Clinical Presentation, History and Evolution of Treatment, Prognosis & Natural History
[219]
Murphy GSP, Saleh A, Ayis S et al.. “Tissue Plasminogen Activator or Perfluoropropane for Submacular Hemorrhage in Age-Related Macular Degeneration: A Factorial Randomized Clinical Trial.” JAMA ophthalmology (2024). PMID: 39418015 ↗
L1RCTCited in: Clinical Presentation, Prognosis & Natural History
[220]
Chiang A, Davis M, Stevens W et al.. “Visual Acuity and Quality of Life Outcomes With Pegcetacoplan Treatment: A Post Hoc Analysis From the OAKS and DERBY Trials.” American journal of ophthalmology (2025). PMID: 40449644 ↗
L2RCTCited in: Clinical Presentation, History and Evolution of Treatment, Prognosis & Natural History
[221]
Holekamp NM, Sadda S, Sarraf D et al.. “Effect of Residual Retinal Fluid on Visual Function in Ranibizumab-Treated Neovascular Age-Related Macular Degeneration.” American journal of ophthalmology (2021). PMID: 34289338 ↗
L2RCTCited in: Clinical Presentation, Acute & Vision-Threatening Management, History and Evolution of Treatment, Prognosis & Natural History, Prevention, Screening & Surveillance
[222]
Pfau M, Jolly JK, Wu Z et al.. “Fundus-controlled perimetry (microperimetry): Application as outcome measure in clinical trials.” Progress in retinal and eye research (2020). PMID: 33022378 ↗
L5TRIAL_NONRANDOMCited in: Clinical Presentation, History and Evolution of Treatment, Prognosis & Natural History
[223]
Chen G, Li W, Tzekov R et al.. “Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials.” Retina (Philadelphia, Pa.) (2015). PMID: 25105318 ↗
L1SR_MA_RCTCited in: Clinical Presentation, Clinical Examination and Diagnostic Workup, Prognosis & Natural History, Special Populations & Pregnancy
[224]
Patil NS, Mihalache A, Dhoot AS et al.. “Association Between Visual Acuity and Residual Retinal Fluid Following Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-analysis.” JAMA ophthalmology (2022). PMID: 35551359 ↗
L2SR_OBSCited in: Clinical Presentation
[225]
Lim JI, Ko S, McAllister M et al.. “Systematic review of clinical practice guidelines for the management of neovascular age-related macular degeneration.” Eye (London, England) (2025). PMID: 40374931 ↗
L5GUIDELINECited in: Clinical Presentation, Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing, Acute & Vision-Threatening Management, Complications & Ocular Sequelae, Special Populations & Pregnancy, Prevention, Screening & Surveillance
[226]
Boyer D, Hu A, Warrow D et al.. “LIGHTSITE III: 13-Month Efficacy and Safety Evaluation of Multiwavelength Photobiomodulation in Nonexudative (Dry) Age-Related Macular Degeneration Using the Lumithera Valeda Light Delivery System.” Retina (Philadelphia, Pa.) (2024). PMID: 37972955 ↗
L1RCTCited in: Clinical Presentation, Clinical Examination and Diagnostic Workup, Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations, Special Populations & Pregnancy
[227]
Markowitz SN, Devenyi RG, Munk MR et al.. “A DOUBLE-MASKED, RANDOMIZED, SHAM-CONTROLLED, SINGLE-CENTER STUDY WITH PHOTOBIOMODULATION FOR THE TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION.” Retina (Philadelphia, Pa.) (2020). PMID: 31404033 ↗
L1RCTCited in: Clinical Presentation, Clinical Examination and Diagnostic Workup, Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae, Prognosis & Natural History
[228]
Sun H, Li L, Bu F et al.. “Two-year efficacy and safety of different anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: a network meta-analysis of randomized controlled trials.” Eye (London, England) (2024). PMID: 39261653 ↗
L1SR_MA_RCTCited in: Clinical Presentation, Surgical, Laser & Procedural Considerations
[229]
Chen KY, Chan HC, Chan CM. “Efficacy and Safety of Gene Therapy for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis.” American journal of ophthalmology (2026). PMID: 41941952 ↗
L1SR_OBSCited in: Clinical Presentation, Clinical Examination and Diagnostic Workup, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae, Prognosis & Natural History
[230]
Zhang C, Aboukasm G, Lai DA et al.. “Clinical Efficacy of Switching to Faricimab in Treatment Resistant Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-analysis.” American journal of ophthalmology (2025). PMID: 40849032 ↗
L1SR_OBSCited in: Clinical Presentation, Complications & Ocular Sequelae, Prognosis & Natural History
[231]
Takeda AL, Colquitt J, Clegg AJ et al.. “Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review.” The British journal of ophthalmology (2007). PMID: 17475698 ↗
L1SR_OBSCited in: Clinical Presentation, Clinical Examination and Diagnostic Workup, Severity, Staging & Risk Stratification, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae, Prognosis & Natural History, Special Populations & Pregnancy
[232]
Sepah YJ, Do DV, Mesquida M et al.. “Aqueous humour interleukin-6 and vision outcomes with anti-vascular endothelial growth factor therapy.” Eye (London, England) (2024). PMID: 38622330 ↗
L2RCTCited in: Clinical Presentation, Clinical Examination and Diagnostic Workup, Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae, Special Populations & Pregnancy
[233]
Garg A, Nanji K, Tai F et al.. “The effect of complement C3 or C5 inhibition on geographic atrophy secondary to age-related macular degeneration: A living systematic review and meta-analysis.” Survey of ophthalmology (2023). PMID: 38008405 ↗
L1SR_OBSCited in: Clinical Presentation, Clinical Examination and Diagnostic Workup, Acute & Vision-Threatening Management, Complications & Ocular Sequelae, Special Populations & Pregnancy
[234]
Cassels NK, Wild JM, Margrain TH et al.. “The use of microperimetry in assessing visual function in age-related macular degeneration.” Survey of ophthalmology (2017). PMID: 28579549 ↗
L5SR_OBSCited in: Clinical Presentation, Ophthalmic Imaging and Functional Testing, Surgical, Laser & Procedural Considerations
[235]
Im JHB, Jin YP, Chow R et al.. “Delayed anti-VEGF injections during the COVID-19 pandemic and changes in visual acuity in patients with three common retinal diseases: A systematic review and meta-analysis.” Survey of ophthalmology (2022). PMID: 35970234 ↗
L1SR_OBSCited in: Clinical Presentation
[236]
Lai A, Issa M, Pereira A et al.. “Age-related choroidal atrophy: A systematic review of multimodal imaging, clinical features, and differentiation from other forms of macular degeneration.” Survey of ophthalmology (2025). PMID: 41421557 ↗
L5SR_OBSCited in: Clinical Presentation
[237]
Liu R, Wang T, Zhang B et al.. “Lutein and zeaxanthin supplementation and association with visual function in age-related macular degeneration.” Investigative ophthalmology & visual science (2014). PMID: 25515572 ↗
L1SR_OBSCited in: Clinical Presentation
[238]
Williams MA, Moutray TN, Jackson AJ. “Uniformity of visual acuity measures in published studies.” Investigative ophthalmology & visual science (2008). PMID: 18829857 ↗
L5SR_OBSCited in: Clinical Presentation
[239]
Zhang Y, Chioreso C, Schweizer ML et al.. “Effects of Aflibercept for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis of Observational Comparative Studies.” Investigative ophthalmology & visual science (2017). PMID: 29094167 ↗
L2SR_OBSCited in: Clinical Presentation
[240]
Nichani PAH, Popovic MM, Dhoot AS et al.. “Treat-and-extend dosing of intravitreal anti-VEGF agents in neovascular age-related macular degeneration: a meta-analysis.” Eye (London, England) (2023). PMID: 36859600 ↗
L1SR_OBSCited in: Clinical Presentation
[241]
Spaide RF. “Age-related choroidal atrophy.” American journal of ophthalmology (2009). PMID: 19232561 ↗
L4CASE_REPORTCited in: Clinical Presentation, Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing, Long-term & Definitive Management, History and Evolution of Treatment
[242]
Foster Z, Kini A, Al Othman B et al.. “Seeing is not believing.” Survey of ophthalmology (2019). PMID: 30953621 ↗
L4CASE_REPORTCited in: Clinical Presentation, Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing, Acute & Vision-Threatening Management, History and Evolution of Treatment
[243]
Wykoff CC, Brown DM, Reed K et al.. “Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial.” JAMA ophthalmology (2023). PMID: 37535382 ↗
L1OTHERCited in: Clinical Presentation, Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations, Special Populations & Pregnancy
[244]
Cozzi M, Ziegler A, Fasler K et al.. “Sterile Intraocular Inflammation Associated With Faricimab.” JAMA ophthalmology (2024). PMID: 39388167 ↗
L4OTHERCited in: Clinical Presentation, Ophthalmic Imaging and Functional Testing, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prevention, Screening & Surveillance
[245]
Thangamathesvaran L, Kong J, Bressler SB et al.. “Severe Intraocular Inflammation Following Intravitreal Faricimab.” JAMA ophthalmology (2024). PMID: 38421861 ↗
L4OTHERCited in: Clinical Presentation, Acute & Vision-Threatening Management, Long-term & Definitive Management
[246]
Mettu PS, Allingham MJ, Cousins SW. “Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities.” Progress in retinal and eye research (2020). PMID: 33022379 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Clinical Examination and Diagnostic Workup, Acute & Vision-Threatening Management, Long-term & Definitive Management, Complications & Ocular Sequelae, Special Populations & Pregnancy
[247]
Seiler MJ, Aramant RB. “Cell replacement and visual restoration by retinal sheet transplants.” Progress in retinal and eye research (2012). PMID: 22771454 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[248]
Saksens NT, Fleckenstein M, Schmitz-Valckenberg S et al.. “Macular dystrophies mimicking age-related macular degeneration.” Progress in retinal and eye research (2013). PMID: 24291520 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Clinical Examination and Diagnostic Workup, Severity, Staging & Risk Stratification, Special Populations & Pregnancy
[249]
Vasireddy V, Wong P, Ayyagari R. “Genetics and molecular pathology of Stargardt-like macular degeneration.” Progress in retinal and eye research (2010). PMID: 20096366 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[250]
Schmidt-Erfurth UM, Pruente C. “Management of neovascular age-related macular degeneration.” Progress in retinal and eye research (2007). PMID: 17512238 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Clinical Examination and Diagnostic Workup, Acute & Vision-Threatening Management, Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae, Prognosis & Natural History
[251]
Evans JR, Lawrenson JG. “Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration.” The Cochrane database of systematic reviews (2023). PMID: 37702300 ↗
L1SR_OBSCited in: Clinical Presentation, Severity, Staging & Risk Stratification, Complications & Ocular Sequelae
[252]
Sarwar S, Clearfield E, Soliman MK et al.. “Aflibercept for neovascular age-related macular degeneration.” The Cochrane database of systematic reviews (2016). PMID: 26857947 ↗
L1SR_OBSCited in: Clinical Presentation, Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae, Special Populations & Pregnancy, Prevention, Screening & Surveillance
[253]
Henein C, Steel DH. “Photobiomodulation for non-exudative age-related macular degeneration.” The Cochrane database of systematic reviews (2021). PMID: 34097768 ↗
L1SR_OBSCited in: Clinical Presentation, Clinical Examination and Diagnostic Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae, Prognosis & Natural History
[254]
Tran TH, Rambaud C, Despretz P et al.. “Scene perception in age-related macular degeneration.” Investigative ophthalmology & visual science (2010). PMID: 21123770 ↗
L3CASE_REPORTCited in: Clinical Presentation
[255]
Mansour AM, Al-Ghadban SI, Yunis MH et al.. “Ziv-aflibercept in macular disease.” The British journal of ophthalmology (2015). PMID: 25677668 ↗
L4OTHERCited in: Clinical Presentation, Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[256]
Shao Z, Li A, Lv J et al.. “Patterns and correlates of visual impairment and ocular hypertension among older adults in the general Chinese population: results from the CKB Biobank.” The British journal of ophthalmology (2025). PMID: 40835392 ↗
L2OTHERCited in: Clinical Presentation
[257]
Krezel AK, Hogg R, Lohfeld L et al.. “Core outcomes for geographic atrophy trials.” The British journal of ophthalmology (2019). PMID: 31848211 ↗
L5OTHERCited in: Clinical Presentation
[258]
Wai KM, Vingopoulos F, Garg I et al.. “Contrast sensitivity function in patients with macular disease and good visual acuity.” The British journal of ophthalmology (2021). PMID: 33536229 ↗
L4OTHERCited in: Clinical Presentation
[259]
Jackson TL, Desai R, Wafa HA et al.. “Stereotactic radiotherapy for neovascular age related macular degeneration: year 3 and 4 extended follow up results of a randomised, double masked, sham controlled, device trial (STAR).” BMJ (Clinical research ed.) (2026). PMID: 42315290 ↗
L1RCTCited in: Clinical Presentation, Clinical Examination and Diagnostic Workup, Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations, Prognosis & Natural History, Special Populations & Pregnancy
[260]
Sharma A, Jaber A, Pal B et al.. “Community Optometrist-Led Monitoring of Quiescent Neovascular Age-Related Macular Degeneration: The FENETRE Randomized Clinical Trial.” JAMA network open (2026). PMID: 42295759 ↗
L1RCTCited in: Clinical Presentation, Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing, Acute & Vision-Threatening Management, Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
[261]
Harrabi H, Kergoat MJ, Rousseau J et al.. “Age-related eye disease and cognitive function.” Investigative ophthalmology & visual science (2015). PMID: 25650424 ↗
L3OTHERCited in: Clinical Presentation, Clinical Examination and Diagnostic Workup
[262]
Risseeuw S, Ossewaarde-van Norel J, Klaver CCW et al.. “VISUAL ACUITY IN PSEUDOXANTHOMA ELASTICUM.” Retina (Philadelphia, Pa.) (2019). PMID: 29652691 ↗
L4OTHERCited in: Clinical Presentation
[263]
Friedman SM, Xu Y, Sherman S et al.. “Summary of Research: Aflibercept 8 mg versus Faricimab Treat‑and‑Extend for Diabetic Macular Edema or Neovascular Age‑Related Macular Degeneration: A Bayesian Fixed‑Effect Network Meta‑analysis of Clinical Trials.” Ophthalmology and therapy (2026). PMID: 42332210 ↗
L1TRIAL_NONRANDOMCited in: Clinical Presentation, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae
[264]
Sun G, Zeraatkar D, Man REK et al.. “Vision-related quality of life in non-neovascular age-related macular degeneration: a protocol for systematic review and meta-analysis.” Eye (London, England) (2026). PMID: 42362987 ↗
L5SR_OBSCited in: Clinical Presentation, Complications & Ocular Sequelae
[265]
Bousamri A, Kana'an M, Alharbi F et al.. “Real-World Outcomes of Switching to Aflibercept 8 mg in Previously Treated Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis.” Journal of clinical medicine (2026). PMID: 42355765 ↗
L1SR_OBSCited in: Clinical Presentation, Clinical Examination and Diagnostic Workup, Acute & Vision-Threatening Management, Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae
[266]
Midena E, Pilotto E. “Microperimetry in age: related macular degeneration.” Eye (London, England) (2017). PMID: 28257134 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing, Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
[267]
Zhao X, Yang Y. “Comparative efficacy and safety of Ranibizumab and Aflibercept for neovascular age-related macular degeneration: a systematic review and meta-analysis.” BMC ophthalmology (2026). PMID: 42366374 ↗
L1SR_OBSCited in: Clinical Presentation, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae, Prevention, Screening & Surveillance
[268]
Keenan TDL, Agrón E, Keane PA et al.. “Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration.” Ophthalmology (2024). PMID: 39025435 ↗
L2RCTCited in: Clinical Examination and Diagnostic Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management, History and Evolution of Treatment, Special Populations & Pregnancy
[269]
Schmidt-Erfurth U, Chong V, Loewenstein A et al.. “Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).” The British journal of ophthalmology (2014). PMID: 25136079 ↗
L1GUIDELINECited in: Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing, Acute & Vision-Threatening Management, Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae, Special Populations & Pregnancy
[270]
Pitcher JD, Koh AHC, Tan CS et al.. “Rapid Fluid Resolution and Durability With Faricimab in Neovascular Age-Related Macular Degeneration.” JAMA ophthalmology (2026). PMID: 41712218 ↗
L2RCTCited in: Clinical Examination and Diagnostic Workup, Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae, Prognosis & Natural History
[271]
Krezel AK, Hogg RE, Azuara-Blanco A. “Patient-reported outcomes in randomised controlled trials on age-related macular degeneration.” The British journal of ophthalmology (2015). PMID: 25934846 ↗
L1SR_MA_RCTCited in: Clinical Examination and Diagnostic Workup, Surgical, Laser & Procedural Considerations
[272]
Wykoff CC, Holz FG, Chiang A et al.. “Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE.” American journal of ophthalmology (2025). PMID: 40280279 ↗
L2RCTCited in: Clinical Examination and Diagnostic Workup, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Long-term & Definitive Management, History and Evolution of Treatment, Complications & Ocular Sequelae, Prognosis & Natural History, Special Populations & Pregnancy
[273]
Chakravarthy U, Schwartz R, Guymer RH et al.. “Visual Function Benefit After Treatment With Pegcetacoplan: Microperimetry Analysis From the Phase 3 Oaks Trial.” American journal of ophthalmology (2025). PMID: 39954920 ↗
L2RCTCited in: Clinical Examination and Diagnostic Workup, History and Evolution of Treatment, Prognosis & Natural History, Special Populations & Pregnancy
[274]
Bjerager J, Schneider M, Potapenko I et al.. “Diagnostic Accuracy of the Amsler Grid Test for Detecting Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-analysis.” JAMA ophthalmology (2023). PMID: 36795396 ↗
L1SR_OBSCited in: Clinical Examination and Diagnostic Workup
[275]
Blitzer AL, Ham SA, Colby KA et al.. “Association of Metformin Use With Age-Related Macular Degeneration: A Case-Control Study.” JAMA ophthalmology (2021). PMID: 33475696 ↗
L3CASE_CONTROLCited in: Clinical Examination and Diagnostic Workup
[276]
Bruening W, Kim S, Yeh S et al.. “Inflammation and Occlusive Retinal Vasculitis Post Faricimab.” JAMA ophthalmology (2025). PMID: 39847370 ↗
L4CASE_REPORTCited in: Clinical Examination and Diagnostic Workup, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae, Special Populations & Pregnancy
[277]
Bird AC, Phillips RL, Hageman GS. “Geographic atrophy: a histopathological assessment.” JAMA ophthalmology (2014). PMID: 24626824 ↗
L4OTHERCited in: Clinical Examination and Diagnostic Workup
[278]
Lynch AM, Grove NC, Wagner BD et al.. “Dynamic Risk of Systemic Complement Activation With Time to Progression to Advanced Age-Related Macular Degeneration.” JAMA ophthalmology (2025). PMID: 40504540 ↗
L2OTHERCited in: Clinical Examination and Diagnostic Workup
[279]
Ooto S, Vongkulsiri S, Sato T et al.. “Outer retinal corrugations in age-related macular degeneration.” JAMA ophthalmology (2014). PMID: 24801396 ↗
L4OTHERCited in: Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing, Long-term & Definitive Management
[280]
Spaide RF, Fujimoto JG, Waheed NK et al.. “Optical coherence tomography angiography.” Progress in retinal and eye research (2017). PMID: 29229445 ↗
L5REVIEW_NARRATIVECited in: Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing, History and Evolution of Treatment
[281]
Dysli C, Wolf S, Berezin MY et al.. “Fluorescence lifetime imaging ophthalmoscopy.” Progress in retinal and eye research (2017). PMID: 28673870 ↗
L5REVIEW_NARRATIVECited in: Clinical Examination and Diagnostic Workup, Acute & Vision-Threatening Management
[282]
Sparrow JR, Duncker T, Schuerch K et al.. “Lessons learned from quantitative fundus autofluorescence.” Progress in retinal and eye research (2019). PMID: 31472235 ↗
L5REVIEW_NARRATIVECited in: Clinical Examination and Diagnostic Workup, Acute & Vision-Threatening Management, Long-term & Definitive Management
[283]
Evans JR, Igwe C, Jackson TL et al.. “Radiotherapy for neovascular age-related macular degeneration.” The Cochrane database of systematic reviews (2020). PMID: 32844399 ↗
L1SR_OBSCited in: Clinical Examination and Diagnostic Workup, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[284]
Virgili G, Bini A. “Laser photocoagulation for neovascular age-related macular degeneration.” The Cochrane database of systematic reviews (2007). PMID: 17636773 ↗
L1SR_OBSCited in: Clinical Examination and Diagnostic Workup, Long-term & Definitive Management, Prognosis & Natural History
[285]
Alvarado-Villacorta R, Yim TW, Hernandez-Quintela E et al.. “Surgical interventions for presbyopia.” The Cochrane database of systematic reviews (2025). PMID: 40226888 ↗
L1SR_OBSCited in: Clinical Examination and Diagnostic Workup, Acute & Vision-Threatening Management, Long-term & Definitive Management
[286]
Großpötzl M, Kloeckl L, Guttmann A et al.. “Protective Effect of Amblyopia on Age-Related Macular Degeneration.” American journal of ophthalmology (2023). PMID: 37437833 ↗
L4OTHERCited in: Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing
[287]
Johnston W, Kim SS, Kar D et al.. “Hypertransmission and Vision in Aging and Age-Related Macular Degeneration: Longitudinal Data From ALSTAR2.” American journal of ophthalmology (2025). PMID: 40849031 ↗
L2OTHERCited in: Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing
[288]
Coleman DJ, Silverman RH, Rondeau MJ et al.. “Age-related macular degeneration: choroidal ischaemia?” The British journal of ophthalmology (2013). PMID: 23740965 ↗
L3OTHERCited in: Clinical Examination and Diagnostic Workup
[289]
Sadeghi E, Valsecchi N, Rahmanipour E et al.. “Choroidal biomarkers in age-related macular degeneration.” Survey of ophthalmology (2024). PMID: 39426529 ↗
L5REVIEW_NARRATIVECited in: Clinical Examination and Diagnostic Workup, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Special Populations & Pregnancy
[290]
Sadeghi E, Valsecchi N, Ibrahim MN et al.. “Three-Dimensional Choroidal Vessels Assessment in Age-Related Macular Degeneration.” Investigative ophthalmology & visual science (2024). PMID: 39560628 ↗
L3OTHERCited in: Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing
[291]
Nodecker KN, Romano F, Stettler I et al.. “Reduced Macular Pigment Optical Volume Is Linked to High-Risk OCT Biomarkers and Lower Contrast Sensitivity Function in iAMD.” Investigative ophthalmology & visual science (2026). PMID: 41841653 ↗
L4OTHERCited in: Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing
[292]
Bowes Rickman C, Farsiu S, Toth CA et al.. “Dry age-related macular degeneration: mechanisms, therapeutic targets, and imaging.” Investigative ophthalmology & visual science (2013). PMID: 24335072 ↗
L5REVIEW_NARRATIVECited in: Clinical Examination and Diagnostic Workup, Severity, Staging & Risk Stratification, Prevention, Screening & Surveillance
[293]
Simunovic MP. “METAMORPHOPSIA AND ITS QUANTIFICATION.” Retina (Philadelphia, Pa.) (2015). PMID: 26049620 ↗
L5REVIEW_NARRATIVECited in: Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing, Prevention, Screening & Surveillance
[294]
Mikhail D, Tao BK, Yu P et al.. “Risk of Retinal Detachment After Intravitreal Injection of Anti-VEGF: A Systematic Review and Meta-Analysis.” American journal of ophthalmology (2026). PMID: 42219076 ↗
L2SR_OBSCited in: Clinical Examination and Diagnostic Workup, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
[295]
Vidal-Oliver L, Fernández-Avellaneda P, Fragiotta S et al.. “Non-exudative OCT findings in neovascular AMD.” Eye (London, England) (2024). PMID: 39587331 ↗
L5REVIEW_NARRATIVECited in: Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing
[296]
von der Emde L, Pfau M, Holz FG et al.. “AI-based structure-function correlation in age-related macular degeneration.” Eye (London, England) (2021). PMID: 33767409 ↗
L5REVIEW_NARRATIVECited in: Clinical Examination and Diagnostic Workup, Ophthalmic Imaging and Functional Testing, History and Evolution of Treatment
[297]
Cheng S, Han R, Zhang W et al.. “Development and validation of a machine learning model to predict recurrence in polypoidal choroidal vasculopathy: a multicentre prospective study.” The British journal of ophthalmology (2026). PMID: 42086315 ↗
L2COHORTCited in: Clinical Examination and Diagnostic Workup
[298]
Kuo BI, Wang TA, Chu TC et al.. “Artificial Intelligence-Assisted Screening for Patients With Diabetic Retinopathy and Age-Related Macular Degeneration in Family Medicine and Geriatric and Gerontology Care: Protocol for a Pragmatic Randomized Clinical Trial.” JMIR research protocols (2026). PMID: 42406913 ↗
L5TRIAL_NONRANDOMCited in: Clinical Examination and Diagnostic Workup, Long-term & Definitive Management, Complications & Ocular Sequelae, Prevention, Screening & Surveillance
[299]
Holz FG, Sadda SR, Staurenghi G et al.. “Imaging Protocols in Clinical Studies in Advanced Age-Related Macular Degeneration: Recommendations from Classification of Atrophy Consensus Meetings.” Ophthalmology (2017). PMID: 28109563 ↗
L5GUIDELINECited in: Ophthalmic Imaging and Functional Testing
[300]
Jackson TL, Boyer D, Brown DM et al.. “Oral Tyrosine Kinase Inhibitor for Neovascular Age-Related Macular Degeneration: A Phase 1 Dose-Escalation Study.” JAMA ophthalmology (2017). PMID: 28570723 ↗
L4RCTCited in: Ophthalmic Imaging and Functional Testing, Prognosis & Natural History
[301]
Schaal KB, Rosenfeld PJ, Gregori G et al.. “Anatomic Clinical Trial Endpoints for Nonexudative Age-Related Macular Degeneration.” Ophthalmology (2016). PMID: 26952592 ↗
L5TRIAL_NONRANDOMCited in: Ophthalmic Imaging and Functional Testing, Surgical, Laser & Procedural Considerations, Prevention, Screening & Surveillance
[302]
Chang AA, Li H, Broadhead GK et al.. “Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration.” Ophthalmology (2013). PMID: 24144450 ↗
L4TRIAL_NONRANDOMCited in: Ophthalmic Imaging and Functional Testing
[303]
Castillo MM, Mowatt G, Elders A et al.. “Optical coherence tomography for the monitoring of neovascular age-related macular degeneration: a systematic review.” Ophthalmology (2014). PMID: 25444343 ↗
L5SR_OBSCited in: Ophthalmic Imaging and Functional Testing
[304]
Shah AR, Del Priore LV. “Natural history of predominantly classic, minimally classic, and occult subgroups in exudative age-related macular degeneration.” Ophthalmology (2009). PMID: 19592101 ↗
L1SR_OBSCited in: Ophthalmic Imaging and Functional Testing
[305]
AlAshwal SM, Yassin SH, Kalaw FGP et al.. “PRPH2-ASSOCIATED RETINAL DISEASES: A SYSTEMATIC REVIEW OF PHENOTYPIC FINDINGS.” American journal of ophthalmology (2024). PMID: 39515456 ↗
L2SR_OBSCited in: Ophthalmic Imaging and Functional Testing
[306]
Holt CA, Niedert C, Gedtal M et al.. “Prognostic factors for age-related macular degeneration progression: An overview of systematic reviews.” Survey of ophthalmology (2025). PMID: 41412300 ↗
L5SR_OBSCited in: Ophthalmic Imaging and Functional Testing, Severity, Staging & Risk Stratification, Prognosis & Natural History
[307]
Cole ED, Ferrara D, Novais EA et al.. “CLINICAL TRIAL ENDPOINTS FOR OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.” Retina (Philadelphia, Pa.) (2016). PMID: 28005666 ↗
L5TRIAL_NONRANDOMCited in: Ophthalmic Imaging and Functional Testing, Severity, Staging & Risk Stratification
[308]
Faes L, Bodmer NS, Locher S et al.. “Test performance of optical coherence tomography angiography in detecting retinal diseases: a systematic review and meta-analysis.” Eye (London, England) (2019). PMID: 30971815 ↗
L1SR_OBSCited in: Ophthalmic Imaging and Functional Testing, Prevention, Screening & Surveillance
[309]
Bressler NM. “Antiangiogenic approaches to age-related macular degeneration today.” Ophthalmology (2009). PMID: 19800535 ↗
L5REVIEW_NARRATIVECited in: Ophthalmic Imaging and Functional Testing
[310]
Holz FG, Strauss EC, Schmitz-Valckenberg S et al.. “Geographic atrophy: clinical features and potential therapeutic approaches.” Ophthalmology (2014). PMID: 24433969 ↗
L5REVIEW_NARRATIVECited in: Ophthalmic Imaging and Functional Testing
[311]
de Carlo TE, Bonini Filho MA, Chin AT et al.. “Spectral-domain optical coherence tomography angiography of choroidal neovascularization.” Ophthalmology (2015). PMID: 25795476 ↗
L3OTHERCited in: Ophthalmic Imaging and Functional Testing
[312]
Pellegrini M, Acquistapace A, Oldani M et al.. “Dark Atrophy: An Optical Coherence Tomography Angiography Study.” Ophthalmology (2016). PMID: 27448830 ↗
L4OTHERCited in: Ophthalmic Imaging and Functional Testing
[313]
Thottarath S, Gurudas S, Kubravi S et al.. “Nonexudative Macular Neovascularization in Age-Related Macular Degeneration.” JAMA ophthalmology (2026). PMID: 41954906 ↗
L2OTHERCited in: Ophthalmic Imaging and Functional Testing
[314]
Berlin A, Cabral D, Chen L et al.. “Correlation of Optical Coherence Tomography Angiography of Type 3 Macular Neovascularization With Corresponding Histology.” JAMA ophthalmology (2022). PMID: 35446357 ↗
L4OTHERCited in: Ophthalmic Imaging and Functional Testing
[315]
Antaki F, Chopra R, Keane PA. “Vision-Language Models for Feature Detection of Macular Diseases on Optical Coherence Tomography.” JAMA ophthalmology (2024). PMID: 38696177 ↗
L4OTHERCited in: Ophthalmic Imaging and Functional Testing
[316]
Enríquez AB, Baumal CR, Crane AM et al.. “Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration.” JAMA ophthalmology (2021). PMID: 33630045 ↗
L4OTHERCited in: Ophthalmic Imaging and Functional Testing
[317]
Dow ER, Jeong HK, Katz EA et al.. “A Deep-Learning Algorithm to Predict Short-Term Progression to Geographic Atrophy on Spectral-Domain Optical Coherence Tomography.” JAMA ophthalmology (2023). PMID: 37856139 ↗
L2OTHERCited in: Ophthalmic Imaging and Functional Testing
[318]
Borrelli E, Sarraf D, Freund KB et al.. “OCT angiography and evaluation of the choroid and choroidal vascular disorders.” Progress in retinal and eye research (2018). PMID: 30059755 ↗
L5REVIEW_NARRATIVECited in: Ophthalmic Imaging and Functional Testing
[319]
Jin ZB, Gao ML, Deng WL et al.. “Stemming retinal regeneration with pluripotent stem cells.” Progress in retinal and eye research (2018). PMID: 30419340 ↗
L5REVIEW_NARRATIVECited in: Ophthalmic Imaging and Functional Testing, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae
[320]
Kashani AH, Chen CL, Gahm JK et al.. “Optical coherence tomography angiography: A comprehensive review of current methods and clinical applications.” Progress in retinal and eye research (2017). PMID: 28760677 ↗
L5REVIEW_NARRATIVECited in: Ophthalmic Imaging and Functional Testing
[321]
Chowers I, Tiosano L, Audo I et al.. “Adult-onset foveomacular vitelliform dystrophy: A fresh perspective.” Progress in retinal and eye research (2015). PMID: 25681578 ↗
L5REVIEW_NARRATIVECited in: Ophthalmic Imaging and Functional Testing
[322]
Trinh M, Kalloniatis M, Jones BW et al.. “Inner-retinal changes in AMD: Evidence, mechanisms, and future perspectives.” Progress in retinal and eye research (2026). PMID: 41871654 ↗
L5REVIEW_NARRATIVECited in: Ophthalmic Imaging and Functional Testing
[323]
Schmidt-Erfurth U, Waldstein SM. “A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration.” Progress in retinal and eye research (2015). PMID: 26307399 ↗
L5REVIEW_NARRATIVECited in: Ophthalmic Imaging and Functional Testing, Surgical, Laser & Procedural Considerations
[324]
Pang CE, Freund KB. “Pachychoroid neovasculopathy.” Retina (Philadelphia, Pa.) (2015). PMID: 25158945 ↗
L4CASE_REPORTCited in: Ophthalmic Imaging and Functional Testing, Acute & Vision-Threatening Management, Complications & Ocular Sequelae
[325]
Warrow DJ, Hoang QV, Freund KB. “Pachychoroid pigment epitheliopathy.” Retina (Philadelphia, Pa.) (2013). PMID: 23751942 ↗
L4CASE_REPORTCited in: Ophthalmic Imaging and Functional Testing, History and Evolution of Treatment
[326]
Rosenfeld PJ, Trivizki O, Gregori G et al.. “An Update on the Hemodynamic Model of Age-Related Macular Degeneration.” American journal of ophthalmology (2021). PMID: 34509436 ↗
L5OTHERCited in: Ophthalmic Imaging and Functional Testing
[327]
Wang X, Sadda SR, Ip MS et al.. “In Vivo Longitudinal Measurement of Cone Photoreceptor Density in Intermediate Age-Related Macular Degeneration.” American journal of ophthalmology (2022). PMID: 36436549 ↗
L4OTHERCited in: Ophthalmic Imaging and Functional Testing, Long-term & Definitive Management
[328]
Shen M, Berni A, Liu J et al.. “Real-World Experience With Intravitreal Pegcetacoplan for the Treatment of Geographic Atrophy in Age-Related Macular Degeneration.” American journal of ophthalmology (2025). PMID: 40915520 ↗
L4OTHERCited in: Ophthalmic Imaging and Functional Testing
[329]
Borrelli E, Abdelfattah NS, Uji A et al.. “Postreceptor Neuronal Loss in Intermediate Age-related Macular Degeneration.” American journal of ophthalmology (2017). PMID: 28624323 ↗
L3OTHERCited in: Ophthalmic Imaging and Functional Testing
[330]
Kim DI, Yoon CK, Yu HG. “Unilateral Cilioretinal Artery and Advanced Age-Related Macular Degeneration: A Retrospective Cross-Sectional Study.” American journal of ophthalmology (2021). PMID: 34780795 ↗
L4OTHERCited in: Ophthalmic Imaging and Functional Testing
[331]
Zur D, Guymer R, Korobelnik JF et al.. “Impact of residual retinal fluid on treatment outcomes in neovascular age-related macular degeneration.” The British journal of ophthalmology (2025). PMID: 39033013 ↗
L5REVIEW_NARRATIVECited in: Ophthalmic Imaging and Functional Testing, Acute & Vision-Threatening Management, Long-term & Definitive Management
[332]
Ghasemi Falavarjani K, Al-Sheikh M, Akil H et al.. “Image artefacts in swept-source optical coherence tomography angiography.” The British journal of ophthalmology (2016). PMID: 27439739 ↗
L4OTHERCited in: Ophthalmic Imaging and Functional Testing
[333]
Coscas F, Lupidi M, Boulet JF et al.. “Optical coherence tomography angiography in exudative age-related macular degeneration: a predictive model for treatment decisions.” The British journal of ophthalmology (2018). PMID: 30467129 ↗
L4OTHERCited in: Ophthalmic Imaging and Functional Testing
[334]
Zeng X, Chen R, Zhang X et al.. “Associations between a healthy lifestyle score and retinal neurovascular health.” The British journal of ophthalmology (2025). PMID: 39929700 ↗
L2OTHERCited in: Ophthalmic Imaging and Functional Testing
[335]
Goh KL, Kumar H, Hadoux X et al.. “Hyperpigmentary abnormalities in age-related macular degeneration: association with progression and impact on visual sensitivity.” The British journal of ophthalmology (2024). PMID: 36564147 ↗
L2OTHERCited in: Ophthalmic Imaging and Functional Testing
[336]
Cicinelli MV, Rabiolo A, Sacconi R et al.. “Optical coherence tomography angiography in dry age-related macular degeneration.” Survey of ophthalmology (2017). PMID: 28648383 ↗
L5REVIEW_NARRATIVECited in: Ophthalmic Imaging and Functional Testing
[337]
Sambhav K, Grover S, Chalam KV. “The application of optical coherence tomography angiography in retinal diseases.” Survey of ophthalmology (2017). PMID: 28579550 ↗
L5REVIEW_NARRATIVECited in: Ophthalmic Imaging and Functional Testing
[338]
Tanaka M, Yasuda H, Nakamura S et al.. “H-151, a Selective STING Inhibitor, Has Potential as a Treatment for Neovascular Age-Related Macular Degeneration.” Investigative ophthalmology & visual science (2024). PMID: 38980271 ↗
L5OTHERCited in: Ophthalmic Imaging and Functional Testing, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Special Populations & Pregnancy
[339]
Borrelli E, Reibaldi M, Barresi C et al.. “Choroidal Hyper-Reflective Foci in Geographic Atrophy.” Investigative ophthalmology & visual science (2023). PMID: 37922157 ↗
L4OTHERCited in: Ophthalmic Imaging and Functional Testing
[340]
Saßmannshausen M, Vaisband M, von der Emde L et al.. “Hyper-Reflective Foci in Intermediate Age-Related Macular Degeneration: Spatial Abundance and Impact on Retinal Morphology.” Investigative ophthalmology & visual science (2023). PMID: 36705929 ↗
L3OTHERCited in: Ophthalmic Imaging and Functional Testing
[341]
Villafuerte-Trisolini C, Le SM, Sin TN et al.. “Systemic and Local Lipids in Nonhuman Primates With Drusen and Age-Related Maculopathies.” Investigative ophthalmology & visual science (2025). PMID: 40965406 ↗
L5OTHERCited in: Ophthalmic Imaging and Functional Testing
[342]
Pandya BU, Grinton M, Mandelcorn ED et al.. “RETINAL OPTICAL COHERENCE TOMOGRAPHY IMAGING BIOMARKERS: A Review of the Literature.” Retina (Philadelphia, Pa.) (2024). PMID: 37903455 ↗
L5REVIEW_NARRATIVECited in: Ophthalmic Imaging and Functional Testing, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management
[343]
Spaide RF. “Pilot Study of Choroidal Synphlebia.” Retina (Philadelphia, Pa.) (2026). PMID: 41468573 ↗
L4OTHERCited in: Ophthalmic Imaging and Functional Testing
[344]
Heinke A, Agnihotri A, Nagel ID et al.. “OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY ANALYSIS OF COHORT WITH PERIPAPILLARY CHOROIDAL NEOVASCULARIZATION.” Retina (Philadelphia, Pa.) (2025). PMID: 40712125 ↗
L4OTHERCited in: Ophthalmic Imaging and Functional Testing
[345]
Servillo A, Kesim C, Sacconi R et al.. “NONEXUDATIVE INTRARETINAL FLUID IN INTERMEDIATE AGE-RELATED MACULAR DEGENERATION.” Retina (Philadelphia, Pa.) (2024). PMID: 38261803 ↗
L4OTHERCited in: Ophthalmic Imaging and Functional Testing
[346]
Domalpally A, Haas AM, Chandra S et al.. “Photoreceptor assessment in age-related macular degeneration.” Eye (London, England) (2024). PMID: 39578549 ↗
L5REVIEW_NARRATIVECited in: Ophthalmic Imaging and Functional Testing, Severity, Staging & Risk Stratification, Surgical, Laser & Procedural Considerations
[347]
Cheung CMG. “Macular neovascularization and polypoidal choroidal vasculopathy: phenotypic variations, pathogenic mechanisms and implications in management.” Eye (London, England) (2023). PMID: 37803144 ↗
L5REVIEW_NARRATIVECited in: Ophthalmic Imaging and Functional Testing, Long-term & Definitive Management
[348]
Mathis T, Holz FG, Sivaprasad S et al.. “Characterisation of macular neovascularisation subtypes in age-related macular degeneration to optimise treatment outcomes.” Eye (London, England) (2022). PMID: 36104522 ↗
L5REVIEW_NARRATIVECited in: Ophthalmic Imaging and Functional Testing
[349]
El-Mulki OS, Badla O, Kumar BS et al.. “Detection of Hyporeflective Core Drusen and the Onset of Large Choroidal Hypertransmission Defects in Intermediate AMD.” American journal of ophthalmology (2026). PMID: 42425279 ↗
L2OTHERCited in: Ophthalmic Imaging and Functional Testing
[350]
Badla O, Shen M, El-Mulki OS et al.. “Comparing Eye-Level and Site-Specific High-Risk OCT Biomarkers Preceding the Onset of Large Hypertransmission Defects.” American journal of ophthalmology (2026). PMID: 42425278 ↗
L2OTHERCited in: Ophthalmic Imaging and Functional Testing
[351]
Quarta A, Huang J, Abbasgholizadeh R et al.. “Clinical and Imaging Characteristics of Thin and Thick Idiopathic Epiretinal Membranes Assessed by High-Resolution OCT.” Investigative ophthalmology & visual science (2026). PMID: 42423410 ↗
L4OTHERCited in: Ophthalmic Imaging and Functional Testing
[352]
Olivieri C, Perin G, Zhuang X et al.. “Baseline Optical Coherence Tomography Biomarkers Associated with the 2-Year Development of Macular Atrophy or Fibrosis in Neovascular Age-related Macular Degeneration.” Ophthalmology science (2026). PMID: 42421757 ↗
L3OTHERCited in: Ophthalmic Imaging and Functional Testing, Long-term & Definitive Management
[353]
Beretta F, Scalabrin G, Balduzzi E et al.. “Real-Life 1-Year Results and Predictors of Visual Outcome with Intravitreal Faricimab for Treatment of Exudative Neovascular Age-Related Macular Degeneration.” Ophthalmology and therapy (2026). PMID: 42410200 ↗
L4OTHERCited in: Ophthalmic Imaging and Functional Testing
[354]
Schmidt-Erfurth U, Mai J, Reiter GS et al.. “Disease Activity and Therapeutic Response to Pegcetacoplan for Geographic Atrophy Identified by Deep Learning-Based Analysis of OCT.” Ophthalmology (2024). PMID: 39151755 ↗
L4RCTCited in: Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Long-term & Definitive Management, History and Evolution of Treatment
[355]
Agrón E, Mares J, Clemons TE et al.. “Dietary Nutrient Intake and Progression to Late Age-Related Macular Degeneration in the Age-Related Eye Disease Studies 1 and 2.” Ophthalmology (2020). PMID: 32858063 ↗
L2RCTCited in: Severity, Staging & Risk Stratification
[356]
Liu TY, Shah AR, Del Priore LV. “Progression of lesion size in untreated eyes with exudative age-related macular degeneration: a meta-analysis using Lineweaver-Burk plots.” JAMA ophthalmology (2013). PMID: 23494038 ↗
L1SR_OBSCited in: Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
[357]
McGuinness MB, Le J, Mitchell P et al.. “Physical Activity and Age-related Macular Degeneration: A Systematic Literature Review and Meta-analysis.” American journal of ophthalmology (2017). PMID: 28549846 ↗
L1SR_OBSCited in: Severity, Staging & Risk Stratification, Complications & Ocular Sequelae
[358]
Jeong H, Shaia JK, Markle JC et al.. “Melatonin and Risk of Age-Related Macular Degeneration.” JAMA ophthalmology (2024). PMID: 38842832 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification, History and Evolution of Treatment
[359]
Aggarwal S, Moir J, Hyman MJ et al.. “Metformin Use and Age-Related Macular Degeneration in Patients Without Diabetes.” JAMA ophthalmology (2024). PMID: 38019527 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification
[360]
Kaarniranta K, Uusitalo H, Blasiak J et al.. “Mechanisms of mitochondrial dysfunction and their impact on age-related macular degeneration.” Progress in retinal and eye research (2020). PMID: 32298788 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification
[361]
Cremers FPM, Lee W, Collin RWJ et al.. “Clinical spectrum, genetic complexity and therapeutic approaches for retinal disease caused by ABCA4 mutations.” Progress in retinal and eye research (2020). PMID: 32278709 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management
[362]
Ding X, Patel M, Chan CC. “Molecular pathology of age-related macular degeneration.” Progress in retinal and eye research (2008). PMID: 19026761 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification
[363]
Alshaikh RA, Ryan KB, Waeber C. “Sphingosine 1-phosphate, a potential target in neovascular retinal disease.” The British journal of ophthalmology (2021). PMID: 33962970 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Long-term & Definitive Management, Prognosis & Natural History
[364]
Schloesser L, Klose SM, Mauschitz MM et al.. “The role of immune modulators in age-related macular degeneration.” Survey of ophthalmology (2024). PMID: 39097172 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification, Prevention, Screening & Surveillance
[365]
Berni A, Shen M, Liu J et al.. “Novel Clinical Trial Designs for Intermediate Age-Related Macular Degeneration.” Ophthalmology science (2026). PMID: 42211726 ↗
L2TRIAL_NONRANDOMCited in: Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History
[366]
Gemenetzi M, Lotery AJ. “Complement pathway biomarkers and age-related macular degeneration.” Eye (London, England) (2015). PMID: 26493033 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification
[367]
Nam SW, Noh H, Yoon JM et al.. “Macular lesions associated with age-related macular degeneration in pachydrusen eyes.” Eye (London, England) (2023). PMID: 37773436 ↗
L4OTHERCited in: Severity, Staging & Risk Stratification
[368]
Gabrielle PH, Delyfer MN, Glacet-Bernard A et al.. “Surgery, Tissue Plasminogen Activator, Antiangiogenic Agents, and Age-Related Macular Degeneration Study: A Randomized Controlled Trial for Submacular Hemorrhage Secondary to Age-Related Macular Degeneration.” Ophthalmology (2023). PMID: 37088447 ↗
L1RCTCited in: Acute & Vision-Threatening Management, Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations
[369]
Holz FG, Sadda SR, Busbee B et al.. “Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials.” JAMA ophthalmology (2018). PMID: 29801123 ↗
L1RCTCited in: Acute & Vision-Threatening Management
[370]
Li B, Powell AM, Hooper PL et al.. “Prospective evaluation of teleophthalmology in screening and recurrence monitoring of neovascular age-related macular degeneration: a randomized clinical trial.” JAMA ophthalmology (2015). PMID: 25473945 ↗
L1RCTCited in: Acute & Vision-Threatening Management
[371]
Cehajic-Kapetanovic J, Xue K, Edwards TL et al.. “First-in-Human Robot-Assisted Subretinal Drug Delivery Under Local Anesthesia.” American journal of ophthalmology (2021). PMID: 34788592 ↗
L1RCTCited in: Acute & Vision-Threatening Management, History and Evolution of Treatment
[372]
Wykoff CC, Ou WC, Croft DE et al.. “Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial.” The British journal of ophthalmology (2017). PMID: 28779006 ↗
L1RCTCited in: Acute & Vision-Threatening Management
[373]
Ha A, Kim SH, Kang G et al.. “Association between Sight-Threatening Eye Diseases and Death by Suicide in South Korea: A Nationwide Population-based Cohort Study.” Ophthalmology (2023). PMID: 37001591 ↗
L3COHORTCited in: Acute & Vision-Threatening Management
[374]
Mai J, Reiter GS, Riedl S et al.. “Dynamics of the EZ/RPE Loss Ratio on OCT Over Time During Geographic Atrophy Progression and Treatment With Pegcetacoplan.” Investigative ophthalmology & visual science (2025). PMID: 40833323 ↗
L1RCTCited in: Acute & Vision-Threatening Management, History and Evolution of Treatment
[375]
Berni A, Foti C, Ulla L et al.. “Choriocapillaris in Age-Related Macular Degeneration: A Systematic Review of Optical Coherence Tomography Angiography-Based Assessments and Challenges in Standardization.” American journal of ophthalmology (2025). PMID: 40484298 ↗
L1SR_OBSCited in: Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae
[376]
Heng Wong MY, Tan NYQ, Sabanayagam C. “Time trends, disease patterns and gender imbalance in the top 100 most cited articles in ophthalmology.” The British journal of ophthalmology (2018). PMID: 30002071 ↗
L5SR_OBSCited in: Acute & Vision-Threatening Management
[377]
Patil NS, Dhoot AS, Popovic MM et al.. “RISK OF INTRAOCULAR INFLAMMATION AFTER INJECTION OF ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS: A Meta-analysis.” Retina (Philadelphia, Pa.) (2022). PMID: 36269802 ↗
L1SR_OBSCited in: Acute & Vision-Threatening Management
[378]
Kim LN, Mehta H, Barthelmes D et al.. “METAANALYSIS OF REAL-WORLD OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.” Retina (Philadelphia, Pa.) (2016). PMID: 27388744 ↗
L2SR_OBSCited in: Acute & Vision-Threatening Management, Prognosis & Natural History
[379]
Rathi S, Tsui E, Mehta N et al.. “The Current State of Teleophthalmology in the United States.” Ophthalmology (2017). PMID: 28647202 ↗
L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management, Prevention, Screening & Surveillance
[380]
Ben Ghezala I, Gabrielle PH, Sibert M et al.. “Severe Intraocular Inflammation After Intravitreal Injection of Faricimab: A Single-Site Case Series of Six Patients.” American journal of ophthalmology (2024). PMID: 39134258 ↗
L4CASE_REPORTCited in: Acute & Vision-Threatening Management
[381]
Ho AC, Albini TA, Brown DM et al.. “The Potential Importance of Detection of Neovascular Age-Related Macular Degeneration When Visual Acuity Is Relatively Good.” JAMA ophthalmology (2017). PMID: 28114653 ↗
L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management
[382]
Dutheil C, Le Goff M, Cougnard-Grégoire A et al.. “Incidence and Risk Factors of Reticular Pseudodrusen Using Multimodal Imaging.” JAMA ophthalmology (2020). PMID: 32163116 ↗
L2OTHERCited in: Acute & Vision-Threatening Management
[383]
Varma R, Choudhury F, Chen S et al.. “Prevalence of Age-Related Macular Degeneration in Chinese American Adults: The Chinese American Eye Study.” JAMA ophthalmology (2016). PMID: 27055183 ↗
L2OTHERCited in: Acute & Vision-Threatening Management
[384]
Burlina PM, Joshi N, Pekala M et al.. “Automated Grading of Age-Related Macular Degeneration From Color Fundus Images Using Deep Convolutional Neural Networks.” JAMA ophthalmology (2017). PMID: 28973096 ↗
L4OTHERCited in: Acute & Vision-Threatening Management
[385]
Sun Y, Li F, Liu Y et al.. “Targeting inflammasomes and pyroptosis in retinal diseases-molecular mechanisms and future perspectives.” Progress in retinal and eye research (2024). PMID: 38657834 ↗
L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management, Special Populations & Pregnancy
[386]
Wormald R, Evans J, Smeeth L et al.. “Photodynamic therapy for neovascular age-related macular degeneration.” The Cochrane database of systematic reviews (2007). PMID: 17636693 ↗
L1SR_OBSCited in: Acute & Vision-Threatening Management, Long-term & Definitive Management, Special Populations & Pregnancy
[387]
Solomon SD, Lindsley K, Vedula SS et al.. “Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.” The Cochrane database of systematic reviews (2014). PMID: 25170575 ↗
L1SR_OBSCited in: Acute & Vision-Threatening Management, Long-term & Definitive Management, Prognosis & Natural History
[388]
Solomon SD, Lindsley K, Vedula SS et al.. “Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.” The Cochrane database of systematic reviews (2019). PMID: 30834517 ↗
L1SR_OBSCited in: Acute & Vision-Threatening Management, Long-term & Definitive Management
[389]
Vedula SS, Krzystolik MG. “Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration.” The Cochrane database of systematic reviews (2008). PMID: 18425911 ↗
L1SR_OBSCited in: Acute & Vision-Threatening Management
[390]
Ooi KG, Khoo P, Vaclavik V et al.. “Statins in ophthalmology.” Survey of ophthalmology (2019). PMID: 30703407 ↗
L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management, Complications & Ocular Sequelae, Special Populations & Pregnancy
[391]
Ersoz MG, Karacorlu M, Arf S et al.. “Retinal pigment epithelium tears: Classification, pathogenesis, predictors, and management.” Survey of ophthalmology (2017). PMID: 28336128 ↗
L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management, Prevention, Screening & Surveillance
[392]
Seddon JM. “Genetic and environmental underpinnings to age-related ocular diseases.” Investigative ophthalmology & visual science (2013). PMID: 24335064 ↗
L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management
[393]
Leclercq B, Mejlachowicz D, Zhu L et al.. “Differential Effect of Aldosterone or Mineralocorticoid Receptor Overexpression on Retinal Inflammation.” Investigative ophthalmology & visual science (2024). PMID: 39453673 ↗
L5OTHERCited in: Acute & Vision-Threatening Management
[394]
Trinh M, Kalloniatis M, Nivison-Smith L. “Radial Peripapillary Capillary Plexus Sparing and Underlying Retinal Vascular Impairment in Intermediate Age-Related Macular Degeneration.” Investigative ophthalmology & visual science (2021). PMID: 33792619 ↗
L3OTHERCited in: Acute & Vision-Threatening Management
[395]
Wong DT, Lambrou GN, Loewenstein A et al.. “SUSPENDING TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN CASES OF FUTILITY.” Retina (Philadelphia, Pa.) (2020). PMID: 31876889 ↗
L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management, Long-term & Definitive Management
[396]
Chen TL, Tsai HR, Chang WC et al.. “RISK OF AGE-RELATED MACULAR DEGENERATION IN LATE-ONSET ATOPIC DERMATITIS: A Multidatabase Cohort Analysis.” Retina (Philadelphia, Pa.) (2026). PMID: 40729752 ↗
L2OTHERCited in: Acute & Vision-Threatening Management
[397]
Menna F, De Luca L, Meduri A et al.. “New Clinical Trials and Therapeutic Advances with Faricimab and Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: A Durability-Oriented Comparative Perspective.” Biomedicines (2026). PMID: 42072314 ↗
L5TRIAL_NONRANDOMCited in: Acute & Vision-Threatening Management
[398]
Li Y, Fu X, Huang L et al.. “Global research trends and hotspots in the pathophysiology, imaging and therapy of type 3 macular neovascularization (MNV3) in age-related macular degeneration (AMD).” Frontiers in medicine (2026). PMID: 42110464 ↗
L5SR_OBSCited in: Acute & Vision-Threatening Management, Prognosis & Natural History
[399]
Novarese C, Vyas C, Berni A et al.. “Macular Neovascularization in Neovascular Age-Related Macular Degeneration: A systematic review of OCT angiography-based assessments and challenges in standardization.” Ophthalmology. Retina (2026). PMID: 42107776 ↗
L2SR_OBSCited in: Acute & Vision-Threatening Management
[400]
Mohamed MI, Halwag MI, Mahmoud NH et al.. “Migraine as a risk factor for retinal vascular events and maculopathies: a systematic review and meta-analysis of 47 million individuals.” The journal of headache and pain (2026). PMID: 41987034 ↗
L2SR_OBSCited in: Acute & Vision-Threatening Management, Prevention, Screening & Surveillance
[401]
Talks J, de Salvo G, Patel PJ et al.. “Real-world treatment patterns and visual outcomes of faricimab in patients with neovascular age-related macular degeneration in the UK at 12 months: the FARWIDE-nAMD study.” Eye (London, England) (2026). PMID: 41807615 ↗
L2OTHERCited in: Acute & Vision-Threatening Management, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[402]
Loewenstein A, Berger A, Daly A et al.. “Save our Sight (SOS): a collective call-to-action for enhanced retinal care across health systems in high income countries.” Eye (London, England) (2023). PMID: 37280350 ↗
L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management
[403]
Ashraf M, Souka AAR. “Aflibercept in age-related macular degeneration: evaluating its role as a primary therapeutic option.” Eye (London, England) (2017). PMID: 28548650 ↗
L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations
[404]
Tong N, Fan W, Su L et al.. “RELATIONSHIP BETWEEN OPTICAL COHERENCE TOMOGRAPHY BIOMARKERS AND NUMBER OF INTRAVITREAL RANIBIZUMAB INJECTIONS IN EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE HARBOR STUDY.” Retina (Philadelphia, Pa.) (2024). PMID: 39287532 ↗
L2RCTCited in: Long-term & Definitive Management, Special Populations & Pregnancy
[405]
Avery RL, Castellarin AA, Steinle NC et al.. “SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.” Retina (Philadelphia, Pa.) (2017). PMID: 28106709 ↗
L2TRIAL_NONRANDOMCited in: Long-term & Definitive Management, Complications & Ocular Sequelae, Special Populations & Pregnancy
[406]
Browning DJ. “The Trouble With Photodynamic Therapy.” American journal of ophthalmology (2026). PMID: 41687799 ↗
L5CASE_REPORTCited in: Long-term & Definitive Management, History and Evolution of Treatment, Special Populations & Pregnancy
[407]
Domalpally A, Whittier SA, Pan Q et al.. “Association of Metformin With the Development of Age-Related Macular Degeneration.” JAMA ophthalmology (2023). PMID: 36547967 ↗
L2OTHERCited in: Long-term & Definitive Management, History and Evolution of Treatment, Prevention, Screening & Surveillance
[408]
Sugita S, Mandai M, Kamao H et al.. “Immunological aspects of RPE cell transplantation.” Progress in retinal and eye research (2021). PMID: 33482342 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[409]
Binder S, Stanzel BV, Krebs I et al.. “Transplantation of the RPE in AMD.” Progress in retinal and eye research (2007). PMID: 17532250 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae
[410]
Xu H, Pu J, Yi C et al.. “Macular fibrosis secondary to neovascular age-related macular degeneration: from clinic to biology.” Progress in retinal and eye research (2026). PMID: 42259444 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[411]
Virgili G, Michelessi M, Parodi MB et al.. “Laser treatment of drusen to prevent progression to advanced age-related macular degeneration.” The Cochrane database of systematic reviews (2015). PMID: 26493180 ↗
L1SR_OBSCited in: Long-term & Definitive Management
[412]
Evans JR. “Ginkgo biloba extract for age-related macular degeneration.” The Cochrane database of systematic reviews (2013). PMID: 23440785 ↗
L1SR_OBSCited in: Long-term & Definitive Management, Special Populations & Pregnancy, Prevention, Screening & Surveillance
[413]
Geltzer A, Turalba A, Vedula SS. “Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degeneration.” The Cochrane database of systematic reviews (2013). PMID: 23440797 ↗
L1SR_OBSCited in: Long-term & Definitive Management, Special Populations & Pregnancy, Prevention, Screening & Surveillance
[414]
Browning DJ, Kaiser PK, Rosenfeld PJ et al.. “Aflibercept for age-related macular degeneration: a game-changer or quiet addition?” American journal of ophthalmology (2012). PMID: 22813448 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations, Special Populations & Pregnancy
[415]
Campochiaro PA. “Sustained Suppression of VEGF for Treatment of Retinal and Choroidal Vascular Diseases.” American journal of ophthalmology (2025). PMID: 40320193 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
[416]
Nussenblatt RB, Lee RW, Chew E et al.. “Immune responses in age-related macular degeneration and a possible long-term therapeutic strategy for prevention.” American journal of ophthalmology (2014). PMID: 24709810 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, Prevention, Screening & Surveillance
[417]
Daien V, Finger RP, Talks JS et al.. “Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence.” The British journal of ophthalmology (2020). PMID: 33130553 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, History and Evolution of Treatment, Prognosis & Natural History
[418]
Chang JH, Garg NK, Lunde E et al.. “Corneal neovascularization: an anti-VEGF therapy review.” Survey of ophthalmology (2012). PMID: 22898649 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
[419]
Sim SY, Lim LT, Chaudhary S et al.. “Update on subthreshold micropulse laser treatment for retinal diseases: A narrative review.” Survey of ophthalmology (2026). PMID: 41763458 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[420]
Stanescu-Segall D, Balta F, Jackson TL. “Submacular hemorrhage in neovascular age-related macular degeneration: A synthesis of the literature.” Survey of ophthalmology (2015). PMID: 26212151 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
[421]
Merle DA, Beretta F, Sacconi R et al.. “Fibrogliosis in neovascular age-related macular degeneration: A new mechanistic perspective.” Survey of ophthalmology (2025). PMID: 41043515 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
[422]
Lee E, Hunt D, Cakir Y et al.. “Artificial intelligence in age-related macular degeneration: Advancing diagnosis, prognosis, and treatment.” Survey of ophthalmology (2025). PMID: 40975441 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, Prognosis & Natural History
[423]
Finger RP, Wickremasinghe SS, Baird PN et al.. “Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration.” Survey of ophthalmology (2014). PMID: 24332379 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
[424]
Simpson AR, Petrarca R, Jackson TL. “Vitreomacular adhesion and neovascular age-related macular degeneration.” Survey of ophthalmology (2012). PMID: 23068973 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[425]
Calton MA, Croze RH, Burns C et al.. “Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies.” Investigative ophthalmology & visual science (2024). PMID: 39620832 ↗
L5OTHERCited in: Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae, Prognosis & Natural History
[426]
Zhang JY, Xiao J, Xie B et al.. “Oral Metformin Inhibits Choroidal Neovascularization by Modulating the Gut-Retina Axis.” Investigative ophthalmology & visual science (2023). PMID: 38108689 ↗
L5OTHERCited in: Long-term & Definitive Management, Complications & Ocular Sequelae
[427]
Sharma D, Zachary I, Jia H. “Mechanisms of Acquired Resistance to Anti-VEGF Therapy for Neovascular Eye Diseases.” Investigative ophthalmology & visual science (2023). PMID: 37252731 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
[428]
Kashani AH. “Stem Cell Therapy in Nonneovascular Age-Related Macular Degeneration.” Investigative ophthalmology & visual science (2016). PMID: 27116669 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[429]
Du Y, Feng L, Tang J et al.. “C5a-Induced Autophagy Dysfunction Promotes Choroidal Neovascularization Through the ROS-Inflammatory Pathway.” Investigative ophthalmology & visual science (2025). PMID: 40662890 ↗
L5OTHERCited in: Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations
[430]
Cui K, Tang X, Yang B et al.. “Sema4D Knockout Attenuates Choroidal Neovascularization by Inhibiting M2 Macrophage Polarization Via Regulation of the RhoA/ROCK Pathway.” Investigative ophthalmology & visual science (2024). PMID: 38913005 ↗
L5OTHERCited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[431]
Skeie JM, Nishimura DY, Wang CL et al.. “Mitophagy: An Emerging Target in Ocular Pathology.” Investigative ophthalmology & visual science (2021). PMID: 33724294 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
[432]
Peyman GA, Lad EM, Moshfeghi DM. “Intravitreal injection of therapeutic agents.” Retina (Philadelphia, Pa.) (2009). PMID: 19584648 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[433]
Parodi MB, Zucchiatti I, Cicinelli MV et al.. “NUTRITIONAL SUPPLEMENTATION IN AGE-RELATED MACULAR DEGENERATION.” Retina (Philadelphia, Pa.) (2016). PMID: 26579787 ↗
L4OTHERCited in: Long-term & Definitive Management
[434]
You QS, Gaber R, Meshi A et al.. “HIGH-DOSE HIGH-FREQUENCY AFLIBERCEPT FOR RECALCITRANT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.” Retina (Philadelphia, Pa.) (2018). PMID: 28604541 ↗
L4OTHERCited in: Long-term & Definitive Management
[435]
Shirian JD, Shukla P, Singh RP. “Exploring new horizons in neovascular age-related macular degeneration: novel mechanisms of action and future therapeutic avenues.” Eye (London, England) (2024). PMID: 39379521 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, Complications & Ocular Sequelae, Special Populations & Pregnancy
[436]
Kang-Mieler JJ, Rudeen KM, Liu W et al.. “Advances in ocular drug delivery systems.” Eye (London, England) (2020). PMID: 32071402 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
[437]
Armendariz BG, Chakravarthy U. “Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era.” Eye (London, England) (2024). PMID: 39198703 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, History and Evolution of Treatment, Prognosis & Natural History
[438]
Iglicki M, González DP, Loewenstein A et al.. “Longer-acting treatments for neovascular age-related macular degeneration-present and future.” Eye (London, England) (2021). PMID: 33432165 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, History and Evolution of Treatment, Surgical, Laser & Procedural Considerations
[439]
Dogru E, Chavez MP, Toth O et al.. “Port Delivery System Vs Monthly Ranibizumab in VEGF-Driven Macular Disease: A Systematic Review and Meta-Analysis.” Seminars in ophthalmology (2026). PMID: 42360009 ↗
L1SR_OBSCited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae
[440]
Cozzi M, Zweifel SA, Spooner K et al.. “Non-advanced age-related macular degeneration: current concepts and future perspectives.” Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) (2026). PMID: 42431462 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
[441]
Schmidt R, Weissenbacher LM, Vécsei-Marlovits V et al.. “Comparison of intravitreal anti-VEGF treatment burden in different retinal diseases.” Eye (London, England) (2026). PMID: 42426273 ↗
L4OTHERCited in: Long-term & Definitive Management, Prognosis & Natural History
[442]
Wright DM, Trifonov I, Shahar-Gonen M et al.. “Machine Learning to Predict Outcomes of Anti-VEGF Therapy in Neovascular Age-Related Macular Degeneration.” Ophthalmology science (2026). PMID: 42421758 ↗
L4OTHERCited in: Long-term & Definitive Management, Prognosis & Natural History
[443]
Keenan TDL, Bailey C, Abraham M et al.. “Phase 2 Trial Evaluating Minocycline for Geographic Atrophy in Age-Related Macular Degeneration: A Nonrandomized Controlled Trial.” JAMA ophthalmology (2024). PMID: 38483382 ↗
L4RCTCited in: History and Evolution of Treatment
[444]
Klein R, Myers CE, Buitendijk GH et al.. “Lipids, lipid genes, and incident age-related macular degeneration: the three continent age-related macular degeneration consortium.” American journal of ophthalmology (2014). PMID: 24879949 ↗
L2SR_OBSCited in: History and Evolution of Treatment, Surgical, Laser & Procedural Considerations
[445]
Borodoker N, Spaide RF, Maranan L et al.. “Verteporfin infusion-associated pain.” American journal of ophthalmology (2002). PMID: 11812424 ↗
L2RCTCited in: History and Evolution of Treatment
[446]
Ristau T, Ersoy L, Hahn M et al.. “Nongenetic risk factors for neovascular age-related macular degeneration.” Investigative ophthalmology & visual science (2014). PMID: 25074767 ↗
L3RCTCited in: History and Evolution of Treatment
[447]
Merle BM, Benlian P, Puche N et al.. “Circulating omega-3 Fatty acids and neovascular age-related macular degeneration.” Investigative ophthalmology & visual science (2014). PMID: 24557349 ↗
L3RCTCited in: History and Evolution of Treatment, Prognosis & Natural History
[448]
Schmidt-Erfurth U, Waldstein SM, Klimscha S et al.. “Prediction of Individual Disease Conversion in Early AMD Using Artificial Intelligence.” Investigative ophthalmology & visual science (2018). PMID: 29971444 ↗
L4RCTCited in: History and Evolution of Treatment
[449]
Moshfeghi DM, Kim BY, Kaiser PK et al.. “Appositional suprachoroidal hemorrhage: a case-control study.” American journal of ophthalmology (2004). PMID: 15629286 ↗
L3CASE_CONTROLCited in: History and Evolution of Treatment
[450]
Wang Z, Liu CH, Huang S et al.. “Wnt Signaling in vascular eye diseases.” Progress in retinal and eye research (2018). PMID: 30513356 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[451]
Tang J, Zhou C, Ye F et al.. “RNA methylation homeostasis in ocular diseases: All eyes on Me.” Progress in retinal and eye research (2025). PMID: 39880118 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[452]
Boscia G, Feo A, Quarta A et al.. “Intraretinal hyperreflective foci: Pathophysiology, imaging features, and clinical implications across retinal diseases.” Progress in retinal and eye research (2026). PMID: 41887320 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[453]
Anderson DH, Radeke MJ, Gallo NB et al.. “The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited.” Progress in retinal and eye research (2009). PMID: 19961953 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[454]
Kim BJ, Mastellos DC, Li Y et al.. “Targeting complement components C3 and C5 for the retina: Key concepts and lingering questions.” Progress in retinal and eye research (2020). PMID: 33321207 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[455]
Kampling H, Baumeister H, Bengel J et al.. “Prevention of depression in adults with long-term physical conditions.” The Cochrane database of systematic reviews (2021). PMID: 33667319 ↗
L1SR_OBSCited in: History and Evolution of Treatment, Prevention, Screening & Surveillance
[456]
Klein R, Peto T, Bird A et al.. “The epidemiology of age-related macular degeneration.” American journal of ophthalmology (2004). PMID: 15013873 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[457]
Curcio CA, Johnson M, Rudolf M et al.. “The oil spill in ageing Bruch membrane.” The British journal of ophthalmology (2011). PMID: 21890786 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[458]
Alten F, Eter N. “Current knowledge on reticular pseudodrusen in age-related macular degeneration.” The British journal of ophthalmology (2014). PMID: 25232026 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[459]
Tolentino M. “Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.” Survey of ophthalmology (2011). PMID: 21335144 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[460]
Keane PA, Patel PJ, Liakopoulos S et al.. “Evaluation of age-related macular degeneration with optical coherence tomography.” Survey of ophthalmology (2012). PMID: 22898648 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[461]
Bachmeier I, Armendariz BG, Yu S et al.. “Fibrosis in neovascular age-related macular degeneration: A review of definitions based on clinical imaging.” Survey of ophthalmology (2023). PMID: 37023894 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, Special Populations & Pregnancy
[462]
Heath Jeffery RC, Chen FK. “Macular neovascularization in inherited retinal diseases: A review.” Survey of ophthalmology (2023). PMID: 37544613 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[463]
Chen Y, Jiang F, Zeng Y et al.. “The role of retinal pigment epithelial senescence and the potential of senotherapeutics in age-related macular degeneration.” Survey of ophthalmology (2025). PMID: 40089029 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[464]
Ţurcaş C, Nicoară SD. “A comprehensive review of structure-function correlations in age-related macular degeneration: Contributions of microperimetry.” Survey of ophthalmology (2025). PMID: 39828006 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[465]
Parmar UPS, Arora A, Agarwal A et al.. “Detection and quantification of fluorescein angiography leakage: From manual grading to advances in machine learning.” Survey of ophthalmology (2025). PMID: 40902824 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[466]
Rosenfeld PJ. “Optical Coherence Tomography and the Development of Antiangiogenic Therapies in Neovascular Age-Related Macular Degeneration.” Investigative ophthalmology & visual science (2016). PMID: 27409464 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[467]
Pauleikhoff D. “neovascular age-related macular degeneration: Natural History and Treatment Outcomes.” Retina (Philadelphia, Pa.) (2005). PMID: 16340538 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[468]
Sadda SR, Chakravarthy U, Birch DG et al.. “CLINICAL ENDPOINTS FOR THE STUDY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION.” Retina (Philadelphia, Pa.) (2016). PMID: 27652913 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[469]
Mrejen S, Sarraf D, Mukkamala SK et al.. “Multimodal imaging of pigment epithelial detachment: a guide to evaluation.” Retina (Philadelphia, Pa.) (2013). PMID: 23873168 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[470]
Terheyden JH, Dunbar HMP, Schmitz-Valckenberg S et al.. “Validating candidate endpoints for intermediate age-related macular degeneration trials in a multi-centre setting-lessons from the MACUSTAR study.” Eye (London, England) (2025). PMID: 39910281 ↗
L2REVIEW_NARRATIVECited in: History and Evolution of Treatment, Prognosis & Natural History
[471]
Bradley DT, Zipfel PF, Hughes AE. “Complement in age-related macular degeneration: a focus on function.” Eye (London, England) (2011). PMID: 21394116 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, Prevention, Screening & Surveillance
[472]
Teo KYC, Eldem B, Joussen A et al.. “Treatment regimens for optimising outcomes in patients with neovascular age-related macular degeneration.” Eye (London, England) (2024). PMID: 39379523 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[473]
Votruba M, Gregor Z. “Neovascular age-related macular degeneration: present and future treatment options.” Eye (London, England) (2001). PMID: 11450768 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[474]
Alsoudi AF, Wai KM, Koo E et al.. “Curcuma-Based Nutritional Supplements and Risk of Age-Related Macular Degeneration.” JAMA ophthalmology (2024). PMID: 39446346 ↗
L2OTHERCited in: History and Evolution of Treatment
[475]
El Mallah MK, Chakravarthy U, Hart PM. “Amblyopia: is visual loss permanent?” The British journal of ophthalmology (2000). PMID: 10966943 ↗
L4OTHERCited in: History and Evolution of Treatment
[476]
Shen LL, Sun M, Ahluwalia A et al.. “Natural history of central sparing in geographic atrophy secondary to non-exudative age-related macular degeneration.” The British journal of ophthalmology (2020). PMID: 33361441 ↗
L2OTHERCited in: History and Evolution of Treatment
[477]
Akuffo KO, Nolan J, Stack J et al.. “Prevalence of age-related macular degeneration in the Republic of Ireland.” The British journal of ophthalmology (2015). PMID: 25712825 ↗
L2OTHERCited in: History and Evolution of Treatment
[478]
Storey PP, Aziz HA, O'Keefe GAD et al.. “Decreased severity of age-related macular degeneration in amblyopic eyes.” The British journal of ophthalmology (2018). PMID: 29437581 ↗
L4OTHERCited in: History and Evolution of Treatment
[479]
Gale RP, Loewenstein A, Zhang X et al.. “PULSAR: Clinical Outcomes of Aflibercept 8 mg with Extended Dosing and 2 mg in Neovascular Age-Related Macular Degeneration in Subgroups Defined by Baseline Characteristics.” Ophthalmology. Retina (2026). PMID: 41861959 ↗
L2RCTCited in: History and Evolution of Treatment
[480]
Curcio CA, Medeiros NE, Millican CL. “Photoreceptor loss in age-related macular degeneration.” Investigative ophthalmology & visual science (1996). PMID: 8641827 ↗
L5OTHERCited in: History and Evolution of Treatment
[481]
Chen CH, Lin CW, Wu SH et al.. “NOTCH3 Pathogenic Variant and Risk of Age-Related Macular Degeneration: Findings From the Taiwan Biobank and Small Vessel Disease Registry.” Investigative ophthalmology & visual science (2026). PMID: 41841652 ↗
L3OTHERCited in: History and Evolution of Treatment
[482]
Harada N, Nagai N, Mushiga Y et al.. “Choriocapillaris Flow Imbalance in Fellow Eyes in Age-Related Macular Degeneration.” Investigative ophthalmology & visual science (2022). PMID: 35943731 ↗
L3OTHERCited in: History and Evolution of Treatment
[483]
Saßmannshausen M, Döngelci S, Vaisband M et al.. “Spatially Resolved Association of Structural Biomarkers on Retinal Function in Non-Exudative Age-Related Macular Degeneration Over 4 Years.” Investigative ophthalmology & visual science (2024). PMID: 38687492 ↗
L2OTHERCited in: History and Evolution of Treatment
[484]
Meer EA, Targ S, Zhang N et al.. “AGE-RELATED MACULAR DEGENERATION INJECTION FREQUENCY: Effects of Distance Traveled and Travel Support.” Retina (Philadelphia, Pa.) (2024). PMID: 37756667 ↗
L2OTHERCited in: History and Evolution of Treatment
[485]
von der Emde L, Guymer RH, Pfau M et al.. “NATURAL HISTORY OF QUANTITATIVE AUTOFLUORESCENCE IN INTERMEDIATE AGE-RELATED MACULAR DEGENERATION.” Retina (Philadelphia, Pa.) (2021). PMID: 32740494 ↗
L2OTHERCited in: History and Evolution of Treatment
[486]
Tran J, Chhablani J. “Unsuccessful Clinical Trials in Retina: Lessons Learned.” American journal of ophthalmology (2026). PMID: 42082070 ↗
L5TRIAL_NONRANDOMCited in: History and Evolution of Treatment, Special Populations & Pregnancy
[487]
Klufas MA, Regillo CD, Mandava NK et al.. “Evolution of Anti-Vascular Endothelial Growth Factor Clinical Trial Design for Treating Neovascular Age-Related Macular Degeneration.” Journal of vitreoretinal diseases (2026). PMID: 41822409 ↗
L5TRIAL_NONRANDOMCited in: History and Evolution of Treatment
[488]
Şatırtav G, Lövestam-Adrian MK, Chang W et al.. “Discontinuing Anti-VEGF Therapy in Patients with Neovascular Age-Related Macular Degeneration That Remains Inactive with Treatment at the Maximum Injection Interval.” Clinical ophthalmology (Auckland, N.Z.) (2026). PMID: 42389069 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[489]
Borrelli E, Neri G, Berni A et al.. “Review of emerging imaging findings to reveal a broader spectrum of lesions in AMD.” Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2026). PMID: 42347990 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[490]
Zong Y, Fan Q, Huang L. “Biosimilars of anti-VEGF agents in retinal diseases: a narrative review of regulatory, clinical, and pharmacoeconomic aspects.” International journal of retina and vitreous (2026). PMID: 42218559 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[491]
Szymańska K, Sałasińska K, Młynarczyk A et al.. “The Gut-Eye Axis and Microbiome in Ophthalmic Diseases: A Narrative Review.” Journal of clinical medicine (2026). PMID: 42194525 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[492]
Ezzine S, Gale R, Bailey C et al.. “Pharmacological principles of intravitreal drug therapy and their implications for clinical practice: a primer for the ophthalmologist.” Eye (London, England) (2026). PMID: 42162254 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[493]
Anegondi N, Steffen V, Sadda SR et al.. “Visual Loss in Geographic Atrophy: Learnings from the Lampalizumab Trials.” Ophthalmology (2024). PMID: 39581330 ↗
L2RCTCited in: Surgical, Laser & Procedural Considerations
[494]
Yaldo L, Ngo A, Yaldo M et al.. “Obstructive sleep apnea and risk of age-related macular degeneration: A systematic review and meta-analysis.” American journal of ophthalmology (2026). PMID: 41692178 ↗
L1SR_OBSCited in: Surgical, Laser & Procedural Considerations
[495]
Bockelbrink A, Roll S, Ruether K et al.. “Cataract surgery and the development or progression of age-related macular degeneration: a systematic review.” Survey of ophthalmology (2008). PMID: 18572053 ↗
L2SR_OBSCited in: Surgical, Laser & Procedural Considerations
[496]
Grant A, Leung G, Freeman EE. “Ambient Air Pollution and Age-Related Eye Disease: A Systematic Review and Meta-Analysis.” Investigative ophthalmology & visual science (2022). PMID: 35960515 ↗
L1SR_OBSCited in: Surgical, Laser & Procedural Considerations
[497]
van Nispen RM, Virgili G, Hoeben M et al.. “Low vision rehabilitation for better quality of life in visually impaired adults.” The Cochrane database of systematic reviews (2020). PMID: 31985055 ↗
L1SR_OBSCited in: Surgical, Laser & Procedural Considerations, Complications & Ocular Sequelae
[498]
Gupta A, Lam J, Custis P et al.. “Implantable miniature telescope (IMT) for vision loss due to end-stage age-related macular degeneration.” The Cochrane database of systematic reviews (2018). PMID: 29847689 ↗
L1SR_OBSCited in: Surgical, Laser & Procedural Considerations, Prevention, Screening & Surveillance
[499]
Wu E, Hasan N, Vupparaboina S et al.. “Predicting Early Onset of Age-Related Macular Degeneration: A Machine Learning Approach.” American journal of ophthalmology (2025). PMID: 40701376 ↗
L3OTHERCited in: Surgical, Laser & Procedural Considerations, Prevention, Screening & Surveillance
[500]
Teh BL, Megaw R, Borooah S et al.. “Optimizing cataract surgery in patients with age-related macular degeneration.” Survey of ophthalmology (2016). PMID: 28012877 ↗
L5REVIEW_NARRATIVECited in: Surgical, Laser & Procedural Considerations, Prognosis & Natural History
[501]
Carlà MM, Mottola F, Cusato M et al.. “Vitreoretinal interface abnormalities in age-related macular degeneration: Prevalence, pathophysiology, and reciprocal influence.” Survey of ophthalmology (2025). PMID: 40712801 ↗
L5REVIEW_NARRATIVECited in: Surgical, Laser & Procedural Considerations
[502]
Atchison EA, Omar AF, Iezzi R et al.. “OUTCOMES OF AN INTRAVITREAL INJECTION CLINIC.” Retina (Philadelphia, Pa.) (2017). PMID: 27759581 ↗
L4OTHERCited in: Surgical, Laser & Procedural Considerations
[503]
Huang AY, Ehrlich JR, Hamedani AG. “Visual impairment, age-related eye disease, and sleep dysfunction in older adults.” Eye (London, England) (2025). PMID: 40221561 ↗
L2OTHERCited in: Surgical, Laser & Procedural Considerations
[504]
Khanani AM, Bakri SJ, Regillo C et al.. “Novel targets beyond vascular endothelial growth factor-A inhibition: improving vision with neovascular age-related macular degeneration treatment.” Eye (London, England) (2025). PMID: 41076458 ↗
L5REVIEW_NARRATIVECited in: Surgical, Laser & Procedural Considerations
[505]
Assi L, Chamseddine F, Ibrahim P et al.. “A Global Assessment of Eye Health and Quality of Life: A Systematic Review of Systematic Reviews.” JAMA ophthalmology (2021). PMID: 33576772 ↗
L1SR_OBSCited in: Complications & Ocular Sequelae, Prevention, Screening & Surveillance
[506]
Tran L, Kandel H, Sari D et al.. “Artificial Intelligence and Ophthalmic Clinical Registries.” American journal of ophthalmology (2024). PMID: 39111520 ↗
L2SR_OBSCited in: Complications & Ocular Sequelae
[507]
Datta S, Cano M, Ebrahimi K et al.. “The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD.” Progress in retinal and eye research (2017). PMID: 28336424 ↗
L5REVIEW_NARRATIVECited in: Complications & Ocular Sequelae, Special Populations & Pregnancy
[508]
Kim SJ, Flach AJ, Jampol LM. “Nonsteroidal anti-inflammatory drugs in ophthalmology.” Survey of ophthalmology (2010). PMID: 20159228 ↗
L5REVIEW_NARRATIVECited in: Complications & Ocular Sequelae, Special Populations & Pregnancy
[509]
Reiter GS, Birner K, Schrittwieser J et al.. “Deep-Learning-Based Analysis of Disease-Specific Structural Biomarkers on Retinal Sensitivity in Neovascular Age-Related Macular Degeneration.” Investigative ophthalmology & visual science (2025). PMID: 41025875 ↗
L2OTHERCited in: Complications & Ocular Sequelae
[510]
Szczepan M, Llorián-Salvador M, Yi C et al.. “Differential Roles of Macrophages and Microglia in Subretinal Fibrosis Secondary to Neovascular Age-Related Macular Degeneration.” Investigative ophthalmology & visual science (2025). PMID: 40111356 ↗
L5OTHERCited in: Complications & Ocular Sequelae
[511]
Muftuoglu IK, Alam M, You QS et al.. “Reply.” Retina (Philadelphia, Pa.) (2017). PMID: 28820853 ↗
L5OTHERCited in: Complications & Ocular Sequelae
[512]
Okada M, Kandasamy R, Chong EW et al.. “The Treat-and-Extend Injection Regimen Versus Alternate Dosing Strategies in Age-related Macular Degeneration: A Systematic Review and Meta-analysis.” American journal of ophthalmology (2018). PMID: 29885297 ↗
L1SR_OBSCited in: Prognosis & Natural History
[513]
Hagag AM, Kaye R, Hoang V et al.. “Systematic review of prognostic factors associated with progression to late age-related macular degeneration: Pinnacle study report 2.” Survey of ophthalmology (2023). PMID: 37890677 ↗
L2SR_OBSCited in: Prognosis & Natural History
[514]
Shin HJ, Kim SN, Chung H et al.. “Intravitreal Anti-Vascular Endothelial Growth Factor Therapy and Retinal Nerve Fiber Layer Loss in Eyes With Age-Related Macular Degeneration: A Meta-Analysis.” Investigative ophthalmology & visual science (2016). PMID: 27077733 ↗
L1SR_OBSCited in: Prognosis & Natural History
[515]
Del Priore LV, Tezel TH, Kaplan HJ. “Maculoplasty for age-related macular degeneration: reengineering Bruch's membrane and the human macula.” Progress in retinal and eye research (2006). PMID: 17071125 ↗
L5REVIEW_NARRATIVECited in: Prognosis & Natural History
[516]
Zhang SX, Wang JJ, Starr CR et al.. “The endoplasmic reticulum: Homeostasis and crosstalk in retinal health and disease.” Progress in retinal and eye research (2023). PMID: 38092262 ↗
L5REVIEW_NARRATIVECited in: Prognosis & Natural History
[517]
Zaluski J, Bassetto M, Kiser PD et al.. “Advances and therapeutic opportunities in visual cycle modulation.” Progress in retinal and eye research (2025). PMID: 40280538 ↗
L5REVIEW_NARRATIVECited in: Prognosis & Natural History
[518]
Pfeiffer RL, Marc RE, Jones BW. “Persistent remodeling and neurodegeneration in late-stage retinal degeneration.” Progress in retinal and eye research (2019). PMID: 31356876 ↗
L5REVIEW_NARRATIVECited in: Prognosis & Natural History
[519]
Eandi CM, Giansanti F, Virgili G. “Macular translocation for neovascular age-related macular degeneration.” The Cochrane database of systematic reviews (2008). PMID: 18843739 ↗
L1SR_OBSCited in: Prognosis & Natural History, Special Populations & Pregnancy
[520]
Cheung R, Trinh M, Nivison-Smith L. “Retinal Pigment Epithelium Curvature Can Predict Late Age-Related Macular Degeneration.” Investigative ophthalmology & visual science (2024). PMID: 39365260 ↗
L2OTHERCited in: Prognosis & Natural History
[521]
Yiu G, Chung SH, Mollhoff IN et al.. “Long-term Evolution and Remodeling of Soft Drusen in Rhesus Macaques.” Investigative ophthalmology & visual science (2020). PMID: 32084273 ↗
L5OTHERCited in: Prognosis & Natural History
[522]
Barreto P, Farinha C, Coimbra R et al.. “Unveiling Statins and Genetics in Age-Related Macular Degeneration: The Coimbra Eye Study-Report 9.” Investigative ophthalmology & visual science (2024). PMID: 38935028 ↗
L2OTHERCited in: Prognosis & Natural History
[523]
Chichagova V, Hallam D, Collin J et al.. “Cellular regeneration strategies for macular degeneration: past, present and future.” Eye (London, England) (2018). PMID: 29503449 ↗
L5REVIEW_NARRATIVECited in: Prognosis & Natural History
[524]
Stuard Sambhariya W, Bowes Rickman C, D'Amore PA et al.. “Age-related macular degeneration and cerebral amyloid angiopathy have similar pathologies from cholesterol-APOE-amyloid-β-complement mediated inflammation.” Progress in retinal and eye research (2026). PMID: 41708012 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy
[525]
Choudhary M, Malek G. “Potential therapeutic targets for age-related macular degeneration: The nuclear option.” Progress in retinal and eye research (2022). PMID: 36220751 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy
[526]
Yoshida N, Kobayakawa Y, Funakoshi K et al.. “Protocol for the SACLA trial: Efficacy and safety of subretinal monteplase for submacular hemorrhage in a phase II single-arm multicenter decentralized clinical trial.” PloS one (2026). PMID: 42391281 ↗
L4TRIAL_NONRANDOMCited in: Special Populations & Pregnancy
[527]
Zhou Q, Zhang Z, Wu Y et al.. “A critical role for mitochondrial dynamics in cigarette smoke condensate-induced RPE senescence.” Free radical biology & medicine (2026). PMID: 42385795 ↗
L5OTHERCited in: Special Populations & Pregnancy
[528]
Bihorel S, Chiu J, Chittenden J et al.. “Integrated Population Pharmacokinetic Analysis of Intravitreal Aflibercept Drug Products.” CPT: pharmacometrics & systems pharmacology (2026). PMID: 42381356 ↗
L2OTHERCited in: Special Populations & Pregnancy
[529]
Li X, Wang C, Duan J et al.. “Personalized Dosing System Guided by Cross-Scale Metabolic Imaging Biomarkers in Neovascular Age-Related Macular Degeneration.” Translational vision science & technology (2026). PMID: 42334128 ↗
L3OTHERCited in: Special Populations & Pregnancy
[530]
Chang MA, Kapre A, Kaufman D et al.. “Patient Preference and Treatment Satisfaction With a Port Delivery System for Ranibizumab vs Intravitreal Injections in Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.” JAMA ophthalmology (2022). PMID: 35708706 ↗
L1RCTCited in: Prevention, Screening & Surveillance
[531]
Ying GS, Kim BJ, Maguire MG et al.. “Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials.” JAMA ophthalmology (2014). PMID: 24875610 ↗
L2RCTCited in: Prevention, Screening & Surveillance
[532]
Hwang S, Kang SW, Kim SJ et al.. “Impact of Age-Related Macular Degeneration and Related Visual Disability on the Risk of Depression: A Nationwide Cohort Study.” Ophthalmology (2023). PMID: 36717001 ↗
L2COHORTCited in: Prevention, Screening & Surveillance
[533]
Sun D, Tseng VL, Yu F et al.. “Cardiovascular Risk and Eye Health: A Cohort Study of the Pooled Cohort Equations and Ocular Disease Incidence.” Ophthalmology (2025). PMID: 41475545 ↗
L2COHORTCited in: Prevention, Screening & Surveillance
[534]
Kaiser PK, Symons RC, Shah SM et al.. “RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027.” American journal of ophthalmology (2010). PMID: 20609706 ↗
L4TRIAL_NONRANDOMCited in: Prevention, Screening & Surveillance
[535]
Bourne RRA, Jonas JB, Bron AM et al.. “Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe in 2015: magnitude, temporal trends and projections.” The British journal of ophthalmology (2018). PMID: 29545417 ↗
L2SR_OBSCited in: Prevention, Screening & Surveillance
[536]
Cheng CY, Wang N, Wong TY et al.. “Prevalence and causes of vision loss in East Asia in 2015: magnitude, temporal trends and projections.” The British journal of ophthalmology (2019). PMID: 31462416 ↗
L2SR_OBSCited in: Prevention, Screening & Surveillance
[537]
Jin K, Yu T, Grzybowski A. “Multimodal artificial intelligence in ophthalmology: Applications, challenges, and future directions.” Survey of ophthalmology (2025). PMID: 40683606 ↗
L2SR_OBSCited in: Prevention, Screening & Surveillance
[538]
Deimazar G, Sabbaghi H, Ahmadieh H et al.. “Artificial intelligence for detection of age-related macular degeneration based on fundus images: A systematic review.” Survey of ophthalmology (2025). PMID: 41173219 ↗
L2SR_OBSCited in: Prevention, Screening & Surveillance
[539]
Wu H, Jin K, Yip CC et al.. “A systematic review of economic evaluation of artificial intelligence-based screening for eye diseases: From possibility to reality.” Survey of ophthalmology (2024). PMID: 38492584 ↗
L2SR_OBSCited in: Prevention, Screening & Surveillance
[540]
Choi S, Jahng WJ, Park SM et al.. “Association of Age-Related Macular Degeneration on Alzheimer or Parkinson Disease: A Retrospective Cohort Study.” American journal of ophthalmology (2019). PMID: 31712068 ↗
L2COHORTCited in: Prevention, Screening & Surveillance
[541]
Klaassen I, Vader MJC, Aissa K et al.. “Several Common Genetic Variations Associate With Functional or Anatomic Effects of Anti-VEGF Treatment in Conditions With Macular Edema.” Investigative ophthalmology & visual science (2025). PMID: 40455044 ↗
L2SR_OBSCited in: Prevention, Screening & Surveillance
[542]
Hwang S, Kang SW, Kim SJ et al.. “Diabetes-Related Risk Factors for Exudative Age-Related Macular Degeneration: A Nationwide Cohort Study of a Diabetic Population.” Investigative ophthalmology & visual science (2023). PMID: 37432847 ↗
L2COHORTCited in: Prevention, Screening & Surveillance
[543]
Hwang S, Kang SW, Han J et al.. “FEMALE REPRODUCTIVE FACTORS AND THE RISK OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION: A Nationwide Cohort Study.” Retina (Philadelphia, Pa.) (2021). PMID: 33675332 ↗
L2COHORTCited in: Prevention, Screening & Surveillance
[544]
Cheung R, Chun J, Sheidow T et al.. “Diagnostic accuracy of current machine learning classifiers for age-related macular degeneration: a systematic review and meta-analysis.” Eye (London, England) (2021). PMID: 33958739 ↗
L2SR_OBSCited in: Prevention, Screening & Surveillance
[545]
Faes L, Bodmer NS, Bachmann LM et al.. “Diagnostic accuracy of the Amsler grid and the preferential hyperacuity perimetry in the screening of patients with age-related macular degeneration: systematic review and meta-analysis.” Eye (London, England) (2014). PMID: 24788016 ↗
L2SR_OBSCited in: Prevention, Screening & Surveillance
[546]
Yoon JM, Lim DH, Lee YB et al.. “The risk of fracture in age-related macular degeneration according to the presence of visual disability: a nationwide cohort study.” Eye (London, England) (2023). PMID: 37598260 ↗
L2COHORTCited in: Prevention, Screening & Surveillance
[547]
Cheung CMG, Lai TYY, Teo K et al.. “Polypoidal Choroidal Vasculopathy: Consensus Nomenclature and Non-Indocyanine Green Angiograph Diagnostic Criteria from the Asia-Pacific Ocular Imaging Society PCV Workgroup.” Ophthalmology (2020). PMID: 32795496 ↗
L5OTHERCited in: Prevention, Screening & Surveillance
[548]
Xue CC, Li H, Yu M et al.. “Omega-3 Fatty Acids as Protective Factors for Age-Related Macular Degeneration: Prospective Cohort and Mendelian Randomization Analyses.” Ophthalmology (2024). PMID: 39662686 ↗
L2OTHERCited in: Prevention, Screening & Surveillance
[549]
Li JO, Liu H, Ting DSJ et al.. “Digital technology, tele-medicine and artificial intelligence in ophthalmology: A global perspective.” Progress in retinal and eye research (2020). PMID: 32898686 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[550]
Sobrin L, Seddon JM. “Nature and nurture- genes and environment- predict onset and progression of macular degeneration.” Progress in retinal and eye research (2013). PMID: 24374240 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[551]
Ting DSW, Peng L, Varadarajan AV et al.. “Deep learning in ophthalmology: The technical and clinical considerations.” Progress in retinal and eye research (2019). PMID: 31048019 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[552]
Ramkumar HL, Zhang J, Chan CC. “Retinal ultrastructure of murine models of dry age-related macular degeneration (AMD).” Progress in retinal and eye research (2010). PMID: 20206286 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[553]
Wen X, Hu X, Miao L et al.. “Epigenetics, microbiota, and intraocular inflammation: New paradigms of immune regulation in the eye.” Progress in retinal and eye research (2018). PMID: 29357307 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[554]
Evans JR, Lawrenson JG. “Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration.” The Cochrane database of systematic reviews (2012). PMID: 22696317 ↗
L1SR_OBSCited in: Prevention, Screening & Surveillance
[555]
Giansanti F, Eandi CM, Virgili G. “Submacular surgery for choroidal neovascularisation secondary to age-related macular degeneration.” The Cochrane database of systematic reviews (2009). PMID: 19370663 ↗
L1SR_OBSCited in: Prevention, Screening & Surveillance
[556]
Padnick-Silver L, Weinberg AB, Lafranco FP et al.. “Pilot study for the detection of early exudative age-related macular degeneration with optical coherence tomography.” Retina (Philadelphia, Pa.) (2012). PMID: 22186740 ↗
L4CASE_REPORTCited in: Prevention, Screening & Surveillance
[557]
Chen L, Messinger JD, Sloan KR et al.. “ABUNDANCE AND MULTIMODAL VISIBILITY OF SOFT DRUSEN IN EARLY AGE-RELATED MACULAR DEGENERATION: A Clinicopathologic Correlation.” Retina (Philadelphia, Pa.) (2020). PMID: 32568988 ↗
L4CASE_REPORTCited in: Prevention, Screening & Surveillance
[558]
Hussain ZS, Chauhan MZ, Muayad J et al.. “Potency Matters: The Role of Statin Intensity in Modulating Risk for Age-Related Macular Degeneration.” American journal of ophthalmology (2025). PMID: 40829697 ↗
L2OTHERCited in: Prevention, Screening & Surveillance
[559]
Zhou J, He Y, Wang J et al.. “Exposure-wide approaches identifying modifiable factors for age-related macular degeneration.” The British journal of ophthalmology (2026). PMID: 41513432 ↗
L2OTHERCited in: Prevention, Screening & Surveillance
[560]
Benet D, Pellicer-Valero OJ. “Artificial intelligence: the unstoppable revolution in ophthalmology.” Survey of ophthalmology (2021). PMID: 33741420 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[561]
Querques G, Souied EH. “The role of omega-3 and micronutrients in age-related macular degeneration.” Survey of ophthalmology (2014). PMID: 24657038 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[562]
Furtado JM, Lansingh VC, Carter MJ et al.. “Causes of blindness and visual impairment in Latin America.” Survey of ophthalmology (2011). PMID: 22137039 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[563]
Hang A, Shao A, Shea M et al.. “Ocular Phenotyping of Knockout Mice Identifies Genes Associated With Late Adult Retinal Phenotypes.” Investigative ophthalmology & visual science (2025). PMID: 40548636 ↗
L5OTHERCited in: Prevention, Screening & Surveillance
[564]
Ji R, Ishikawa K, Tan W et al.. “Liposome Encapsulation Enhances Ripasudil Therapeutic Efficacy Against Proliferative Vitreoretinal Diseases: Implications in Advanced Ocular Treatment.” Investigative ophthalmology & visual science (2025). PMID: 40525920 ↗
L5OTHERCited in: Prevention, Screening & Surveillance
[565]
Shaw EM, Anderson DM, Periasamy R et al.. “Porcine Sub-Retinal Pigment Epithelium Deposits: A Model for Dry Age-Related Macular Degeneration With Comparison to Human Drusen.” Investigative ophthalmology & visual science (2025). PMID: 40048184 ↗
L5OTHERCited in: Prevention, Screening & Surveillance
[566]
Velez-Montoya R, Oliver SC, Olson JL et al.. “Current knowledge and trends in age-related macular degeneration: genetics, epidemiology, and prevention.” Retina (Philadelphia, Pa.) (2014). PMID: 24285245 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[567]
Al-Salem KM, Schaal S. “Mini-cognitive testing in patients with age-related macular degeneration.” Retina (Philadelphia, Pa.) (2014). PMID: 24756035 ↗
L3OTHERCited in: Prevention, Screening & Surveillance
[568]
Crincoli E, Parravano MC, Sacconi R et al.. “Updates on novel and traditional OCT and OCTA biomarkers in nAMD.” Eye (London, England) (2025). PMID: 40253504 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[569]
Chhetri J, Jacobson G, Gueven N. “Zebrafish--on the move towards ophthalmological research.” Eye (London, England) (2014). PMID: 24503724 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
[570]
Chen PJ, Wan L, Yip HT et al.. “Bidirectional Association Between Age-Related Macular Degeneration and Cardiovascular Disease: A Population-Based Cohort Study in Taiwan with 15-Year Follow-up.” Ophthalmic epidemiology (2026). PMID: 42149082 ↗
L2COHORTCited in: Prevention, Screening & Surveillance
[571]
Tseng CH, Lin MY, Chiou DI et al.. “Preliminary Observations of Bilateral Neovascular Age-Related Macular Degeneration Progression: A Real-World Retrospective Case Series.” Journal of clinical medicine (2026). PMID: 42278913 ↗
L4CASE_REPORTCited in: Prevention, Screening & Surveillance
[572]
Kim HM, Woo SJ. “Association between screening duration and treatment outcomes in the clinical trials of ranibizumab and aflibercept for neovascular age-related macular degeneration.” Scientific reports (2026). PMID: 41927600 ↗
L2RCTCited in: Prevention, Screening & Surveillance

Age-Related Macular Degeneration

Quick Reference

Overview and Recommendations

Background

Evaluation

Management

Board Review — High Yield

Deep Dive — Evidence Details

Definition, Classification & Nomenclature

Stages and Classification

Neovascular AMD Subtypes

Clinical Significance

Pathophysiology & Mechanism

Complement Dysregulation and Chronic Inflammation

Geographic Atrophy: The Final Common Pathway of RPE Loss

The Angiogenic Switch: From Dry to Neovascular AMD

Lipid Metabolism, Drusen Biogenesis, and the Choroid

Additional Modifiers: Mitochondrial Dysfunction, Epigenetics, and Systemic Inflammation

Epidemiology, Etiology & Risk Factors

Modifiable Risk Factors

Temporal Trends and Comorbidities

Clinical Presentation

Presenting Symptoms

Examination Signs

Phenotypic Variants

Red Flags

Atypical Presentations

Clinical Examination and Diagnostic Workup

Bedside Examination Battery

Diagnostic Algorithm

Test of Choice and Gold Standard

Ophthalmic Imaging and Functional Testing

Optical Coherence Tomography

Fluorescein and Indocyanine Green Angiography

OCT Angiography

Functional Testing

Emerging AI and Deep Learning

Severity, Staging & Risk Stratification

AREDS Simplified Severity Scale (Updated)

Risk Stratification for Geographic Atrophy

Risk Stratification for Neovascular AMD

Risk Modifiers

Clinical Application

Acute & Vision-Threatening Management

Step 1: Initiate Anti-VEGF Therapy

Step 2: Manage Submacular Hemorrhage

Step 3: Monitor for Safety and Complications

Step 4: Switch Therapy for Incomplete Response

Long-term & Definitive Management

Step 2: Switching and Escalation Strategies

Step 3: Geographic Atrophy, Complement Inhibition and Neuroprotection

Drug / Modality Comparison Table

Dosing Table

Controversies and Guideline Disagreement

Treatment Failure Protocol

What NOT to Do

Monitoring and Safety

History and Evolution of Treatment

The Anti-VEGF Revolution

Next-Generation Agents

Treatment for Geographic Atrophy

Abandoned and Investigational Approaches

Controversies and Guideline Disagreement

Surgical, Laser & Procedural Considerations

Intravitreal Injection Technique and Safety Profile

Laser Therapies

Surgical Management of Submacular Hemorrhage

Device Implants

Gene Therapy and Cell Transplantation

Radiotherapy

Complications & Ocular Sequelae

Macular Fibrosis and Disciform Scar

Geographic Atrophy Progression

Macular Neovascularization (Conversion to Wet AMD)

Retinal Pigment Epithelium Tears

Submacular Hemorrhage

Treatment-Related Complications

Functional Sequelae and Quality of Life

Prognosis & Natural History

Untreated Natural History

Surgical of Submacular Hemorrhage